Check for updates

OPEN ACCESS

EDITED BY Panagiotis G. Korovessis, AIMIS (American Institute of Minimal Invasive Surgery), Cyprus

REVIEWED BY

Xin Feng Zheng, Shanghai Jiao Tong University, China Cao Donghui, Ningxia Medical University, China

*CORRESPONDENCE Lei Luo I 14066203@qq.com Ting Li I litingsrh1225@163.com

[†]These authors share first authorship

RECEIVED 11 March 2025 ACCEPTED 17 April 2025 PUBLISHED 16 May 2025

CITATION

Xiao L, Li W, Yan J, Luo L and Li T (2025) Indepth meta-analysis: unilateral PKP demonstrates significant advantages in treating osteoporotic vertebral compression fractures—an expanded RCT study with GRADE scoring. Front. Surg. 12:1591686. doi: 10.3389/fsurg.2025.1591686

COPYRIGHT

© 2025 Xiao, Li, Yan, Luo and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

In-depth meta-analysis: unilateral PKP demonstrates significant advantages in treating osteoporotic vertebral compression fractures—an expanded RCT study with GRADE scoring

Lin Xiao^{1†}, Wei Li^{1†}, Jingxin Yan², Lei Luo^{1*} and Ting Li^{3*}

¹Department of Orthopedics, The Sixth People's Hospital of Chengdu, Chengdu, China, ²School of Medicine, South China University of Technology, Guangzhou, China, ³Department of Orthopedics, No. 1 Orthopedics Hospital of Chengdu, Chengdu, China

Background: Percutaneous kyphoplasty (PKP) has become a mainstream intervention for osteoporotic vertebral compression fractures (OVCFs). While existing systematic reviews comparing unilateral and bilateral PKP approaches provide preliminary insights, they are limited by methodological inconsistencies and inconclusive evidence regarding comparative efficacy.

Methods: We conducted a comprehensive systematic review of randomized controlled trials (RCTs) up to July 2024, searching major English databases (Cochrane Library, Embase, PubMed, Scopus, Web of Science) and Chinese databases (CNKI, VIP, and Wanfang).

Results: The pooled analysis of 35 RCTs (N = 3,362) revealed no statistically significant differences between unilateral and bilateral PKP in long-term outcomes, including visual analog scale scores (P = 0.62), Oswestry Disability Index scores (P = 0.77), and Cobb angle correction (P = 0.64). However, unilateral PKP demonstrated significant perioperative advantages: shorter operative time (P < 0.00001), a lower dose of bone cement injection (P < 0.00001), and a reduced radiation dose (P < 0.00001). Furthermore, the study also found that unilateral PKP had a lower rate of bone cement leakage (P < 0.0001) and a reduced overall complication rate (P < 0.0001) compared to bilateral PKP.

Conclusion: Unilateral PKP offers advantages over bilateral PKP, including shorter operation time, lower polymethylmethacrylate injection dose, reduced radiation exposure, lower bone cement leakage, and fewer complications. Therefore, unilateral PKP may be a preferable option for patients with OVCF, providing similar clinical outcomes with reduced procedural risks and resource requirements.

KEYWORDS

meta-analysis, osteoporotic vertebral compression fractures, RCTs, percutaneous kyphoplasty, unilateral and bilateral

Introduction

Osteoporotic vertebral compression fractures (OVCFs) represent a growing global health burden, with osteoporosis affecting over 200 million individuals worldwide and contributing to approximately 700,000 vertebral fractures annually in the United States alone (1, 2). This condition, characterized by diminished bone mineral density (BMD) and disrupted trabecular architecture, disproportionately impacts postmenopausal women due to estrogen deficiency but increasingly affects aging males, particularly those undergoing androgen deprivation therapy (2-4). Key modifiable risk factors include inadequate calcium/vitamin D intake, a sedentary lifestyle, and secondary endocrine dysregulation (5). OVCFs frequently occur spontaneously or following minimal trauma, manifesting as acute pain, progressive kyphotic deformity, and functional decline that collectively impair quality of life and independence (6). The socioeconomic consequences are substantial, with U.S. healthcare costs exceeding \$18 billion annually for osteoporosis-related fractures.

Percutaneous kyphoplasty (PKP) has revolutionized OVCF management through minimally invasive vertebral augmentation using polymethylmethacrylate (PMMA) cement (7, 8). Despite its widespread use, the optimal approach, i.e., unilateral vs. bilateral PKP, remains a subject of debate among clinicians. Unilateral PKP involves the injection of bone cement through a single access point, while bilateral PKP requires two access points, one on each side of the vertebra (9). Proponents of bilateral PKP argue that it offers better vertebral body symmetry and improved cement distribution, potentially leading to superior clinical outcomes (10). Conversely, advocates of unilateral PKP highlight its simplicity, reduced procedural time, and lower risk of complications, such as bone cement leakage and radiation exposure (10, 11).

The current clinical guidelines lack consensus on the optimal surgical approach (unilateral vs. bilateral PKP) due to insufficient high-quality comparative evidence. This review intends to provide clinicians with evidence-based selection criteria to prioritize unilateral PKP for frail patients or resource-limited settings and reserve bilateral approaches for cases requiring enhanced vertebral stabilization. By establishing evidence-based selection criteria, this work advances standardized yet personalized decision-making in OVCF management, ultimately improving clinical outcomes and healthcare efficiency.

Materials and methods

Study design

This PRISMA-guided meta-analysis systematically compares the efficacy and safety profiles of unilateral vs. bilateral PKP in managing OVCFs with rigorous adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (12).

Literature retrieval strategy

A comprehensive search of electronic databases, including English databases (Cochrane Library, Embase, PubMed, Scopus, and Web of Science) and Chinese databases [China National Knowledge Infrastructure (CNKI), Chongqing VIP (VIP), and Wan Fang], was performed up to July 2024. We manually searched the bibliographies of randomized controlled trials (RCTs) comparing unilateral and bilateral PKP for OVCFs. Our search strategy incorporated both subject headings and free-text keywords: [(vertebral compression fracture OR osteoporosis) AND (percutaneous kyphoplasty OR unilateral OR bilateral)] AND (RCT). This literature retrieval strategy is detailed in Supplementary File 1.

Inclusion and exclusion criteria

Inclusion criteria

To compare the advantages and disadvantages and the clinical outcomes of unilateral and bilateral PKP, studies were included based on the following PICOS criteria:

Population (P): Patients with OVCFs.

Intervention (I) vs. Control (C): Unilateral vs. bilateral PKP.

Outcomes (O): Operation time, bone cement injection dose, x-ray radiation dose, Cobb angle, visual analog scale (VAS) and Oswestry Disability Index (ODI) at preoperative and postoperative follow-up time points, bone cement leakage, and overall complication rate.

Study Design (S): Only RCTs.

Exclusion criteria

Studies were excluded based on the following criteria:

P: Non-osteoporotic vertebral fractures (e.g., traumatic, neoplastic, or infectious fractures). Patients with non-vertebral fragility fractures fulfilling WHO osteoporosis diagnostic criteria (T-score ≤ -2.5) (e.g., hip or wrist fractures).

I vs. C: Studies comparing PKP with non-PKP techniques (e.g., vertebroplasty, conservative therapy). Hybrid approaches (e.g., unilateral PKP + contralateral vertebroplasty or pedicle screw placement).

O: Studies lacking quantitative data on prespecified outcomes (operation time, cement volume, VAS/ODI, Cobb angle, complications).

S: Non-RCTs (e.g., cohort studies, case series).

Additional exclusions: Duplicate publications or overlapping datasets. Studies with <12 months of follow-up for primary outcomes. Patients with spinal comorbidities (e.g., degenerative stenosis, prior fusion surgery).

Data extraction

Data were extracted jointly by two reviewers and screened and sorted using the Microsoft Word 2021 table tool in accordance

with the Cochrane Collaboration guidelines for systematic reviews. Any disagreements between the reviewers were resolved by consultation with a third reviewer. All studies included in the study were collected based on outcome metrics (authorship, year, participants, intervention treatment, control treatment, vertebral fractures, and clinical outcomes). When information was lacking, we tried to reach out to the primary author via email to obtain clarification or to exclude the study.

Risk of bias assessment

The assessment of bias in the included studies was performed utilizing the Cochrane tool (https://methods.cochrane.org/riskbias-2). The tool assesses the following aspects of bias (13). (1)Random sequence generation: Assessed whether randomization methods (e.g., computer-generated numbers, block randomization) were explicitly reported. For example, studies using "computer-generated numbers" were classified as low risk; those stating only "randomized" without details were classified as unclear risk. (2) Allocation concealment: Evaluated safeguards against selection bias (e.g., centralized allocation vs. open randomization lists). For example, studies not using "sealed opaque envelopes" were classified as high risk. (3) Blinding: A study design in which both the investigators and participants remain unaware of group assignments is termed double-blind. For example, an article that describes the utilization of a doubleblind methodology is considered to be associated with a low risk of bias. (4) Incomplete outcome data: A threshold of >20% loss to follow-up without intention-to-treat analysis was classified as high risk. (5) Selective reporting: Cross-checked outcomes against trial registrations and protocols. The evaluation of bias was performed by two independent researchers, and the overall quality assessment was carried out by the same two reviewers. RevMan 5.4 was used to construct a risk bias map.

Statistical analysis

The meta-analysis was conducted for each outcome using RevMan 5.4 software. For the incidence of cement leakage and overall complication, odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using the dichotomous variable method. The standardized mean differences (SMD) and mean differences (MD) were calculated using the continuous variable method. To evaluate the heterogeneity of the included studies, we applied the Chi-square test. A lack of heterogeneity was indicated by $P \ge 0.1$ and $I^2 \le 50\%$, which led to the use of a fixed-effect model. If $I^2 < 50\%$ or P < 0.1, a random-effects model was used. In addition, we evaluated publication bias by generating funnel plots corresponding to each category of failure mode.

We strictly adhered to the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) guidelines for assessing risk ratios, applying a 1-point downgrade if the 95% confidence interval of the risk ratio crossed the null value. Additional downgrades for imprecision were applied to very small sample sizes in the pooled analyses: a "serious" quality downgrade was used for sample sizes with one study arm of <50 individuals and a "very serious" quality downgrade was used for total sample sizes \leq 30 individuals. GRADE quality assessments were conducted by two independent reviewers, who resolved discrepancies through discussion and consensus.

Results

Search result

Our systematic search identified 1,670 potentially relevant articles published between 1990 and 2024. After removing 895 duplicates through automated and manual verification, two independent reviewers screened the titles/abstracts of 775 unique records. Subsequently, 312 articles were excluded due to nontarget topics, 7 due to case report formats, and 64 due to review article types during full-text evaluation. Ultimately, 35 studies (17 English-language and 18 Chinese-language RCTs) met the predefined inclusion criteria and were included in the metaanalysis (14–48). Figure 1 shows the selection process for the relevant studies.

Study characteristics

A total of 35 RCTs comparing unilateral vs. bilateral PKP for the treatment of OVCFs were retrieved and analyzed, involving a total of 3,362 participants. Participants' ages ranged from 62.13 to 82.5 years, and the sample sizes ranged from 22 to 383. The shortest follow-up time was 12 months, and the longest was 98 months. Two articles lacked participant age information, 15 articles did not specify the location of vertebral fractures, and 9 articles were missing data on study duration. The basic characteristics of the included studies are detailed in Table 1.

Bias risk assessment

The bias risk assessment of the included trials based on Cochrane criteria is summarized in Figure 2. The results for each quality item are presented as percentages across studies. Ten articles did not report RCT design details, 14 articles had ambiguous random sequence generation, and 11 studies explicitly stated RCT design. Furthermore, 16 articles did not report details of allocation concealment, 15 articles provided unclear descriptions of allocation concealment, and 4 articles explicitly detailed the specifics of allocation concealment. Moreover, 21 articles did not report details of the blinding method, 11 articles provided unclear descriptions of the blinding, and 3 articles explicitly detailed the specifics of the blinding method. The quality assessment at the outcome level, conducted using the GRADE methodology, is summarized in Table 2. The overall evidence quality, evaluated according to GRADE criteria, was determined to be moderate to very low.



Primary meta-analysis results

Operation time

A total of 30 articles (15, 16, 18–27, 29–39, 41, 42, 44–48) reported the operation time with high heterogeneity (P < 0.00001, $I^2 = 97\%$), prompting the use of a random-effects model. The results revealed that unilateral PKP had shorter operation times compared to bilateral PKP (SMD = -15.09, 95% CI: -17.72 to -12.46, P < 0.00001; Figure 3). A sensitivity analysis was conducted to explore potential sources of heterogeneity, but no specific source was identified. The outcome quality level for operation time, as assessed by GRADE, was "very low."

Bone cement dose

A total of 27 articles (14–16, 18–27, 29, 30, 32–37, 41, 42, 44, 46–48) reported the bone cement dose. Significant heterogeneity was detected (P < 0.00001, $I^2 = 97\%$), necessitating the use of a random-effects model. The analysis indicated that unilateral PKP had a lower bone cement dose compared to bilateral PKP (SMD = -1.34, 95% CI: -1.76 to -0.93, P < 0.00001; Figure 4). A sensitivity analysis was performed to identify potential sources of heterogeneity, but no specific source was found. The outcome quality level for bone cement dose, as assessed by GRADE, was "very low."

Radiation dose

A total of 18 articles (18, 19, 21–23, 26, 27, 30–34, 38, 39, 41, 42, 47, 48) reported the radiation dose. High heterogeneity was observed (P < 0.00001, $I^2 = 94\%$), requiring a random-effects model. The meta-analysis indicated that unilateral PKP had a lower radiation dose compared to bilateral PKP (SMD = -2.14, 95% CI: -2.62 to -1.67, P < 0.00001; Figure 5). A sensitivity analysis was conducted to explore potential sources of heterogeneity, but no specific sources were identified. The outcome quality level for radiation dose, as assessed by GRADE, was "very low."

Cobb angle

A total of 20 articles (17, 19, 20, 22, 25–27, 29, 31–39, 46–48) reported the Cobb angle at post-operation and 1, 3, 6, and 12 months after surgery. High heterogeneity was observed (P < 0.00001, $I^2 = 66\%$), so a random-effects model was applied. Although the meta-analysis showed that unilateral PKP had a larger Cobb angle compared to bilateral PKP at 6 months after surgery (MD = 0.50, 95% CI: 0.29–0.71, P < 0.00001, Figure 6), there was no significant difference in post-operation, and 1, 3, and 12 months after surgery between unilateral PKP and bilateral PKP (P = 1.00, P = 0.54, P = 0.28, and P = 0.14, respectively; Figure 6). The outcome quality level for Cobb angle, as assessed by GRADE, was "low."

TABLE 1 Basic characteristics of the included studies.

Author	Year	Number of persons (I/C)	Age (I/C)	Intervention group	Control group	Vertebral fractures (I/C)	Study duration (months)	Outcome
Ceng YW	2013	12/14	NA	Unilateral bone cement	Bilateral bone cement	NA	6-12 (9)	28
Chen CM	2010	33/25	67.73/68.52	Unilateral bone cement	Bilateral bone cement	NA	NA	1289
Chen CM	2014	20/19	69.43/68.66	Unilateral bone cement	Bilateral bone cement	NA	NA	1291213
Chen L	2011	24/25	70.4/72.4	Unilateral bone cement	Bilateral bone cement	Lumbar 26 (I)/23(C); thoracic 29 (I)/36(C)	31.8/35.2	45671213
Cheng YH	2019	26/22	68.9/69.8	Unilateral bone cement	Bilateral bone cement	Lumbar 14 (I)/16(C); thoracic 16 (I)/16(C)	3	123803
Feng YH	2023	50/50	63.98/63.87	Unilateral bone cement	Bilateral bone cement	Lumbar 22 (I)/20(C); thoracic 28 (I)/30(C)	NA	1237891213
Geng ZH	2021	40/31	70.6/70.4	Unilateral bone cement	Bilateral bone cement	Lumbar 27 (I)/19(C); thoracic 13 (I)/12(C)	NA	127891213
Huang SC	2021	46/46	72.05/71.72	Unilateral bone cement	Bilateral bone cement	NA	NA	1234581213
Li L	2014	38/37	71.13/67.65	Unilateral bone cement	Bilateral bone cement	Lumbar 24 (I)/20(C); thoracic 18 (I)/20 (C)	24	12345780000203
Li Q	2012	50/41	73.1/70.8	Unilateral bone cement	Bilateral bone cement	NA	12-36	1238
Liu CL	2015	48/50	70.14/70.52	Unilateral bone cement	Bilateral bone cement	NA	15.81/15.42	128911213
Liu MX	2018	42/43	67.7/70.5	Unilateral bone cement	Bilateral bone cement	NA	12	1278911213
Lu JH	2022	37/42	67.4/70.3	Unilateral bone cement	Bilateral bone cement	Lumbar 20 (I)/21(C); thoracic 17 (I)/21(C)	24	1234567111213
Lu ZH	2022	175/208	72.3/74.1	Unilateral bone cement	Bilateral bone cement	Lumbar 79 (I)/93(C); thoracic 96 (I)/115(C)	28-98 (43.3)	1237891011213
Mu ZZ	2022	80/73	62.13/63.51	Unilateral bone cement	Bilateral bone cement	Lumbar 44 (I)/43(C); thoracic 36 (I)/36(C)	29.92/30.28	111213
Rebollede BJ	2013	23/21	78.7/79.3	Unilateral bone cement	Bilateral bone cement	Lumbar 7 (I)/2(C); thoracic 21 (I)/26(C)	NA	1271213
Shi X	2022	40/45	71.38/70.64	Unilateral bone cement	Bilateral bone cement	NA	NA	1234891213
Tan HT	2018	66/66	69.3/68.4	Unilateral bone cement	Bilateral bone cement	Lumbar 35 (I)/38(C); thoracic 44 (I)/48(C)	12	134781213
Tang J	2019	83/95	72.3/73.9	Unilateral bone cement	Bilateral bone cement	Lumbar 42 (I)/51(C); thoracic 41 (I)/44(C)	9.3/8.5	12345789113
Xiong XM	2019	38/25	69.7/69.4	Unilateral bone cement	Bilateral bone cement	Lumbar 26 (I)/14(C); thoracic 12 (I)/11(C)	12	1235789
Xu DL	2024	62/74	69.4/68.8	Unilateral bone cement	Bilateral bone cement	Lumbar 36 (I)/39(C); thoracic 26 (I)/35(C)	12	1237891213
Xue W	2017	38/38	67.89/69.37	Unilateral bone cement	Bilateral bone cement	Lumbar 23 (I)/22(C); thoracic 15 (I)/16(C)	12	125789
Yan L	2015	55/53	68.9	Unilateral bone cement	Bilateral bone cement	NA	12	127823
Yan L	2014	158/151	71.9/71.1	Unilateral bone cement	Bilateral bone cement	NA	12-28 (16.8)	12711213
Yang AF	2018	45/46	75.2/76.1	Unilateral bone cement	Bilateral bone cement	Lumbar 20 (I)/21(C); thoracic 25 (I)/25(C)	6–12	137890013
Yin F	2016	11/11	81.3/82.5	Unilateral bone cement	Bilateral bone cement	Thoracic 11 (I)/11(C)	13-35 (15.3)	137803
Yu Q	2020	16/16	68.74/70.91	Unilateral bone cement	Bilateral bone cement	NA	6	1213
Zhang L	2015	24/26	69.2/70.5	Unilateral bone cement	Bilateral bone cement	NA	24	123891213
Zhang LC	2023	36/35	72.69/71.86	Unilateral bone cement	Bilateral bone cement	Lumbar 31 (I)/30(C); thoracic 9 (I)/10(C)	NA	12389
Zhang LG	2015	36/32	70/70.7	Unilateral bone cement	Bilateral bone cement	NA	12	81213
Zhang YH	2020	32/28	NA	Unilateral bone cement	Bilateral bone cement	Lumbar 11 (I)/10(C); thoracic 25(I)/23(C)	6-13	181213
Zhang YT	2022	29/38	73.6/74.1	Unilateral bone cement	Bilateral bone cement	NA	14-27 (17.1)	128
Zhou MW	2013	30/37	67.1/67.1	Unilateral bone cement	Bilateral bone cement	NA	18-54 (28.6)	12457811213
Zhou RL	2020	59/59	72.3/72.3	Unilateral bone cement	Bilateral bone cement	Lumbar 30 (I)/32(C); thoracic 16(I)/15 (C)	NA	1234567891213
Zhou X	2019	69/69	71.47/70.47	Unilateral bone cement	Bilateral bone cement	Lumbar 14 (I)/16(C); thoracic 12(I)/10(C)	12	1237001213

① Operation time (min); ② cement dose (ml); ③ radiation dose; ④ anterior vertebral height; ⑤ Middle vertebral height; ⑥ Posterior vertebral height; ⑦ Cobb angle (°); ⑧ VAS; ⑨ ODI; ⑩ hospital stays; ⑪ refracture; ⑫ cement leakage; ⑬ overall complication rate;

05

NA, not available.



VAS scores

A total of 27 articles (14, 16, 18–25, 27, 30–36, 38, 39, 41–47) reported the VAS scores at post-operation, and 7 days, 1 month, 3 months, 6 months, 12 months, and 24 months after surgery. The heterogeneity was 30% (P = 0.02, $I^2 = 30\%$), necessitating the use of a random-effects model. There was no significant difference post-operation and 7 days, 1 month, 3 months, 12 months, and 24 months after surgery between unilateral PKP and bilateral PKP for VAS scores (P = 0.87, P = 0.58, P = 0.48, P = 0.67, P = 51, P = 0.99, and P = 0.91, respectively, Figure 7). The outcome quality level for VAS scores, as assessed by GRADE, was "moderate."

ODI scores

A total of 16 articles (15, 16, 19, 20, 24, 25, 27, 30, 32–35, 38, 41, 42, 47) reported the ODI scores at post-operation and 14 days, 1 month, 3 months, 6 months, 12 months, and 24 months after surgery. High heterogeneity was observed (P < 0.00001, $I^2 = 61\%$), so a random-effects model was applied. Although the metaanalysis showed that unilateral PKP had a higher ODI score compared to bilateral PKP at 6 months after surgery (MD = 0.53, 95% CI: 0.02–1.05, P = 0.04, Figure 8), there was no significant difference post-operation and 14 days, 1 month, 3 months, 12 months, and 24 months after surgery between unilateral PKP and bilateral PKP (P = 0.71, P = 0.27, P = 0.99, P = 0.17, P = 0.83, and P = 0.37, respectively, Figure 8). The outcome quality level for ODI scores, as assessed by GRADE, was "low."

Bone cement leakage

A total of 26 articles (15, 17–22, 24–31, 34, 36, 37, 39–41, 43, 45–48) reported bone cement leakage. No heterogeneity was observed (P = 0.12, $I^2 = 25\%$), so a fixed-effect model was used. The meta-analysis showed that unilateral PKP had a lower bone cement leakage rate compared to bilateral PKP (OR = 0.64, 95% CI: 0.51–0.80, P < 0.0001; Figure 9). The outcome quality level for bone cement leakage, as assessed by GRADE, was "moderate."

Overall complication rate

A total of 28 articles (15, 17–22, 24–32, 34, 36–41, 43, 45–48) reported the overall complication rate. No heterogeneity was observed (P = 0.002, $I^2 = 49\%$), so a fixed-effect model was used. The meta-analysis showed that unilateral PKP had a lower overall complication rate compared to bilateral PKP (OR = 0.67, 95% CI: 0.56–0.81, P < 0.0001; Figure 10). The outcome quality level for overall complication rate, as assessed by GRADE, was "moderate."

Secondary meta-analysis results

Vertebral height

A total of nine articles (17, 21, 22, 26, 30–32, 46, 47) reported the anterior vertebral height, nine articles (17, 21, 22, 26, 32, 33, 35, 46, 47) reported the mid-vertebral height, and three articles (17, 26, 47) reported the posterior vertebral height. These results did not have significant heterogeneity (P = 0.66, $I^2 = 0\%$; P = 0.59, $I^2 = 0\%$; P = 0.83, $I^2 = 0\%$, respectively), so fixed-effect model was used. There was no significant difference in anterior vertebral height (SMD = -0.04, 95% CI: -0.17 to 0.10, P = 0.59; see Supplementary File 2, Figure S1), mid-vertebral height (SMD = -0.05, 95% CI: -0.19 to 0.09, P = 0.51; see Supplementary File 2, Figure S2), and posterior vertebral height (SMD = 0.04, 95% CI: -0.21-0.29, P = 0.74; see Supplementary File 2, Figure S3) between unilateral PKP and bilateral PKP. The outcome quality level for vertebral height, as assessed by GRADE, was "low."

Follow-up of vertebral height

A total of five articles (32, 33, 44, 46, 48) reported vertebral height at a 6-month follow-up, including anterior vertebral height and mid-vertebral height. No significant heterogeneity was observed (P = 0.59, $I^2 = 0\%$; P = 0.17, $I^2 = 41\%$, respectively), so a fixed-effect model was applied. There was no significant difference at a 6-month follow-up, including anterior vertebral height (SMD = -0.15, 95% CI: -0.34 to 0.03, P = 0.11; see

TABLE 2. GRADE assessment of clinical outcomes.

Certainty asse	essment						No. of p	atients	Efi	fect	Certainty	Importance
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Unilateral PKP	Bilateral PKP	Relative (95% CI)	Absolute (95% CI)		
OT (N = 30)	RCTs	Serious ^a	Very serious ^c	Not serious	Very Serious ^e	No	1,530	1,556	MD -15.09 (-	17.72 to -12.46)	⊕⊖⊖⊖ Very low	Important
Bone cement dose $(N = 27)$	RCTs	Serious ^a	Very serious ^c	Not serious	No	No	1,355	1,402	MD -1.34 (-	-1.76 to -0.93)	⊕⊖⊖⊖ Very low	Important
Radiation dose $(N = 18)$	RCTs	Serious ^a	Very serious ^c	Not serious	Very Serious ^e	No	955	997	SMD -2.14 (*	-2.62 to -1.67)	⊕⊖⊖⊖ Very low	Important
Cobb angle $(N = 20)$	RCTs	Serious ^a	Serious ^b	Not serious	No	No	1,902	1,953	MD 0.05 (-	-0.17 to 0.28)	⊕⊕⊖⊖ Low	Important
VAS (N = 27)	RCTs	Serious ^a	Not serious	Not serious	Not serious	No	2,559	2,598	MD 0.01 (-	-0.03 to 0.05)	⊕⊕⊕⊖ Moderate	Important
ODI (N = 16)	RCTs	Serious ^a	Serious ^b	Not serious	Not serious	No	1,700	1,745	MD -0.06 (-0.44 to 0.32)	⊕⊕⊖⊖ Low	Important
Bone cement leakage $(N = 26)$	RCTs	Serious ^a	No serious	Not serious	Not serious	No	165/1,330 (12.4%)	236/1,355 (17.4%)	OR 0.64 (0.51 to 0.80)	⊕⊕⊕⊖ Moderate	Important
Overall complication (N = 28)	RCTs	Serious ^a	Not serious	Not serious	Not serious	No	243/1,548 (15.7%)	334/1,516 (22.0%)	OR 0.67 (0.56 to 0.81)	⊕⊕⊕() Moderate	Important
Anterior vertebral height $(N=9)$	RCTs	Serious ^a	Not serious	Not serious	Serious ^d	No	422	453	SMD -0.04	(-0.17 to 0.1)	⊕⊕⊖⊖ Low	Not important
Middle vertebral height $(N = 9)$	RCTs	Serious ^a	Not serious	Not serious	Serious ^d	No	392	405	SMD -0.05	(-0.19 to 0.09)	⊕⊕⊖⊖ Low	Not important
Posterior vertebral height $(N=3)$	RCTs	Serious ^a	Not serious	Not serious	Serious ^d	No	120	126	SMD 0.04 (-0.21 to 0.29)	⊕⊕⊖⊖ Low	Not important
6 months follow-up height $(N = 5)$	RCTs	Serious ^a	Not serious	Not serious	Serious ^d	No	440	460	SMD -0.14	(-0.27 to 0.00)	⊕⊕⊖⊖ Low	Not important
12 months follow- up height $(N=3)$	RCTs	Serious ^a	Not serious	Not serious	Not serious	No	142	129	MD 0.07 (-	-0.33 to 0.47)	⊕⊕⊕⊖ Moderate	Not important
Cobb angle improvement (N=3)	RCTs	Serious ^a	Not serious	Not serious	Very Serious ^e	No	144	137	SMD -0.03	(-0.35 to 0.29)	⊕⊖⊖⊖ Very low	Not important
Hospital days (N = 4)	RCTs	Serious ^a	Not serious	Not serious	Not serious	No	327	360	MD -0.16 (-0.57 to 0.26)	⊕⊕⊕⊖ Moderate	Not important
Refracture $(N = 11)$	RCTs	Serious ^a	Not serious	Not serious	Not serious	No	73/802 (9.1%)	75/846 (8.9%)	OR 1.00 (0.71 to 1.40)	⊕⊕⊕⊖ Moderate	Important
Postoperative pain $(N = 3)$	RCTs	Serious ^a	Not serious	Not serious	Not serious	No	17/208 (8.2%)	25/211 (11.8%)	OR 0.60 (0.31 to 1.17)	⊕⊕⊕() Moderate	Not important

CI, confidence interval; OR, odds ratio; SMD, standardized mean difference; MD, mean difference.

a>50% of trials received a "high" risk of bias rating (≥ 1 out of six dimensions in the Cochrane Risk of Bias tool).

 ${}^{b}I^{2}$ between >50% and \leq 75% in either direction.

 $^{\rm c}I^2 > 75\%$ in either direction.

^d95% CI of an SMD extends between >0.2 and ≤0.5 points in either direction, 95% CI of an MD extends between >2.0 and ≤5.0 points in either direction.

°95% CI of an SMD extends >0.5 points in either direction, 95% CI of an MD extends >5.0 points in either direction.

	Ur	nllatera	l i	В	llateral			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV. Random, 95% Cl
Chen CM 2010	33.84	4.02	33	59.37	5.34	25	3.5%	-25.53 [-28.03, -23.03]	
Chen CM 2014	31.12	5.23	20	52.34	6.45	19	3.4%	-21.22 [-24.92, -17.52]	
Cheng YH 2019	20.7	10.6	26	37.9	6.9	22	3.2%	-17.20 [-22.19, -12.21]	
Feng YH 2023	31.98	4.28	50	40.98	4.32	50	3.6%	-9.00 [-10.69, -7.31]	T
Geng ZH 2021	39.61	4.48	40	55.42	5.72	31	3.5%	-15.81 [-18.26, -13.36]	
Huang SC 2021	24.18	6.83	46	34.58	7.14	46	3.5%	-10.40 [-13.26, -7.54]	
Li L 2014	44.92	11.93	38	69.86	17.07	37	2.9%	-24.94 [-31.62, -18.26]	
Li Q. 2012	40	22	50	54	25	41	2.4%	-14.00 [-23.78, -4.22]	
Liu CL 2015	34.87	5.91	48	41.66	6.9	50	3.5%	-6.79 [-9.33, -4.25]	
Liu MX 2018	25.6	4.2	42	36.6	8.7	43	3.5%	-11.00 [-13.89, -8.11]	
Lu JH 2022	49.6	7.4	37	58.3	9	42	3.4%	-8.70 [-12.32, -5.08]	
Lu ZH 2022	50.7	16.7	175	63.6	17.8	208	3.4%	-12.90 [-16.36, -9.44]	
Rebollede BJ 2013	47.6	7.8	23	71.4	21.5	21	2.4%	-23.80 [-33.53, -14.07]	
Shi X 2022	43.3	19.58	40	55.16	11.56	45	2.9%	-11.86 [-18.80, -4.92]	
Tan HT 2018	40.3	7.6	66	56.1	8.3	66	3.5%	-15.80 [-18.52, -13.08]	
Tang J 2019	29.8	2.7	83	31.5	3.9	95	3.6%	-1.70 [-2.68, -0.72]	-
Xiong XM 2019	36.54	10.23	38	50.26	12.06	25	3.1%	-13.72 [-19.46, -7.98]	
Xu DL 2024	35.9	3.3	62	44.9	3.8	74	3.6%	-9.00 [-10.19, -7.81]	-
Xue W 2017	38.55	4.54	38	58.23	5.93	38	3.5%	-19.68 [-22.0517.31]	-
Yan L 2014	33.2	5.1	158	52.5	10.9	151	3.6%	-19.30 [-21.21, -17.39]	
Yan L 2015	15.6	4.2	55	38.6	7.9	53	3.5%	-23.00 [-25.4020.60]	
Yang AF 2018	31	3	45	40	4	46	3.6%	-9.00 [-10.45, -7.55]	-
Yin F 2016	37.2	2.7	11	53.8	3.6	11	3.5%	-16.60 [-19.2613.94]	
Zhang L 2015	41.2	5.2	24	55.7	7.3	26	3.4%	-14.50 [-17.99, -11.01]	
Zhang LC 2023	35.08	3.71	36	44.71	3.73	35	3.6%	-9.63 [-11.36, -7.90]	-
Zhang YH 2020	37.3	7.13	59	42.29	9.03	53	3.5%	-4.99 [-8.03, -1.95]	
Zhang YT 2022	34.3	5.7	29	48.1	6.6	38	3.5%	-13.80 [-16.7510.85]	
Zhou MW 2013	56	23	30	98	21	37	2.3%	-42.00 [-52.65, -31.35]	←
Zhou RL 2020	34.23	9.01	59	55.22	6.38	59	3.5%	-20.99 [-23.8118.17]	
Zhou X 2019	25.47	5.69	69	44.68	6.13	69	3.6%	-19.21 [-21.18, -17.24]	-
Total (95% CI)			1530			1556	100.0%	-15.09 [-17.72, -12.46]	◆
Heterogeneity: Tau ² =	49.44: C	;hi² = 10	009.25.	df = 29	(P < 0.0)0001):	² = 97%		
Test for overall effect:	Z = 11.2	6 (P < 0	0.0000	1)		,			-20 -10 0 10 20
									Favours [Unilateral] Favours [Bilateral]
iURE 3									
orest plot showing	the one	ration t	time						

Supplementary File 2 Figure S4) and mid-vertebral height (SMD = -0.12, 95% CI: -0.31 to 0.07, P = 0.22; see Supplementary File 2, Figure S4) between unilateral PKP and bilateral PKP. The outcome quality level for vertebral height at a 6-month follow-up, as assessed by GRADE, was "low."

A total of three articles (31, 33, 35) reported vertebral height at a 12-month follow-up. No significant heterogeneity was observed (P = 0.21, $I^2 = 36\%$), so a fixed-effect model was applied. There was no significant difference at a 12-month follow-up between unilateral PKP and bilateral PKP (MD = 0.07, 95% CI: -0.33 to 0.47, P = 0.73; see Supplementary File 2, Figure S5). The outcome quality level for vertebral height at a 12-month follow-up, as assessed by GRADE, was "moderate."

Cobb angle improvement

A total of three articles (21, 23, 24) reported Cobb angle improvement. No significant heterogeneity was observed (P = 0.16, $I^2 = 46\%$). There was no significant difference in Cobb angle improvement between unilateral PKP and bilateral PKP (SMD = -0.03, 95% CI: -0.35 to 0.29, P = 0.86; see Supplementary File 2, Figure S6). The outcome quality level for Cobb angle improvement, as assessed by GRADE, was "very low."

Hospital stays

A total of four articles (22, 27, 38, 48) reported hospital stays. No significant heterogeneity was observed (P = 0.78, $I^2 = 0\%$). There was no significant difference in hospital stays between unilateral PKP and bilateral PKP (MD = -0.16, 95% CI: -0.57 to 0.26, P = 0.46; see Supplementary File 2, Figure S7). The outcome quality level for hospital stays, as assessed by GRADE, was "moderate."

Refracture rate

A total of 11 articles (22, 24–28, 32, 37, 38, 46, 48) reported a refracture rate. No significant heterogeneity was observed (P = 0.71, $I^2 = 0\%$). There was no significant difference in refracture rate between unilateral PKP and bilateral PKP (OR = 1.00, 95% CI: 0.71–1.40, P = 1.00; see Supplementary File 2: Figure S8). The outcome quality level for refracture rate, as assessed by GRADE, was "moderate."

Postoperative pain rate

A total of three articles (28, 34, 48) reported a postoperative pain rate. No significant heterogeneity was observed (P = 0.36, $I^2 = 1\%$). There was no significant difference in postoperative pain rate between unilateral PKP and bilateral PKP (OR = 0.60, 95% CI: 0.31–1.17, P = 0.13; see Supplementary File 2, Figure S9).

Pérusha an Prohanaran	Maan	en	Tetal	Maan	en	Tetel	Walashi	Near Difference	Wear ofference
Study of Subgroup	mean	- 30		Mean	30	Total		IV. Kandom, 95% CI	14. Random, 95% Ci
Ceng YW 2013	4.3	2.3	12	4.6	2.5	14	2.2%	-0.30 [-2.15, 1.55]	
Chen CM 2010	4.11	1.25	27	5.82	1.9/	33	3.5%	-1.71 [-2.53, -0.89]	
Chen CM 2014	3.17	1.24	20	4.35	1.14	19	3.6%	-1.19 [-1.94, -0.44]	
Cheng YH 2019	3.5	1.1	26	6.3	1.6	22	3.5%	-2.80 [-3.59, -2.01]	
Feng YH 2023	4.28	0.72	50	5.99	0.68	50	4.0%	-1.71 [-1.98, -1.44]	
Geng ZH 2021	3.46	0.33	40	5.06	0.37	31	4.0%	-1.60 [-1.77, -1.43]	
Huang SC 2021	4.38	1.04	46	5.22	1.17	46	3.9%	-0.84 [-1.29, -0.39]	
Li L 2014	4.6	0.97	38	6.49	0.97	37	3.9%	-1.89 [-2.33, -1.45]	
Li Q 2012	2.6	1.8	50	5.4	2.2	41	3.5%	-2.80 [-3.64, -1.96]	
Liu CL 2015	6.2	0.66	48	4.88	0.52	50	4.0%	1.32 [1.08, 1.56]	
Liu MX 2018	6.2	3.5	42	8.5	2.2	43	3.0%	-2.30 [-3.55, -1.05]	
Lu JH 2022	5	0.8	37	6.3	0.7	42	4.0%	-1.30 [-1.63, -0.97]	
Lu ZH 2022	3.7	1.9	175	6.5	2.1	208	3.9%	-2.80 [-3.20, -2.40]	
Rebollede BJ 2013	4.8	1.7	23	6.3	2.4	21	3.0%	-1.50 [-2.74, -0.26]	
Shi X 2022	5.08	0.97	40	5.56	0.85	45	3.9%	-0.48 [-0.87, -0.09]	
Tang J 2019	3.1	0.7	83	3.5	1.2	95	4.0%	-0.40 [-0.68, -0.12]	-
Xiong XM 2019	4.62	1.03	38	5.57	1.08	25	3.8%	-0.95 [-1.49, -0.41]	
Xu DL 2024	4.2	5	62	5	0.3	74	3.0%	-0.80 [-2.05, 0.45]	
Xue W 2017	3.43	0.41	38	5.73	0.52	38	4.0%	-2.30 [-2.51, -2.09]	-
Yan L 2014	3.4	0.8	158	5.5	0.7	151	4.0%	-2.10 [-2.27, -1.93]	-
Yan L 2015	6.2	0.6	55	8.5	0.8	53	4.0%	-2.30 [-2.57, -2.03]	-
Zhang L 2015	3.1	0.4	24	5	0.5	26	4.0%	-1.90 [-2.15, -1.65]	-
Zhang LC 2023	6.68	1.08	36	5.81	0.76	35	3.9%	0.87 [0.44, 1.30]	
Zhang YT 2022	4.3	1.1	29	4.1	1.3	38	3.8%	0.20 [-0.38, 0.78]	- <u>+</u>
Zhou MW 2013	3	1.5	30	4.4	1.9	37	3.5%	-1.40 [-2.21, -0.59]	
Zhou RL 2020	3.21	0.42	59	5.07	0.69	59	4.0%	-1.86 [-2.07, -1.65]	-
Zhou X 2019	3.37	0.82	69	4.68	0.91	69	4.0%	-1.31 [-1.60, -1.02]	-
Total (95% Cl)			1355			1402	100.0%	-1.34 [-1.76, -0.93]	◆
Heterogeneity: Tau ² =	1.10; Ch	ni² = 10	026.90,	df = 26	(P < 0	.00001); l² = 97%	. –	
Test for overall effect:	Z = 6.35	(P < (0.00001)					-+ -2 U 2 4 Eavoure [Bilateral] Eavoure [Unilateral]
SURE 4									

	В	llateral		Un	llatera	ıl		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Cheng YH 2019	9.3	3.9	26	18	3.1	22	5.4%	-2.41 [-3.16, -1.65]	
Feng YH 2023	15.98	3.12	50	19.34	3.09	50	5.9%	-1.07 [-1.49, -0.65]	-
Huang SC 2021	16.17	4.05	46	27.68	4.28	46	5.7%	-2.74 [-3.31, -2.16]	
Li L 2014	20.89	6.12	38	46.78	9.65	37	5.5%	-3.18 [-3.87, -2.49]	
Li Q 2012	11.9	2.2	50	19.5	2	41	5.5%	-3.57 [-4.24, -2.90]	-
Lu JH 2022	32.7	4.6	37	34.4	5.7	42	5.9%	-0.32 [-0.77, 0.12]	
Lu ZH 2022	15.2	10.8	175	28.6	12.9	208	6.1%	-1.12 [-1.33, -0.90]	*
Shi X 2022	30.05	17.41	40	43.42	8.64	45	5.9%	-0.98 [-1.43, -0.53]	-
Tan HT 2018	15.3	4.2	66	26.5	5.6	66	5.9%	-2.25 [-2.69, -1.81]	+
Tang J 2019	9.3	2.6	83	11.2	3.7	95	6.1%	-0.58 [-0.89, -0.28]	+
Xiong XM 2019	17.98	2.58	38	20.16	3.02	25	5.8%	-0.78 [-1.30, -0.26]	-
Xu DL 2024	30	4.3	62	38.5	2.6	74	5.9%	-2.43 [-2.88, -1.98]	
Yang AF 2018	18	2	45	27	5	46	5.8%	-2.33 [-2.87, -1.80]	
Yin F 2016	28.7	2.6	11	52	4.9	11	2.9%	-5.71 [-7.76, -3.67]	
Zhang L 2015	33.7	5.2	24	46.5	6.6	26	5.5%	-2.11 [-2.81, -1.41]	
Zhang LC 2023	18.44	1.61	36	28.49	1.52	35	4.5%	-6.35 [-7.52, -5.18]	
Zhou RL 2020	19.42	6.22	59	31.05	7.54	59	5.9%	-1.67 [-2.09, -1.25]	+
Zhou X 2019	10.47	3.25	69	18.96	4.76	69	5. 9 %	-2.07 [-2.49, -1.66]	-
Total (95% CI)			955			997	100.0%	-2.14 [-2.62, -1.67]	•
Heterogeneity: Tau ² =	0.94; Cł	ni² = 302	2.93, df	= 17 (P	< 0.00	0001); I	² = 94%	-	
Test for overall effect:	Z = 8.89	(P < 0.	00001)						
									Favours [Bilateral] Favours [Unilateral]

FIGURE 5

A forest plot showing the radiation dose.

	Bi	lateral	1 10-11 - 100 - 100	Uni	ilatera	I		Mean Difference	Mean Difference
itudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.8.1 Post-operation								The second dense with the residence	
Chen L 2011	17.2	7.8	24	19.8	9.1	25	0.2%	-2.60 [-7.34, 2.14]	
Geng ZH 2021	11.16	6.1	40	10.65	5.53	31	0.7%	0.51 [-2.20, 3.22]	
_i L 2014	11.22	4.92	38	11.18	3.66	37	1.2%	0.04 [-1.92, 2.00]	
Liu MX 2018	9.1	4.3	42	11.8	3.8	43	1.4%	-2.70 [-4.43, -0.97]	•
Lu JH 2022	9.86	2.55	37	9.45	3.41	42	2.2%	0.41 [-0.91, 1.73]	
Rebollede BJ 2013	4.8	4	23	4.7	4.6	21	0.7%	0.10 [-2.46, 2.66]	
Fan HT 2018	18.1	4.1	66	17.2	3.3	66	2.3%	0.90 [-0.37, 2.17]	
Fang J 2019	23.5	2.8	83	22.8	2.6	95	3.9%	0.70 [-0.10, 1.50]	
Kiong XM 2019	8.66	2.51	38	8.46	2.66	25	2.2%	0.20 [-1.11, 1.51]	
Ku DL 2024	6.9	0.9	62	6.6	1	74	6.6%	0.30 [-0.02, 0.62]	
(ue W 2017	14.73	1.44	38	14.49	1.34	38	4.8%	0.24 [-0.39, 0.87]	-
/an L 2015	9.1	4.7	55	11.8	3.9	53	1.6%	-2.70 [-4.33, -1.07]	
/in F 2016	14.1	1.9	11	15	2	11	1.6%	-0.90 [-2.53, 0.73]	
Chou MW 2013	12.89	1.84	30	12.51	2.15	37	3.3%	0.38 [-0.58, 1.34]	
2hou RL 2020	8.52	4.34	59	8.04	4.45	59	1.6%	0.48 [-1.11, 2.07]	
Subtotal (95% CI)			646			657	34.2%	-0.00 [-0.45, 0.45]	
leterogeneity: Tau ² = (0.31; CH	11 ² = 29	.64, df	= 14 (P	= 0.00)9); l² =	: 53%		
est for overall effect: 2	2 = 0.01	(P = 1	.00)						
821 month									
1 7H 2022	11 2	4 9	175	10.9	F 2	200	3 00/	0.50 [_0.51 4.54]	
(iong YM 2010	11.3	4.0	1/0	9.40	0.0	200	3.0%	0.00 [-0.01, 1.01]	
	0.00	2.40	30	0.40	2.02	20	2.2%	0.10[-1.11, 1.47]	
ang AF 2016 Subtotal (95% CI)	11.74	2.00	40 259	11.00	2.12	40 270	2.1%	-0.14 [-1.24, 0.90] 0.20 [_0.45 0.851	
Heterogeneity: Tou ² - /		ni² = ∩ *	200 70 -#-	= 2 (P -	0 701.	 2 ∩0/	0.078	0.20 [-0.40, 0.00]	
Test for overall effect: 2	2.00, Of 7 = 0.61	(P=1)	54)	~ (P =	5.70),	0%	,		
rest for overall effect. 2	0.01	(i – v)						
.8.3 3 months									
ena YH 2023	9.21	1.23	50	9.42	1.32	50	5.6%	-0.21 [-0.71, 0.29]	
Geng ZH 2021	10.89	6.25	40	10.65	5 44	31	0.6%	0.24 [-2.48, 2.96]	
Cang J 2019	23.1	2.4	83	22.4	2.5	95	4.3%	0.70 [-0.02, 1.42]	
(u DI 2024	83	04	62	82	0.6	74	7.3%	0 10 [-0.07 0 27]	
(and AF 2018	11 98	2 54	45	11.87	2 46	46	3.0%	0 11 [-0 92 1 14]	
Subtotal (95% CI)	11.00	2.04	280	11.07	2.40	296	20.8%	0.10 [-0.08, 0.28]	•
Heterogeneity: Tau ² = (0.00: CH	ni² = 4.1	15. df =	= 4 (P =	0.39):	² = 4%			
Fest for overall effect: 2	Z = 1.09	(P = 0	.28)	. (.	,				
		`							
1.8.4 6 months									
Fang J 2019	23.4	2. 9	83	22.6	2.7	95	3.8%	0.80 [-0.03, 1.63]	
Kiong XM 2019	8.67	2.52	38	8.48	2.62	25	2.2%	0.19 [-1.11, 1.49]	
(u DL 2024	9.8	0.7	62	9.3	0.6	74	7.1%	0.50 [0.28, 0.72]	
Zhou X 2019	12.04	3.74	69	11.86	3.51	69	2.4%	0.18 [-1.03, 1.39]	
Subtotal (95% CI)			252			263	15.5%	0.50 [0.29, 0.71]	•
Heterogeneity: Tau ² = (0.00; Cł	1i² = 0.9	99, df =	= 3 (P =	0.80);	l² = 0%		_	
est for overall effect: 2	Z = 4.73	(P < 0	.00001)					
.8.5 12 months									
iu MX 2018	9.3	5.5	42	11.5	3.5	43	1.1%	-2.20 [-4.16, -0.24]	
fan HT 2018	18.6	4.2	66	17.6	3.4	66	2.2%	1.00 [-0.30, 2.30]	· · · ·
Kiong XM 2019	8.69	2.57	38	8.51	2.68	25	2.1%	0.18 [-1.15, 1.51]	
(u DL 2024	9.7	0.6	62	9.2	0.8	74	7.0%	0.50 [0.26, 0.74]	,
'an L 2014	9.25	5.41	158	12.29	5.36	151	2.5%	-3.04 [-4.24, -1.84]	
/an L 2015	9.3	5.1	55	11.5	3.8	53	1.5%	-2.20 [-3.89, -0.51]	••••
ang AF 2018	12.33	1.41	45	12.54	1.34	46	5.2%	-0.21 [-0.78, 0.36]	
iubtotal (95% CI)			466			458	21.6%	-0.70 [-1.65, 0.24]	
leterogeneity: Tau ² = 1	1.25; Cł	1i² = 50	.98, df	= 6 (P <	< 0.000	001); l²	= 88%		
est for overall effect: 2	Z = 1.46	(P = 0	.14)						
			4000			4070	400.00	0 00 F 0 40 0 00-	_
			1902			1953	100.0%	0.05 [-0.17, 0.28]	— — — — — — — — — —
Fotal (95% CI)	AD. 01	ıı² = 95	.85, df	= 33 (P	< 0.00	0001); I	* = 66%		-2 -1 0 1 2
Fotal (95% CI) Heterogeneity: Tau ² = (0.18; Cr	-							
Fotal (95% CI) leterogeneity: Tau ² = (rest for overall effect: 2	2 = 0.47	(P = 0	.64)		_		_		Favours [Bilateral] Favours [Unilateral]
otal (95% CI) leterogeneity: Tau ² = (est for overall effect: 2 est for suboroup differ	z = 0.47 rences:	(P = 0 Chi² =	.64) 13.39.	df = 4 (P = 0.0)10). I²	= 70.1%		Favours [Bilateral] Favours [Unilateral]
otal (95% CI) leterogeneity: Tau ² = (est for overall effect: 2 est for suboroup differ	2 = 0.47 rences:	' (P = 0 Chi² =	.64) 13.39.	df = 4 (P = 0.0)10). I²	= 70.1%		Favours [Bilateral] Favours [Unilateral]

frontiersin.org

<pre>1.1.1 - Transparaments 1.1.1 - Transpara</pre>	Study or Subgroup	Mean SD	Fotal Mean	BD Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Chang Mr 2019 2 2 0 7 20 2 2 1 7 20 2 0 55 0 0 37 0 0 200 0	Cong YW 2013	2.1 0.9	12 2.3	.7 14	0.3%	-0.20 [-0.83. 0.43]	
Li 2014 Li	Cheng YH 2019	2.6 0.7	26 2.7 0	.7 22	0.8%	-0.10 [-0.50, 0.30]	
La C. 2016 La C. 2016 La C. 2016 La C. 2016 Si X. 2022 La C. 2017 Si X. 2022 La C. 2017 Si X. 2022 La C. 2017 La C.	Li L 2014	2.74 0.79	38 2.59 1.	01 37 B 41	0.8%	0.15 [-0.26, 0.56]	
Lis MX 2015 2.7 1.2 42 2.8 1.3 43 0.5% 0.010 0.4% 0.030 The LT 2018 2.4 0.7 4 0.5 2.4 0.67 4 0.1 1.4% 0.010 0.4% 0.030 The LT 2018 2.4 0.7 4 0.5 2.4 0.67 4 0.1 0.4% 0.010 0.4% 0.040 MX DL 2024 2.8 0.9 42 2.8 0.0 74 1.5% 0.010 0.4% 0.040 MX DL 2024 2.8 0.9 42 2.7 0.0 8 0.2% 0.040 0.4% 0.040 MX DL 2024 2.8 0.9 42 2.7 0.0 8 0.2% 0.040 0.4% 0.040 MX DL 2024 2.8 0.9 42 2.7 0.0 8 0.2% 0.040 0.4% 0.040 MX DL 2024 0.2 8 0.4 0.9 3 72 0.0 8 0.2% 0.040 0.7% 0.050 MX DL 2024 0.2 8 0.4 0.9 3 72 0.0 2.3 0.1 4.3 0.2% 0.041 0.7% 0.050 MX DL 2024 0.2 8 0.4 0.9 71 0.2% 0.041 0.7% 0.050 MX DL 2024 0.2 40 1.7 7 0.0 0.07 + 0.000 MX DL 2024 0.2 40 1.7 7 0.0 0.07 + 0.000 MX DL 2026 0.270 0.2 2.8 0.1 4.8 0.2 2.1 0.2% 0.041 0.7% 0.070 MX DL 2026 0.270 0.2 2.8 0.1 4.8 0.2 2.1 0.2% 0.041 0.7% 0.070 MX DL 2026 0.271 0.2 2.8 0.1 4.8 0.2 1.0 0.4 0.2 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	Liu CL 2015	4.05 0.12	48 4.08 (.1 50	8.6%	-0.01 [-0.05, 0.03]	+
Bix X 2022 2.23 6.7 40 2.42 0.57 45 1.1% $-0.16 0.50, 0.16 0.50, 0.16 0.50, 0.16 0.50, 0.50 0.50,$	Liu MX 2018	2.7 1.2	42 2.6	.3 43	0.5%	0.10 [-0.43, 0.63]	
$ \begin{array}{c} \mbox{Int} \ Delta \ D$	Shi X 2022	2.23 0.7	40 2.42 0.	87 45	1.1%	-0.19 [-0.52, 0.14]	
$ \begin{aligned} \begin{split} & \lim_{n \to \infty} X_n (x_n) = 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0$	Tang J 2019	2.4 0.6 3.5 1.4	83 3.2	1 95	2.0%	0.30 [-0.06, 0.66]	<u> </u>
$ \begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Xiong XM 2019	3.5 0.91	38 3.42 1.	07 25	0.5%	0.08 [-0.43, 0.59]	
Add my and hy an	Xu DL 2024	2.9 0.9	62 2.8 0	.8 74	1.5%	0.10 [-0.19, 0.39]	
Zimag L2 2023 3.74 0.06 3.85 2.16 0.06 0.05 0.07 0.22 0.06 0.06 0.05 0.06	Xue W 2017 Zhang L 2015	2.85 0.42	38 2.74 0.	58 38 19 26	2.1%	0.11 [-0.12, 0.34]	
Zhang YH 2020 2.48 1.08 69 2.45 2.39 1.48 7.28 0.06 [0.45, 0.27] Weatering Top: Top: 0.00; To = 4.00; P = 0.02; P = 0.5 2.39 1.48 7.28 0.06 [0.45, 0.27] Weatering Top: Top: 0.00; To = 4.00; P = 0.02; P = 0.5 2.39 1.48 0.28 0.06 [0.45, 0.27] Test for ownell efficit: 2 = 0.17 (P = 0.07) 1.13 0.08 0.06 [0.45, 0.27] 0.07 Test for ownell efficit: 2 = 0.00; Ch ⁺ = 1.07; ell 3.0 1.1 0.35 0.06 [0.45, 0.42] Standp L 2001; Ch ⁺ = 0.07 8.5 0.48 1.02 0.29 [0.45, 0.50] Win F 2018 3.40 0.31 0.35 0.46 0.20 [0.45, 0.50] Win L 2016 2.27 1.28 0.48 0.20 [0.45, 0.50] 0.10 [0.45, 0.57] Win L 2016 2.28 1.17 2.28 0.48 0.20 [0.45, 0.50] Win L 2016 2.28 1.02 2.08 0.44 0.20 [0.45, 0.50] Win L 2016 2.03 2.07 0.8 0.44 0.26 [0.45, 0.57] Win L	Zhang LC 2023	3.74 0.45	36 3.71 0.	41 35	2.6%	0.03 [-0.17, 0.23]	
$ \begin{array}{c} \text{Data law often} & \text{Dia } 1, 24, 1, 7, 28 \\ \text{dia } 1, 39, 28 \\ \text{dia } 1, 39, 20, 10 \\ \text{dia } 1, 39, 20, 11 \\ \text{dia } 1, 30, 20, 10 \\ \text{dia } 1, 30, 20, 11 \\ di$	Zhang YH 2020	2.56 1.08	59 2.65 0.	87 53	1.0%	-0.09 [-0.45, 0.27]	
Text crownel affect 2 = 0.17 (P = 0.87); H = 05, Text crownel affect 2 = 0.17 (P = 0.87); H = 05, Text crownel affect 2 = 0.17 (P = 0.87); H = 05, Text crownel affect 2 = 0.17 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.05 (P = 0.87); H = 05, Text crownel affect 2 = 0.07 (P = 0.87); H = 05, Text crownel affect 2 = 0.07 (P = 0.87); H = 05, Text crownel affect 2 = 0.07 (P = 0.87); H = 05, Text crownel affect 2 = 0.07 (P = 0.87); H = 05, Text crownel affect 2 = 0.07 (P = 0.87); H = 05, Text crownel affect 2 = 0.07 (P = 0.87); H = 05, Text crownel affect 2 = 0.07 (P = 0.87); H = 05, Text crownel affect 2 = 0.07 (P = 0.87); H = 05, Text crownel affect 2 = 0.07 (P = 0.87); H = 05, Text crownel affect 2 = 0.07 (P = 0.87); H = 05, Text crownel affect 2 = 0.07 (P = 0.87); H = 05, Text crownel affect 2 = 0.02 (P = 0.87); H = 05, Text crownel affect 2 = 0.02 (P = 0.87); H = 05, Text crownel affect 2 = 0.02 (P = 0.87); H = 05, Text crownel affect 2 = 0.02 (P = 0.87); H = 05, Text crownel affect 2 = 0.02 (P = 0.87); H = 05, Text crownel affect 2 = 0.02 (P = 0.87); H = 05, Text crownel affect 2 = 0.02 (P = 0.87); H = 05, Text crownel affect 2 = 0.02 (P = 0.88); H = 05, Text crownel affect 2 = 0.02 (P = 0.88); H = 05, Text crownel affect 2 = 0.02 (P = 0.88); H = 05, Text crownel affect 2 = 0.02 (P = 0.88); H = 0	Zhou MW 2013 Subtotal (95% CI)	2.42 1.72	30 2.38 1. 692	34 37 701	23.9%	-0.00 [-0.04, 0.04]	•
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Heterogeneity: Tau ² = 0 Test for overall effect: 2	0.00; Chi² = 8.0 Z = 0.17 (P = 0.	2, df = 15 (P = 0 87)	.92); * = 0	%		
Yin F 2016 3.4 0.8 11 3 0.6 11 0.3% 0.4 010-23.0.05 Zinng LG 2027 2.28 0.74 38 2.59 0.35 2.5% 0.010-238,0.05 Zinng LG 2015 2.89 0.74 38 2.51 0.64 32 1.2% 0.021-031,0.35 Wearcagenity: Trut = 0.00; CPH = 1.87, d= 2 (P = 0.37; h= 0.5 The for own affect 2 = 0.55 (P = 0.37; h= 0.5 The for own affect 2 = 0.55 (P = 0.37; h= 0.5 Xing XM 2019 2.35 0.94 38 2.31 0.98 25 0.5% 0.001-045,0.53 Xing XM 2019 2.35 0.94 38 2.31 0.98 25 0.5% 0.001-045,0.53 Xing XM 2019 2.35 0.94 38 2.31 0.98 25 0.5% 0.001-045,0.53 Xing XM 2019 2.35 0.94 48 2.56 12.7 4.6 0.3% 0.010-045,0.45 Yin L 2016 2.7 1.2 55 2.7 1.2 58 0.5% 0.001-045,0.45 Xing XM 2019 2.28 0.157 4.7 41 1.4 0.29 4.44 3.5% 0.001-045,0.45 Xing XM 2019 2.28 0.157 4.7 1.4 5.26 12.7 4.44 3.5% 0.001-045,0.45 Xing XM 2019 2.28 0.157 4.7 1.4 1.4 0.29 4.44 3.5% 0.001-045,0.45 Xing XM 2019 2.28 0.157 4.1 1.4 0.29 4.44 3.5% 0.001-045,0.45 Xing XM 2019 2.28 0.157 4.5 2.5 1.72 4.6 0.3% 0.011-045,0.28 Xing XM 2019 2.28 0.57 4.5 2.6 1.72 4.44 3.5% 0.021-01.151 Xing XM 2019 2.28 0.157 4.5 2.6 1.72 4.44 3.5% 0.021-01.151 Xing XM 2019 2.26 0.47 88 2.71 0.6 82 2.4 0.5% 0.001-045,0.28 Xing XM 2019 2.76 0.42 8 2.71 0.6 82 2.4 4.5 2.5% 0.001-045,0.28 Xing XM 2019 2.76 0.42 8 2.71 0.6 82 2.74 4.44 3.5% 0.001-045,0.28 Xing XM 2019 2.76 0.42 8 2.10 0.47 8 2.74 4.48 3.7% 0.001-045,0.28 Xing XM 2019 1.7 0.55 38 1.66 0.78 2.2 0.2% 0.061-038,0.48 Xing XM 2019 1.7 0.55 38 1.66 0.78 2.2 0.2% 0.061-038,0.48 Xing XM 2019 1.7 0.55 38 1.66 0.78 2.50 0.57 2.50 0.61 2.8,0.48 Xing XM 2019 1.7 0.55 38 1.66 0.78 2.50 0.57 2.50 0.50 1.23 0.051 2.30 0.48 0.78 0.001-023,0.051 1.48 0.051 2.48 0.44 0.5% 0.031 0.48,0.051 1.48 0.051 0.48,0.051 1.48 0.051 0.48 0.44 0.5% 0.031 0.48,0.051 0.38 0.48 0.001-023,0.051 1.48 0.051 0.48 0.48 0.44 0.5% 0.051-033,0.48 0.001 0.43,0.051 0.38 0.48 0.001 0.43,0.051 0.38 0.48 0.001 0.43,0.051 0.38 0.48 0.001 0.43,0.051 0.38 0.48 0.001 0.43,0.051 0.38 0.48 0.001 0.43,0.051 0.38 0.48 0.001 0.43,0.051 0.38 0.48 0.001 0.43,0.051 0.38 0.48 0.0001	1.11.2 7 days						
$ \begin{array}{c} \mbox{Prime} 12 2023 & 2.43 0.47 & 38 & 2.83 0.48 & 38 & 2.48 & -0.10 [-2.34, 0.36] \\ \mbox{Prime} 12 202 & 2.40 & 1.43 & 102 & 1.48 & -0.02 [-2.34, 0.36] \\ \mbox{Prime} 14 = 0.00; 0.0^{10} + 1.67, df = 2 (P - 0.37); P = 0.4 \\ \mbox{Prim} 14 = 0.00; 0.0^{10} + 1.67, df = 2 (P - 0.37); P = 0.4 \\ \mbox{Prim} 14 = 0.00; 0.0^{10} + 1.67, df = 2 (P - 0.37); P = 0.4 \\ \mbox{Prim} 14 = 0.00; 0.0^{10} + 1.67, df = 2 (P - 0.37); P = 0.4 \\ \mbox{Prim} 12 202 & 2.4 & 1.3 & 175 & 2.2 & 1.7 & 206 & 1.44; 0 & 0.00 [-0.46, 0.65] \\ \mbox{Prim} 22 202 & 2.4 & 0.3 & 2.41 & 0.8 & 2.50 & 0.8 & 0.04 [-0.46, 0.65] \\ \mbox{Prim} 22 202 & 1.47 & 0.57 & 2.56 & 1.57 & 2.56 & 1.7 & 2.56 & -0.00 [-0.46, 0.65] \\ \mbox{Prim} 22 202 & 1.47 & 0.57 & 2.56 & 1.57 & 2.56 & 1.77 & 0.65 & 2.56 & 1.77 \\ \mbox{Prim} 24 202 & 2.26 & 1.57 & 0.57 & 2.5 & 0.57 & 4.50 & 0.04 [-0.46, 0.26] \\ \mbox{Prim} 24 202 & 2.26 & 0.53 & 2.57 & 0.56 & 2.68 & 0.01 [-0.46, 0.26] \\ \mbox{Prim} 24 202 & 2.26 & 0.53 & 2.57 & 0.54 & 50 & 4.55 & 0.02 [-0.46, 0.02] \\ \mbox{Prim} 24 202 & 2.26 & 0.58 & 2.27 & 0.54 & 50 & 4.55 & 0.02 [-0.46, 0.02] \\ \mbox{Prim} 24 202 & 2.16 & 0.57 & 2.28 & 1.77 & 0.65 & 2.84 & 0.01 [-0.46, 0.28] \\ \mbox{Prim} 24 202 & 2.26 & 0.58 & 2.26 & 0.26 & 0.25 & 0.27 & 0.01 [-0.47, 0.08] \\ \mbox{Prim} 24 202 & 2.26 & 0.58 & 2.26 & 0.26 & 0.53 & 2.44 & 0.00 [-0.46, 0.28] \\ \mbox{Prim} 24 202 & 2.26 & 0.58 & 2.28 & 1.74 & 0.64 & 3.8 & 2.75 & 0.07 [-0.46, 0.28] \\ \mbox{Prim} 24 202 & 2.26 & 0.58 & 52 & 2.00 & 0.46 & 53 & 2.44 & 0.00 [-0.46, 0.28] \\ \mbox{Prim} 24 201 & 2.21 & 1.57 & 6.22 & 1.17 & 0.6 & 2.25 & 0.00 [-0.46, 0.28] \\ \mbox{Prim} 24 201 & 2.2 & 0.58 & 1.6 & 0.6 & 72 & 55 & 0.00 [-0.46, 0.28] \\ \mbox{Prim} 12 202 & 1.50 & 6.5 & 2.16 & 0.67 & 2.25 & 0.00 [-0.46, 0.28] \\ \mbox{Prim} 12 202 & 1.50 & 6.5 & 2.16 & 0.67 & 2.25 & 0.56 & 0.00 [-0.46, 0.28] \\ \mbox{Prim} 14 202 & 1.50 & 5.2 & 1.16 & 0.68 & 2.258 & 0.00 [-0.46, 0.28] \\ \mbox{Prim} 14 202 & 1.50 & 5.8 & 2.16 & 0.68 & 2.258 & 0.00 [-0.46, 0.28] \\ \mbox{Prim} 14 & 0.25 & 1.50 & 0.5 $	Yin F 2016	3.4 0.9	11 3 (.8 11	0.3%	0.40 [-0.31, 1.11]	
$ \begin{array}{c} \text{Ling} (L_2, C_0) \\ \text{Less} (L_2, C_0) \\ \text$	Zhang LC 2023	2.43 0.47	36 2.53 0.	35 35	2.8%	-0.10 [-0.29, 0.09]	
Heterogeneity: Tail = 0.05; CPi = 0.57; P = 0	Subtotal (95% CI)	2.03 0.14	30 2.01 U. 83	78	4.2%	-0.05 [-0.21, 0.12]	+
1.1.1.3 1 month Lu 27.1 2022 2.4 1.3 175 2.2 1.7 208 1.4% 0.20 [-0.10, 0.50] X0 DL 2024 2.4 0.5 62 2.8 0.6 74 2.9% -0.20 [-0.38, -0.02] Vul. 2015 2.4 0.5 62 2.8 0.6 74 2.9% -0.20 [-0.38, -0.02] Vul. 2015 2.4 0.5 62 2.5 1.72 4.8 0.5% 0.00 [-0.45, 0.56] Vul. 2015 2.8 0.6% 0.00 [-0.45, 0.03] Vul. 2015 2.8 0.6% 0.01 [-0.45, 0.03] Vul. 2015 2.8 0.6% 0.01 [-0.45, 0.03] Vul. 2015 2.8 0.74 4.2 58 1.72 4.8 0.5% 0.01 [-0.45, 0.07] Vul. 2015 1.87 0.37 0.8 1.4 0.22 4.44 1.3.5% -0.04 [-0.45, 0.26] Vul. 2015 1.6 0.3 26 1.7 0.8 22 1.0% -0.10 [-0.45, 0.26] Vul. 2015 1.6 0.3 26 1.7 0.8 22 1.0% 0.01 [-0.45, 0.26] Vul. 2015 1.6 0.3 26 1.7 0.8 22 1.0% 0.10 [-0.45, 0.26] Vul. 2015 1.2 2.4 0.5 40 2.5 0.3 31 2.4% -0.10 [-0.31, 0.11] Harangenaly: Tay = 0.00; Ch ² = 3.23 2.7 0.6 85 2.8% 0.10 [-0.06, 0.23] Vul. 2015 2.8 0.7 48 2.21 1.03 74 22 1.4% 0.101 [-0.30, 0.03] Vul. 2015 2.8 0.7 48 2.21 7.3 48 0.2% 0.101 [-0.30, 0.03] Vul. 2015 2.8 0.7 48 2.21 1.37 4.2 2.4% 0.001 [-0.21, 0.21] Vul. 2015 2.8 0.7 48 2.21 0.37 4.2 1.4% 0.001 [-0.10, 0.03] Vul. 2015 2.8 0.7 4 0.3 28 1.27 0.40 1.3 20.3% 0.001 [-0.20, 0.03] Vul. 2015 2.8 0.7 4 0.3 2.6 1.8 0.6 5 2.8% 0.005 [-0.30, 0.03] Vul. 2015 2.8 0.7 4 0.3 2.6 1.8 0.6 5 2.8% 0.005 [-0.30, 0.03] Vul. 2015 2.8 0.7 4 0.3 2.6 1.8 0.6 5 2.8% 0.005 [-0.30, 0.03] Vul. 2015 2.8 0.7 4 0.3 2.6 1.8 0.6 5 2.8% 0.005 [-0.30, 0.04] Vul. 2015 2.8 0.7 4 0.3 2.6 1.8 0.6 5 2.8% 0.005 [-0.30, 0.04] Vul. 2015 2.8 0.7 4 0.3 2.6 1.8 0.6 5 2.8% 0.005 [-0.30, 0.04] Vul. 2015 2.8 0.64 0.8 2.05 1.2 0.8% 0.005 [-0.40, 0.02] Vul. 2015 2.8 0.64 0.8 2.05 1.2 0.8% 0.005 [-0.40, 0.03] Vul. 2015 2.8 0.64 0.8 2.05 1.2 0.8% 0.005 [-0.40, 0.04] Vul. 2015 2.8 0.64 0.8 2.0 0.2 0.8 6.8 2.2% 0.005 [-0.30, 0.04] Vul. 2015 2.8 0.14 0.2 0.2 0.9 0.2 0.9 0.8 0.82 0.46 0.82, 0.005 [-0.30, 0.04] Vul. 2015 2.8 0.14 0.2 0.2 0.9 0.2 0.9 0.2 0.9 0.005 0.45 0.05 0.05 0.05 0.05 0.05 0.0	Heterogeneity: Tau ² = 0 Test for overall effect: 2	0.00; Chi ² = 1.9 Z = 0.55 (P = 0.	7, df = 2 (P = 0.3 58)	(7); ² = 0%	6		
Lu 27: 222: 2.4 1.3 175 2.2 1.7 208 1.4% 0.20 [-101 0.60] Norp XV 2012 2.4 0.5 62 2.8 0.6 74 2.9% -0.20 [-0.8,0.02] Yun L 2015 2.7 1.2 65 2.7 1.2 58 0.6% 0.00 [-0.5, 0.64] Strong L2 202 1.37 0.37 46 1.4 0.29 45 3.7% -0.20 [-0.8,0.02] Yun J 2015 2.8 1.57 45 2.58 1.72 46 0.3% 0.10 [-0.58,0.78] Subtolal (9% C) Heatrogeneity: Trat = 0.00; Ch ⁺ = 0.3C; h ⁺ = 11% Tent row wall effect 2 = 0.17 (P = 0.48) Heatrogeneity: Trat = 0.00; Ch ⁺ = 0.50; P = 11% Teng V1 2021 2.4 0.5 0 40 2.5 0.3 31 2.4% -0.10 [-0.45, 0.25] Subtolal (9% C) Tang J 2019 2.5 0.7 48 2.71 0.6 85 2.2% 0.10 [-0.58,0.78] Jung SC 2021 2.4 0.5 0 40 2.5 0.3 31 2.4% -0.10 [-0.45, 0.25] Tang J 2019 2.5 0.7 48 2.27 1.0 48 2.2% -0.10 [-0.45, 0.26] Tang J 2019 2.5 0.7 48 2.27 1.0 48 2.2% -0.10 [-0.45, 0.26] Tang J 2019 2.5 0.7 48 2.27 1.0 48 2.2% -0.10 [-0.45, 0.26] Tang J 2019 2.5 0.7 48 2.27 1.0 48 2.2% -0.10 [-0.45, 0.69] Zhang Y1 2022 2.20 0.68 69 2.09 0.46 33 2.4% 0.00 [-0.21, 0.21] Subtolal (9% C) Tang J 2019 2.7 0.83 2.8 2.7 1.0 48 2.2% -0.10 [-0.30, 0.69] Zhang Y1 2022 2.09 0.68 59 2.09 0.46 33 2.4% 0.00 [-0.21, 0.21] Heatrogeneity: Trat = 0.01; Ch ⁺ = 3.31, d ⁺ = 0 (P - 0.02; h ⁻ = 4.3% Tang J 2019 2.2 1.5 0.5 2 1.8 0.8 2.2 1.9 4.4 13 2.8.3% Tang J 2019 2.2 0.0 6.8 3 2.6 0.4 65 2.2% 0.00 [-0.40, 0.69] Zhang Y1 2022 1.3 0.47 40 124 0.61 45 2.1% 0.00 [-0.40, 0.69] Zhang Y1 2022 1.3 0.47 40 124 0.61 45 2.1% 0.00 [-0.40, 0.69] Zhang Y1 2022 1.3 0.47 40 124 0.61 45 2.1% 0.00 [-0.40, 0.69] Zhang Y1 2022 1.3 0.47 40 124 0.61 48 2.2% 0.00 [-0.40, 0.69] Zhang Y1 2022 1.3 0.47 40 124 0.61 48 2.4% 0.00 [-0.40, 0.69] Zhang Y1 2022 1.3 0.47 40 124 0.61 48 2.4% 0.00 [-0.40, 0.68] Zhang Y1 2022 1.3 0.47 40 124 0.61 48 2.4% 0.00 [-0.40, 0.68] Zhang Y1 2022 1.3 0.47 40 124 0.61 48 2.4% 0.00 [-0.40, 0.68] Zhang Y1 2022 1.3 0.47 40 124 0.61 48 2.4% 0.00 [-0.40, 0.68] Zhang Y1 2022 1.3 0.47 40 124 0.61 48 2.4% 0.00 [-0.40, 0.68] Zhang Y1 2022 1.3 1.7 7 2.7 0.88 2.2 0.4% 0.00 [-0.40, 0.65] Zhang Y1 2022 1.3 0.47 40 124 5.2 0.1 2 8	1.11.3 1 month		,				
Xiong XN 2019 2.23 0.94 38 2.31 0.38 25 0.9% 0.04 [-0.54, 0.33 Xiong XN 2019 2.24 0.55 22 8.06 22 8.06% 0.000 [-0.54, 0.02] Ym L. 2015 2.7 1.2 55 2.7 1.2 53 0.27 4.2 58 0.000 [-0.54, 0.04] Ym L 2015 2.27 1.2 55 2.7 1.2 53 0.2% 0.000 [-0.54, 0.04] Xing AF 2016 2.2023 1.37 0.37 36 1.4 0.29 35 3.7% -0.03 [-0.18, 0.12] Xing AF 2016 2.7 0.17 = 0.51, d = 5 [$\theta = 0.35$], $\mu = 11\%$ Heatrogeneity: That = 0.00; Ch ⁺ = 0.51, d = 5 [$\theta = 0.35$], $\mu = 11\%$ The tor overall effect 2 = 0.17 [$\theta = 0.35$], $\mu = 11\%$ The tor overall effect 2 = 0.01 [$\theta = 0.35$], $\theta = 1.35$, $27.6 0.44 5.2 28\%$ -0.01 [-0.31, 0.11] Huargeneity: That = 0.00; Ch ⁺ = 0.53 0, $d = 0$ ($\theta = 0.35$], $\theta = 1.37$, $2.4 0.65 2.26\%$ Xing Yi 2012 2.40 0.51 46 2.55 0.42 45 2.2% -0.01 [-0.31, 0.11] Huargeneity: That = 0.00; Ch ⁺ = 0.53 0, $d = 0$ ($\theta = 0.40$); $h = 4.5$ Xing Yi 2017 2.76 0.42 38 2.71 0.44 38 2.7% 0.07 [-0.11, 0.35] Zinng H 2020 2.09 0.68 9 2.00 0.46 53 2.4% 0.005 [-0.12, 0.26] Xing Yi 2017 2.76 0.42 38 2.71 0.44 38 2.7% 0.01 [-0.30, 0.08] The tor overall effect 2 = 0.32 ($\theta = 0.35$), $d = 0$ ($\theta = 0.40$); $\theta = 4.5$ The tor overall effect 2 = 0.32 ($\theta = 0.35$), $d = 0$ ($\theta = 0.40$); $\theta = 4.5$ The tor overall effect 2 = 0.32 ($\theta = 0.35$), $d = 0$ ($\theta = 0.40$); $\theta = 4.5$ The tor overall effect 2 = 0.32 ($\theta = 0.35$) and $d = 0.25$ 0.46 32 2.4% 0.01 [-0.30, 0.08] The 2.30 1.20 1.20 ($h = 0.33$ 1.82 2.7 4.09 1.2 23 0.2% -0.16 [-0.30, 0.68] Xing Xing Xing Xing Xing Xing Xing Xing	Lu ZH 2022	2.4 1.3	175 2.2	.7 208	1.4%	0.20 [-0.10, 0.50]	+
Au LL 2020 2.4 0.5 for 2.2 10 0.5 for 2.2 9 0.5 for 2.2 9 0.5 for 2.2 9 0.5 for 2.2 9 0.5 for 2.5 0.5	Xiong XM 2019	2.35 0.94	38 2.31 0.	98 25	0.6%	0.04 [-0.45, 0.53]	
$ \begin{array}{c} \mbox{Yang} LP 2018 & 2.88 1.57 & 45 2.28 1.72 & 46 0.38 & 0.77 \\ \mbox{Zang} LP 2023 & 1.37 0.37 & 36 1.4 0.28 & 53 & 3.7 \\ \mbox{Zang} LP 2023 & 1.37 0.37 & 36 1.4 0.28 & 5.3 & 3.7 \\ \mbox{Zang} LP 2000 & Che Sol, d'= 5 (P 0.35); P = 11% \\ \mbox{Test proval effect } Z = 0.71 (P = 0.46) \\ \mbox{III } 2.03 & 2.5 0 & 2.7 & 0.3 & 20 & 4.5\% & 0.02 [-0.16, 0.67] \\ \mbox{Harogeneity} Train = 0.00 & Che Sol, d'= 5 (P = 0.35); P = 11\% \\ \mbox{Teng} J 2019 & 1.6 & 0.3 & 26 & 1.7 & 0.8 & 22 & 1.0\% & 0.10 [-0.45, 0.26] \\ \mbox{Feng YH 2023 } 2.78 & 0.32 & 50 & 2.76 & 0.3 & 1.2 & 4\% & 0.01 [-0.30, 0.08] \\ \mbox{Teng} J 2019 & 2.8 & 0.7 & 6.8 & 2.8\% & 0.01 [-0.00, 0.29] \\ \mbox{Tang} J 2019 & 2.2 & 1.57 & 6.8 & 2.71 & 0.44 & 38 & 2.7\% & 0.07 [-0.12, 0.26] \\ \mbox{Zang} V 2021 & 2.47 & 0.8 & 6.2 & 2.84 & 0.01 [-0.00, 0.29] \\ \mbox{Zang} V 2021 & 2.09 & 0.66 & 69 & 2.08 & 0.47 & 32 & 2.1\% & 0.07 [-0.12, 0.26] \\ \mbox{Zang} V 2020 & 2.69 & 0.68 & 62 & 2.85 & 0.01 [-0.00, 0.29] \\ \mbox{Zang} V 2020 & 2.69 & 0.68 & 62 & 2.64 & 68 & 2.4\% & 0.08 [-0.44, 0.62] \\ \mbox{Zang} V 1 2021 & 2.9 & 1.58 & 65 & 2.08 & 0.05 [-0.30, 0.46] \\ \mbox{Zang} V 1 2021 & 1.5 & 0.5 & 62 & 1.8 & 0.6 & 7.4 & 2.9\% & 0.05 [-0.30, 0.46] \\ \mbox{Xa V 2010 } 3.83 & 1.82 & 27 & 40.9 & 1.2 & 23 & 5\% & 0.05 [-0.30, 0.46] \\ \mbox{Xa V 2010 } 3.83 & 1.82 & 27 & 40.9 & 1.2 & 23 & 5\% & 0.05 [-0.30, 0.46] \\ \mbox{Xa V 2012 } 1.5 & 0.5 & 62 & 1.8 & 0.6 & 7.4 & 2.9\% & 0.05 [-0.30, 0.46] \\ \mbox{Xa V 2012 } 1.5 & 0.5 & 62 & 1.8 & 0.6 & 7.4 & 2.9\% & 0.05 [-0.30, 0.46] \\ \mbox{Xa V 2012 } 1.5 & 0.5 & 62 & 1.8 & 0.6 & 7.4 & 2.9\% & 0.05 [-0.30, 0.46] \\ \mbox{Xa V 2013 } 3.8 & 0.5 & 6.2 & 1.8 & 0.6 & 7.4 & 2.9\% & 0.05 [-0.30, 0.46] \\ \mbox{Xa V 2013 } 2.8 & 1.46 & 2.7 & 1.1 & 43 & 0.6\% & 0.05 [-0.40, 0.41] \\ \mbox{Zang V 1 2016 } 2.8 & 1.46 & 5.27 & 1.1 & 43 & 0.6\% & 0.06 [-0.40, 0.41] \\ \mbox{Zang V 1 2019 } 1.8 & 0.5 & 62 & 0.9 & 0.5 & 7.4 & 0.08 & 0.00 [-0.40, 0.46] \\ \mbox{Xa V 201 } 1.8 & 0.5 & 62 & 0.9 & 0.5 & 7.4 & 0.03\% & 0.00 [-0.40, 0.46] \\ Xa V 20 $	Xu DL 2024 Yan L 2015	2.4 0.5	62 2.6 C	2 53	2.9%	-0.20 [-0.38, -0.02]	
Zhang LC 2023 1.37 0.37 38 1.4 0.29 35 3.7% -0.04 [-0.18, 0.12] Subbal (85% C) 4+11 4+1 9.5% -0.04 [-0.16, 0.07] Hetaragonalty: Tar ¹ = 0.00; Ch ¹⁺ = 5.81, d ⁺ = 5 (P = 0.35); P = 11% Tat for versal effect Z = 0.71 (P = 0.48) 1.114.3 months Cheng YH 2019 1.6 0.3 26 1.7 0.8 22 1.0% -0.10 [-0.45, 0.25] Geng ZH 2021 2.47 0.82 40 2.5 0.3 31 2.4% -0.10 [-0.31, 0.11] Huang SC 2021 2.44 0.84 40 2.5 0.3 31 2.4% -0.11 [-0.30, 0.06] Tarag J 2019 2.8 0.7 85 2.7 0.6 85 2.8% -0.11 [-0.30, 0.06] Tarag J 2019 2.8 0.7 85 2.7 0.6 85 2.8% -0.11 [-0.30, 0.06] Tarag J 2019 2.8 0.7 85 2.7 0.6 85 2.8% -0.11 [-0.30, 0.06] Tarag J 2019 2.8 0.7 85 2.7 0.6 85 2.8% -0.11 [-0.30, 0.06] Tarag J 2019 2.2 0.00 0.68 40 2.09 0.64 33 2.4% -0.07 [-0.12, 0.26] Tarag J 2016 2.5 0.1% 45 2.18 0.47 32 1.4% -0.01 [-0.46, 0.59] Tarag J 2019 2.5 0.0% 402 2.09 0.64 83 2.4% -0.02 [-0.66, 0.30] Hetarageneity: Tar ² = 0.00; Ch ²⁺ = 8.30, d ⁺ = 8 (P = 0.40); P = +4% Tarag J 2019 2.7 0.85 83 1.65 0.79 25 0.8% -0.05 [-0.46, 0.32] Tarag J 2019 1.7 0.55 33 1.65 0.79 25 0.8% -0.016 [-0.30, 0.63] Tarag J 2019 1.7 0.85 33 1.65 0.79 25 0.8% -0.016 [-0.30, 0.63] Tarag J 2019 1.7 0.85 33 1.65 0.79 25 0.8% -0.016 [-0.30, 0.63] Tarag J 2019 1.7 0.85 33 1.65 0.79 25 0.8% -0.016 [-0.30, 0.63] Tarag J 2019 1.7 0.85 33 1.65 0.79 25 0.8% -0.006 [-0.30, 0.63] Tarag J 2019 1.7 0.85 33 0.4% 1.1 2.9 1.1 2.5 0.2% +0.016 [-0.30, 0.63] Tarag J 2019 1.2 0.12 40 1.5 0.5 2.9 1.1 53 0.6% -0.006 [-0.30, 0.63] Tarag J 2019 1.2 0.12 40 1.5 0.5 2.9 1.1 53 0.6% -0.006 [-0.30, 0.63] Tarag J 2019 1.2 0.12 40 45 2.2% (-0.46 0.608] Tarag J 2019 1.2 0.12 40 1.5 0.5 1.2 1.6% -0.38 [0.06, 0.33] Tarag J 2019 1.2 0.12 40 1.5 0.5 1.2 1.6% -0.30 [0.06, 0.53] Tarag J 2019 1.2 0.12 40 45 2.2% (-0.16 [-0.10, 0.65] Tarag J 2019 1.2 0.12 40 45 2.2% (-0.16 [-0.10, 0.65] Tarag J 2015 2.2 0.77 60 2.1 0.7 22 2.2% (-0.41 [0.06, 0.73] Tarag J 2015 2.2 0.77 6 2.2 0.9 0.8 74 2.2% (-0.36 [-0.40, 0.65] Tarag J 2015 2.2 0.77 8 8 1.84 0.57 32 1.2% (-0.36 [-0.50, 0.73] Tarag J 2015 2.2 0.77 8 3 1.54 0.77 2 2.12%	Yang AF 2018	2.68 1.57	45 2.58 1.	72 46	0.3%	0.10 [-0.58, 0.78]	
Subtranspan(b): Tup' = 0.00; Ch ² = 5.11, df = 5 (P = 0.35); P = 11% Task for overall effect Z = 0.21 (P = 0.48) 1.11.4 3 months Cheng YH 2021 2.47 0.52 10 2.76 0.34 50 4.5% 0.02 (-0.11, 0.15) Geng YH 2023 2.78 0.32 50 2.76 0.34 50 4.5% 0.02 (-0.11, 0.15) Geng YH 2023 2.78 0.32 50 2.76 0.34 50 4.5% 0.02 (-0.11, 0.15) Huang SC 2021 2.44 0.61 44 2.85 0.42 48 2.8% -0.11 (-0.30, 0.08) Tang J 2019 2.8 0.7 85 2.7 0.68 52 2.9% 0.01 (-0.06, 0.29) Yang AF 2016 2.21 1.87 44 2.38 2.71 0.44 38 2.7% 0.07 (-0.12, 0.28) Yang AF 2016 2.21 1.87 44 2.38 2.71 0.44 38 2.7% 0.07 (-0.12, 0.28) Yang AF 2016 2.25 0.74 38 2.21 0.04 53 2.4% 0.03 (-0.02, 0.09) Zhang YH 2020 2.09 0.68 69 2.99 0.46 53 2.4% 0.03 (-0.02, 0.09) Hateragenety: Task = 0.00; Ch ² = 0.00; H = 43 Task for overall effect Z = 0.02 (P = 0.40); H = 4% Test for overall effect Z = 0.02 (P = 0.40); H = 4% Tang J 2019 3.83 1.82 27 4.09 1.2 29 0.2% 0.016 (-0.94, 0.62) Gin X 2020 1.38 31 1.82 0.7 4.85 2.1% 0.06 (-0.14, 0.32) Yan L 2015 2.38 0.44 65 2.04 85 2.4% 0.036 (-0.44, 0.44) Zhang J 2019 1.7 0.85 38 1.85 0.73 25 0.5% 0.05 (-0.36, 0.46) Xion X 2019 1.7 0.85 38 1.85 0.73 25 0.5% 0.05 (-0.36, 0.46) Xion X 2019 1.7 0.85 38 1.85 0.73 25 0.5% 0.05 (-0.36, 0.46) Xion X 2019 1.7 0.85 38 1.85 0.73 25 0.5% 0.05 (-0.36, 0.46) Xion X 2019 1.7 0.85 38 1.85 0.73 25 0.5% 0.05 (-0.36, 0.46) Xion X 2019 1.7 0.85 38 1.85 0.73 25 0.5% 0.05 (-0.36, 0.46) Xion X 2019 1.7 0.85 38 1.85 0.73 25 0.5% 0.05 (-0.36, 0.46) Xion X 2019 1.24 0.81 1.2 29 1.1 1.3 0.6% 0.005 (-0.46, 0.43) Hateragenety: Task = 0.01; Ch ³ = 0.07; H = 0.02; H = 2.02; H = 2.5% Task for overall effect Z = 0.02; (P = 0.000); H = 69% Test for overall effect Z = 0.02; (P = 0.000); H = 69% Test for overall effect Z = 0.02; (P = 0.000); H = 69% Test for overall effect Z = 0.02; (P = 0.000); H = 69% Test for overall effect Z = 0.02; (P = 0.000); H = 69% Test for overall effect Z = 0.02; (P = 0.000); H = 69% Test for overall effect Z = 0.02; (P = 0.000); H = 69% Test for overall effect Z = 0.0	Zhang LC 2023	1.37 0.37	36 1.4 0.	29 35	3.7%	-0.03 [-0.18, 0.12]	
Tast for overall effect $Z = 0.71$ (P = 0.48) 1.11.4 3 months Cheng YH 2023 2.78 0.32 50 2.78 0.34 50 4.5% 0.02 [0.11, 0.15] Feng YH 2023 2.78 0.32 50 2.78 0.34 50 4.5% 0.02 [0.11, 0.15] Huang BC 2021 2.4 0.61 46 2.265 0.42 46 2.8% 0.01 [0.00, 0.28] Tang J 2019 2.8 0.73 4 2.7 0.46 38 2.7% 0.06 [0.2, 0.26] Yang AF 2016 2.21 1.67 45 2.32 1.73 46 0.3% 0.01 [0.12, 0.26] Zhang LG 2015 2.5 0.74 36 2.71 0.44 38 2.7% 0.07 [0.12, 0.26] Zhang LG 2015 2.5 0.74 36 2.21 0.47 32 1.4% 0.31 [0.02, 0.60] Zhang LG 2015 2.5 0.74 36 2.21 0.47 32 1.4% 0.31 [0.02, 0.60] Zhang VH 2020 2.00 0.68 59 2.00 0.46 53 2.4% 0.00 [0.24, 0.21] Subtotal (8% CI) - 423 - 0.42 (P = 0.40); P = 4% Test for overall effect Z = 0.42 (P = 0.40); P = 4% Xing X 2019 1.7 0.85 38 1.68 0.79 2.5 0.8% 0.08 [0.36, 0.48] Yan L 2015 2.3 0.44 46 2.2 1 1.1 53 0.6% 0.00 [0.41, 0.32] Zhang LG 2019 1.7 0.85 38 1.68 0.79 2.5 0.8% 0.08 [0.36, 0.48] Yan L 2015 2.3 0.44 66 2.2 1 1.1 53 0.6% 0.00 [0.41, 0.41] Zhang LG 2015 2.3 0.48 36 2.0 0.13 2.69 5.2.9% 0.00 [0.41, 0.41] Zhang LG 2015 2.3 0.48 36 2.0 1.1 2.48 0.57 2.5 0.8% 0.00 [0.41, 0.41] Zhang LG 2015 2.3 0.48 36 2.0 1.1 2.48 0.57 4.29 (P = 0.40); P = 4.4% Yan L 2015 2.3 0.14 63 5.2 0.13 2.1 6% 0.38 [0.08, 0.48] Zhang YT 2022 1.3 0.11 2.4 0.31 2.29 7.4.1 48 0.6% 0.00 [0.44, 0.41] Zhang YT 2022 1.24 0.31 69 1.3 0.26 69 2.2% 0.00 [0.41, 0.41] Zhang YT 2022 1.24 0.31 69 1.3 0.26 69 2.2% 0.00 [0.41, 0.41] Zhang YT 2022 1.24 0.35 63 1.2 0.75 2.5 0.5% 0.00 [0.38, 0.46] Xuo IX 2024 0.30 0.5 6 3.1 2.1 0.5 8.6% 0.10 [0.08, 0.45] Zhang YT 2022 1.24 0.31 69 1.3 0.27 72 0.58 0.30 [0.08, 0.45] Xuo IX 2024 0.30 0.5 4.2 0.1 2.4 0.57 72 2.5% 0.00 [0.45, 0.46] Xuo IX 2024 0.30 0.5 4.5 0.3 0.5 0.48 (2.5% 0.06 [0.35, 0.47] Xuo IX 2024 0.30 0.5 4.5 2.5 1.37 42 0.53 (6.26% 0.06 [0.45, 0.46] Yan L 2015 2.4 0.06 (P = 0.20); P = 0.20;	Heterogeneity: Tau ² = (0.00; Chi² = 5.6	4111 1,df=5 (P=0.3	44-1 (5); * = 11	9.5% %	-0.04 [-0.16, 0.07]	
1.11.4.3 months Cheng YH 2021 2.78 0.32 2.69 2.78 0.34 50 4.5% 0.02 [-0.11, 0.15] Feng YH 2022 2.74 0.32 50 2.78 0.33 12.44 0.00 [-0.45, 0.25] Feng YH 2023 2.74 0.44 2.65 0.31 12.44 0.00 [-0.60, 0.29] Ting J 2019 2.81 0.76 63 2.77 0.46 65 2.44 0.00 [-0.60, 0.29] Xine W 2017 2.78 0.42 38 2.71 0.44 38 2.75 0.00 [-0.46, 0.62] Zhang MH 2020 2.08 0.66 59 2.04 66 53 2.44% 0.00 [-0.40, 0.69] Haiarognenity: Thuit = 0.00; Chi* = 3.30, dft = 8 (P = 0.40); P = 4% 105 (0.06, 0.29) 1.11 2.14% 0.03 [-0.06, 0.29] Xine X 2021 1.33 0.47 40 1.2 2.05% 0.01 [-0.28, 0.46] 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.	Test for overall effect: 2	Z = 0.71 (P = 0.	48)				
Fing YH 2022 2.72 0.32 50 2.75 0.34 50 4.5% 0.02 [0.11, 0.15] frang YH 2022 2.4 0.51 46 2.265 0.42 46 2.8% -0.11 [0.30, 0.08] Trang J 2019 2.8 0.75 48 2.77 0.46 98 2.9% -0.01 [0.00, 0.29] Yung AF 2016 2.21 1.87 46 2.38 2.77 0.46 95 2.9% -0.01 [0.00, 0.29] Yung AF 2016 2.21 1.87 46 2.38 2.77 0.44 38 2.7% 0.07 [0.12, 0.26] Yung AF 2016 2.21 1.87 46 2.38 2.17 0.44 38 2.7% 0.07 [0.12, 0.26] Yung AF 2016 2.21 1.87 46 2.38 2.17 0.44 38 2.7% 0.07 [0.12, 0.26] Yung AF 2016 2.21 1.87 46 2.38 1.73 46 0.03% -0.01 [0.02, 0.69] Hebrogeneity: Tau" = 0.00; Ch ⁺ = 3.0, d ⁺ = 8 (P = 0.40); P = 4% Time to rownal effect 2 = 0.42 (P = 0.40); P = 4% Yung AF 2016 2.27 0.48 83 2.5 0.4 96 2.4% 0.00 [0.24, 0.32] Yung XH 2017 3.83 1.82 27 4.09 1.2 23 0.2% 0.00 [0.46, 0.32] Yun L 2015 2.2 1.33 0.47 40 1.24 0.61 45 2.1% 0.09 [0.44, 0.32] Yun L 2015 2.2 1.3 0.47 40 1.24 0.61 45 2.1% 0.09 [0.44, 0.32] Yun L 2015 2.2 1.1 50 0.5 62 1.8 0.64 78 2.0% 0.00 [0.46, 0.68] Yun L 2015 2.8 0.44 36 2.05.1 32 1.6% 0.00 [0.44, 0.441] Yun L 2015 2.8 1.1 55 0.5 62 1.8 0.64 78 2.0% 0.00 [0.46, 0.68] Yun L 2015 2.8 0.64 36 2.05.1 32 1.6% 0.39 [0.06, 0.63] Yun L 2015 2.8 0.64 36 2.05.1 32 0.66 62 2.0% 0.01 [0.26, 0.68] Yun L 2015 2.48 0.3 69 1.3 0.32 69 5.2% 0.00 [0.47, 0.08] Yung YH 2010 2.18 1.1 29 1.7 1.3 38 0.4% 0.00 [0.47, 0.08] Yung YH 2010 2.14 0.3 69 1.3 0.32 69 5.2% 0.00 [0.57, 0.37] Shi X 2022 0.83 0.5 40 0.98 0.42 45 2.7% 0.01 [0.57, 0.37] Shi X 2022 0.83 0.5 40 0.98 0.47 2.3% 0.30 [0.26, 0.68] Yung X 2017 3.41 0.32 88 3.2 0.2 38 4.9% 0.00 [0.43, 0.64] Yung X 2015 2.45 1.35 5.26 0.5% 0.00 [0.48, 0.48] Yung X 2017 3.41 0.32 2.8 3.2 0.2 38 4.9% 0.00 [0.57, 0.37] Shi X 2022 0.83 0.5 40 0.98 0.47 2.3% 0.41 [0.06, 0.73] Shi X 2022 0.83 0.5 40 0.98 0.47 2.2% 0.41 [0.06, 0.73] Shi X 2022 0.83 0.5 40 0.98 0.47 2.2% 0.41 [0.06, 0.73] Shi X 2022 0.83 0.5 40 0.98 0.47 2.2% 0.41 [0.06, 0.73] Shi X 2022 0.83 0.5 40 0.98 0.47 2.2% 0.41 [0.06, 0.73] Shi X 202 0.83 0.5 40 0.98 0.47 2.2% 0.44 (0.06, 0.64] Yung AF 2016 2.28 0.16 4	1.11.4 3 menths Cheng YH 2019	1.6 0.3	26 1.7	.8 22	1.0%	-0.10 -0.45. 0.25]	
Geng 2F1 2021 2.24 0.8 40 2.5 0.3 31 2.4% -0.10 [-0.31, 0.11] Tang J 2019 2.8 0.7 8.3 2.7 0.6 95 2.8% -0.11 [-0.30, 0.08] Tang J 2019 2.8 0.7 8.3 2.7 0.6 95 2.8% -0.11 [-0.30, 0.08] Yang JA 2018 2.21 1.87 45 2.32 1.73 46 0.3% -0.11 [-0.81, 0.59] Zhang VH 2020 2.09 0.68 59 2.09 0.46 53 2.4% 0.00 [-0.21, 0.21] Subtotal (95% CI) 423 44 13 20.3% 0.02 [-0.06, 0.09] Heterogonaly: Tau ² = 0.02 (Ch ² = 8.30, df = 8 (P = 0.40); P = 4% Yan J 2.210 2.24 0.3 31 1.82 27 4.09 1.2 23 0.2% -0.16 [-0.44, 0.82] Shi X 2022 1.33 0.47 0.124 0.05 1.25 0.28% 0.00 [-0.44, 0.82] Yan J 2.210 2.7 0.8 83 2.5 0.4 95 2.5 0.28% 0.00 [-0.28, 0.08] Yan J 2019 2.7 0.8 83 2.5 0.4 95 2.5 0.2% 0.00 [-0.44, 0.82] Yan J 2019 2.7 0.8 83 2.5 0.4 95 2.5 0.2% 0.00 [-0.44, 0.41] Yan J 2019 2.7 0.8 83 2.5 0.4 95 2.5 0.2% 0.00 [-0.44, 0.41] Yan J 2019 1.7 0.8 53 1.65 0.73 25 0.8% 0.00 [-0.44, 0.41] Yan J 2015 2.38 0.46 38 0.20 5.1 32 1.6% 0.36 [0.09, 0.63] Yan J 2015 2.38 0.46 38 0.20 5.1 32 1.6% 0.36 [0.09, 0.63] Yan L 2015 2.48 0.43 69 2.05 1.32 1.6% 0.36 [0.09, 0.63] Zhang YT 2022 1.48 1.1 29 1.7 1.3 38 0.4% 0.10 [-0.48, 0.86] Zhang YT 2022 1.48 0.13 69 1.3 0.22 69 5.2% -0.06 [-0.47, 0.66] Subtotal (95% CI) 429 444 18.5% 0.10 [-0.47, 0.33] Yan L 2015 2.46 0.12 6.4 36 2.20 2.3% 4.49 5.0 0.00 [-0.48, 0.41] Yan L 2015 2.46 0.12 48 5.3 0.1 50 8.6% 0.12 [10.80, 0.16] UL CL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.12 [10.80, 0.16] Yan L 2015 2.46 0.13 45 2.77 55 0.4% 0.06 [-0.53, 0.45] Yan L 2015 2.45 0.12 48 5.27 1.57 46 0.3% -0.06 [-0.53, 0.45] Yan J 2014 0.6 0.5 62 2.9 0.8 74 2.2% -0.10 [-0.48, 0.48] Yan J 2015 2.45 0.13 455 2.6 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.48, 0.48] Yan J 2015 2.45 0.13 455 2.6 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.48, 0.48] Yan J 2015 2.45 0.13 465 3.27 45 0.3% 0.00 [-0.48, 0.48] Yan J 2015 2.45 0.13 40 4.57 32 2.2% 0.41 (0.90, 0.73] Subtotal (95% CI) - 258 2.598 100.0%, 0.00 [-0.48, 0.48] Yan J 2015 2.45 0.11 (P = 0.48); P = 0% Test for overall effect Z = -0.02 (Ch ² = 50; A = 0; P = 0.05); P = 0.0% Test for	Feng YH 2023	2.78 0.32	50 2.76 0.	34 50	4.5%	0.02 [-0.11, 0.15]	+
Thing 52 2021 2.24 0.51 48 2.45 0.42 48 2.8% -0.11 [0.30, 0.08] Tang J 2019 2.8 0.7 83 2.7 0.6 96 2.4% 0.07 [-0.12, 0.26] Xue W 2017 2.78 0.42 38 2.71 0.44 38 2.7% 0.07 [-0.12, 0.26] Zhang LG 2016 2.21 0.47 48 2.21 7.3 46 0.3% -0.11 [-0.81, 0.69] Zhang LG 2016 2.25 0.74 88 2.19 0.47 32 1.4% 0.31 [0.02, 0.60] Zhang YL 2020 2.09 0.68 59 2.09 0.46 53 2.4% 0.06 [-0.21, 0.21] Subtoal (85% CI) 423 0.46 12 2.24% 0.06 [-0.21, 0.21] Subtoal (85% CI) 423 0.47 40 124 0.61 45 2.1% 0.06 [-0.40, 0.82] Shi X 2022 1.33 0.47 40 124 0.61 45 2.1% 0.06 [-0.40, 0.82] Shi X 2022 1.33 0.47 40 124 0.61 45 2.1% 0.06 [-0.40, 0.82] Shi X 2022 1.33 0.47 40 124 0.61 45 2.1% 0.06 [-0.40, 0.82] Xiong XM 2019 1.7 0.85 38 1.65 0.79 25 0.8% 0.06 [-0.38, 0.46] Xiong XM 2019 1.7 0.85 38 1.65 0.79 25 0.8% 0.06 [-0.38, 0.46] Xiong XM 2019 1.7 0.85 38 1.65 0.79 25 0.8% 0.01 [-0.48, 0.68] Zhang LG 2015 2.36 0.44 36 2.05 1.32 1.6% 0.36 [0.09, 0.63] Zhang LG 2015 2.36 0.44 36 2.05 1.32 1.6% 0.36 [0.09, 0.68] Zhang LF 2020 1.24 0.31 56 9.13 0.32 66 6.2% -0.06 [-0.17, 0.06] Subtoal (85% CI) 429 0.444 16.5% 0.03 [-0.06, 0.13] Heterogeneity: Tau ² = 0.05 (P = 0.51) 1.11.6 12 con ths Lu KL 2018 2.6 1.1 42 2.7 1.1 43 0.6% -0.10 [-0.57, 0.37] Shi X 2012 2.1 8 1.1 429 1.7 1.3 38 0.4% 0.01 [-0.48, 0.68] Zhang LG 2015 5.42 0.12 48 5.3 0.1 50 6.8% 0.12 [0.08, 0.16] J 1.16 22 0.05 (P = 0.51) 1.11.6 12 con ths Lu KL 2018 2.6 1.1 42 2.7 1.1 43 0.6% -0.10 [-0.57, 0.37] Shi X 2012 0.14 0.5 0.5 0.2 0.9 0.8 74 2.3% -0.30 [-0.66, 0.15] Heterogeneity: Tau ² = 0.00; Ch ² = 0.9 Ch 2.2 2 2.5 0.4% 0.06 [-0.53, 0.46] The tr or overall effect 2 = 0.02; Ch ² = 0.9 Ch 2.2 2% 0.41 (0.06, 0.46] Test for overall effect 2 = 0.02; Ch ² = 0.9 Ch 2.2 2% 0.41 (0.06, 0.46] Test for overall effect 2 = 0.02; Ch ² = 0.9 Ch 2.2 2.5 0.4% 0.00 [-0.48, 0.46] Test for overall effect 2 = 0.02; Ch ² = 0.9 Ch 2.2 2.5 0.4% 0.00 [-0.48, 0.46] Test for overall effect 2 = 0.02; Ch ² = 0.9 Ch 2.2 0.4% 0.00 [-0.53, 0.65] Test for o	Geng ZH 2021	2.4 0.6	40 2.5 0	.3 31	2.4%	-0.10 [-0.31, 0.11]	
No W 2017 2.76 0.42 38 2.71 0.44 38 2.7% 0.07 $[-0.12, 0.26]$ Yang AF 2018 2.21 1.87 45 2.32 1.73 46 0.3% 0.07 $[-0.12, 0.26]$ Zhang LG 2015 2.5 0.74 38 2.18 0.74 33 1.4% 0.31 $[0.02, 0.60]$ Zhang LH 2015 2.5 0.74 38 2.18 0.74 33 1.4% 0.31 $[0.02, 0.60]$ Zhang LH 2015 2.5 0.74 38 2.18 0.74 33 1.4% 0.37 $[0.02, 0.60]$ The for organitized there: 2 - 0.42 ($P = 0.40$); $P = 4\%$ Test for orwall effect 2 - 0.42 ($P = 0.40$); $P = 4\%$ Total for 0.71 $[0.02, 0.60]$ 2.11.5 6 monthe Chen CM 2010 3.93 1.82 27 4.09 1.2 23 0.2% 0.16 $[-0.46, 0.62]$ Shi X 2022 1.33 0.47 40 1.24 0.61 45 2.1% 0.06 $[-0.46, 0.62]$ Shi X 2022 1.33 0.47 40 1.24 0.61 45 2.1% 0.06 $[-0.46, 0.68]$ Yun L 2015 2.8 1.1 55 2.29 1.1 53 0.26% 0.06 $[-0.46, 0.68]$ Zhou RL 2020 1.24 0.31 59 1.3 0.32 59 5.2% 0.016 $[-0.46, 0.68]$ Zhou RL 2020 1.24 0.31 59 1.3 0.32 59 5.2% 0.016 $[-0.46, 0.68]$ Zhou RL 2020 1.24 0.31 59 1.3 0.32 59 5.2% 0.016 $[-0.46, 0.68]$ Zhou RL 2020 1.24 0.31 59 1.3 0.32 59 5.2% 0.016 $[-0.57, 0.37]$ Subtotal (6%% CI) 1.11.6 12 montha LL CL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.12 $[0.08, 0.16]$ LL MX 2018 2.6 1.1 42 2.7 1.1 43 0.6% 0.016 $[-0.57, 0.37]$ Subtotal (6%% CI) 2.0.5 14 0.28 0.12 2.0 2.8 0.42 45 2.7% 0.10 $[-0.53, 0.47]$ Xu DL 2024 0.8 0.5 62 0.9 0.8 74 2.3% 0.00 $[-0.12, 0.32]$ Yun L 2015 2.4 0.3 28 3.2 0.2 38 4.3% 0.00 $[-0.53, 0.46]$ Yun L 2015 2.4 0.3 28 3.12 775 25 0.3% 0.06 $[-0.52, 0.68]$ Yun L 2016 2.25 0.77 38 1.84 0.57 32 1.2% 0.00 $[-0.12, 0.32]$ Yun J 2015 2.46 1.3 255 2.6 1.3 55 2.0 1.3 53 0.6% 0.00 $[-0.48, 0.48]$ Yun J 2015 2.46 1.3 255 2.0 2.38 4.4% 0.00 $[-0.54, 0.46]$ Yun J 2015 2.46 1.3 255 2.0 2.38 4.4% 0.00 $[-0.54, 0.46]$ Yun J 2016 2.82 1.31 27 2.76 0.88 2.3 0.4% 0.00 $[-0.54, 0.46]$ Yun J 2016 2.82 1.31 27 2.76 0.88 2.3 0.4% 0.00 $[-0.54, 0.46]$ Heterogoneity: Tat ² = 0.02; Ch ² = 0.02; I ² = 0.9K) Test for overall effect: 2 - 0.50; Ch ² = 0.02; I ² = 0.9K) Test for overall effect: 2 - 0.50; Ch ² = 0.68; I ² = 0.9C; I ² = 0.9K) Test for overall effect: 2 - 0.50	Huang SC 2021 Tano J 2019	2.54 0.51	46 2.65 0.	42 46	2.8%	-0.11 [-0.30, 0.08] 0.10 [-0.09, 0.29]	
Yeng AF 2018 2.21 1.67 45 2.32 1.73 46 0.3% -0.11 [0.01, 0.69] Zhang y H2 202 2.09 0.68 59 2.09 0.4 53 2.4% 0.00 [0.21, 0.21] Dynap (L2 2016 0.68 92 2.09 0.46 53 2.4% 0.00 [0.21, 0.21] Heterogeneity: Tau ² = 0.00; Ch ² = 8.30, df = 8 (P = 0.40); P = 4% Test for overall effect Z = 0.42 (P = 0.57) 1.11.5 6 monthe Chen CM 2010 3.39 1.62 27 4.09 1.2 23 0.2% -0.16 [-0.94, 0.62] Shi X 2022 1.33 0.47 40 1.24 0.61 45 2.1% 0.09 [-0.44, 0.32] Tang J 2019 2.7 0.68 53 2.6 0.4 95 2.8% 0.10 [-0.09, 0.23] Xiong XM 2019 1.7 0.85 38 1.65 0.79 25 0.8% 0.06 [-0.38, 0.68] Yan L 2015 2.36 0.64 38 2.9 1.1 53 0.8% 0.00 [-0.28, 0.08] Zhang YT 2022 1.8 1.1 29 1.7 1.3 36 0.4% 0.10 [-0.28, 0.68] Zhang YT 2022 1.8 1.1 29 1.7 1.3 36 0.4% 0.01 [-0.48, 0.68] Zhang YT 2022 1.8 1.1 42 0.51 52 1.6% 0.32 [-0.66, 0.61] Zhang YT 2022 1.8 1.1 42 0.51 52 50 5.2% -0.06 [-0.7, 0.05] Subtatal (8% Cl) -0.45 (P = 0.51) 1.11.5 12 months Liu CL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.10 [-0.57, 0.37] Shi X 2022 0.83 0.5 40 0.96 0.42 45 2.7% -0.13 [-0.38, 0.46] Yan L 2020 0.5 0.5 62 0.9 0.8 74 2.3% 0.00 [-0.52, 0.08] Xiong XM 2019 1.38 0.82 38 1.32 0.75 25 0.8% 0.06 [-0.38, 0.46] Yan L 2016 2.6 1.3 65 2.6 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.45, 0.46] Yan L 2024 0.5 0.5 62 0.9 0.8 74 2.3% 0.40 [-0.52, 0.08] Yan L 2024 0.5 0.5 62 0.9 0.8 74 2.3% 0.40 [-0.52, 0.08] Yan L 2015 2.4 1.3 25 2.5 1.3 57 2.5 0.8% 0.00 [-0.45, 0.46] Yan L 2016 2.6 1.3 65 2.6 1.3 53 0.6% 0.00 [-0.45, 0.46] Yan J 2016 2.68 (64 55 2.73 1.57 46 0.3% 0.06 [-0.51, 0.66] Yan J 2016 2.68 1.64 55 2.73 1.57 46 0.3% 0.00 [-0.45, 0.46] Yan J 2016 2.68 1.68 55 2.73 1.57 46 0.3% 0.00 [-0.45, 0.46] Yan J 2016 2.68 1.68 55 2.73 1.57 46 0.3% 0.00 [-0.45, 0.46] Yan J 2016 2.68 1.68 55 2.73 1.57 46 0.3% 0.00 [-0.45, 0.46] Yan J 2016 2.26 0.02 (P = 0.80) The store overall effect Z = 0.01 (P = 0.88); P = 0%. Test for overall effect Z = 0.11 (P = 0.88); P = 0%.	Xue W 2017	2.78 0.42	38 2.71 0.	44 38	2.7%	0.07 [-0.12, 0.26]	
Zhang LG 2015 2.5 0.74 38 2.19 0.47 32 1.4% 0.31 [0.22, 0.60] Subtotal (85% C) 423 413 20.3% 0.02 [-0.66, 0.09] Subtotal (85% C) 423 413 20.3% 0.02 [-0.66, 0.09] Test for overall effect Z = 0.42 ($P = 0.5T$) 1.11.5 f monthe Chen CM 2010 3.39 1.62 27 4.09 1.2 23 0.2% -0.18 [-0.34, 0.62] Si X 2021 1.33 0.47 40 1.24 0.61 46 2.1% 0.09 [-0.36, 0.46] Xu DL 2024 1.5 0.5 62 1.6 0.6 74 2.9% -0.10 [-0.09, 0.29] Xu DL 2024 1.5 0.5 62 1.6 0.6 74 2.9% -0.10 [-0.36, 0.46] Xu DL 2024 1.5 0.5 62 1.6 0.8 74 2.9% -0.10 [-0.36, 0.46] Zhang YL 2022 1.8 1.1 29 1.1 55 2.9 1.1 53 0.8% 0.006 [-0.36, 0.46] Zhang YL 2022 1.8 1.1 29 1.7 1.3 38 0.4% 0.10 [-0.48, 0.68] Zhang YL 2022 1.8 1.1 29 1.7 1.3 38 0.4% 0.006 [-0.37, 0.06] Zhang YL 2022 1.8 1.1 42 0.71 1.3 38 0.4% 0.006 [-0.48, 0.68] Zhang YL 2022 1.8 1.1 42 0.71 1.3 38 0.4% 0.006 [-0.48, 0.68] Zhang YL 2022 1.8 1.1 42 0.71 1.3 38 0.4% 0.006 [-0.48, 0.68] Zhang YL 2020 1.24 0.31 69 1.3 0.32 69 5.2% -0.006 [-0.17, 0.06] Zhang YL 2022 0.83 0.5 40 0.96 0.42 45 2.7% -0.10 [-0.57, 0.37] Shi X 2022 0.83 0.5 40 0.96 0.42 45 2.7% -0.10 [-0.57, 0.37] Shi X 2022 0.83 0.5 40 0.96 0.42 45 2.7% -0.10 [-0.53, 0.07] Shi X 2022 0.83 0.5 40 0.96 0.42 34 0.32, 0.75 25 0.8% 0.006 [-0.33, 0.45] Xu DL 2024 0.6 0.5 62 0.9 0.8 74 2.3% -0.30 [-0.52, 0.06] Xu DL 2024 0.6 0.5 62 0.9 0.8 74 2.3% -0.30 [-0.52, 0.06] Yan L 2015 2.6 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.48, 0.46] Yan L 2015 2.6 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.45, 0.45] Xu DL 2024 0.6 0.5 62 0.9 0.8 74 2.3% -0.30 [-0.52, 0.06] Yan L 2015 2.2 0.7 36 1.84 0.57 32 1.2% 0.41 [0.09, 0.73] Subtotal (85% C) 470 472 2.42.% 0.00 [-0.45, 0.45] Yan AF 2016 2.26 0.77 36 1.84 0.57 32 1.2% 0.41 [0.09, 0.73] Zhang L2015 2.1 0.9 2.4 2.1 0.7 26 0.7% 0.00 [-0.45, 0.45] Test for overall effect Z = 0.51 (P = 0.59) 1.11.724 months Chen CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.55, 0.67] Test for overall effect Z = 0.51 (P = 0.58) F = 0\% Test for overall effect Z = 0.51 (P = 0.59) Test for overall effect Z = 0.51 (P = 0.58) F = 0	Yang AF 2018	2.21 1.67	45 2.32 1.	73 46	0.3%	-0.11 [-0.81, 0.59]	
Link ji 11 222.0 1.24 0.00 1.03 2.03 0.4 0.6 1.04 2.0 2.03 0.4 0.6 1.04 1.04 1.04 1.04 1.04 1.04 1.04 1.04	Zhang LG 2015 Zhang XH 2020	2.5 0.74	36 2.19 0.	47 32	1.4%	0.31 [0.02, 0.60]	
Heterogeneity: Tau ² = 0.00; Ch ² = 0.87) 1.11.5 6 months Chen CM 2010 3.93 1.82 27 4.09 1.2 23 0.2% -0.16 [-0.94, 0.62] Shi X 2022 1.33 0.47 40 1.24 0.61 45 2.1% 0.09 [-0.14, 0.32] Tang J 2019 2.7 0.8 63 2.6 0.4 95 2.8% 0.016 [-0.38, 0.46] Xiong XM 2019 1.7 0.85 33 6 1.65 0.79 25 0.8% 0.05 [-0.38, 0.46] Xiong XM 2019 1.7 0.85 33 6 1.65 0.79 25 0.8% 0.00 [-0.41, 0.41] Zhang LO 2015 2.38 0.64 36 2 0.51 32 1.6% 0.36 [0.09, 0.63] Zhang YI 2022 1.8 1.1 29 1.7 1.3 38 0.4% 0.00 [-0.41, 0.46] Zhang YI 2022 1.8 1.1 29 1.7 1.3 38 0.4% 0.01 [-0.48, 0.68] Zhang YI 2022 1.8 1.1 29 1.7 1.3 38 0.4% 0.01 [-0.47, 0.05] Subtatal (5% Cf) 429 444 16.8% 0.36 [0.09, 0.63] Test for overall effect: Z = 0.85 (P = 0.51) 1.11.6 12 months Liu GL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.12 [0.08, 0.16] Liu GL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.12 [0.08, 0.16] Liu GL 2015 5.42 0.76 66 2.1 0.6 66 2.2% 0.00 [-0.47, 0.37] Shi X 2022 0.83 0.54 00 960 0.42 45 2.7% -0.30 [-0.27, 0.37] Shi X 2022 0.83 0.54 00 960 8.24 45 2.7% -0.30 [-0.27, 0.37] Xiong XM 2019 1.38 0.82 38 1.32 0.75 25 0.8% 0.06 [-0.31, 0.51] Xiong XM 2017 3.14 0.32 38 3.2 0.2 38 4.9% -0.06 [-0.16, 0.06] Yan L 2015 2.45 1.86 45 2.73 1.57 46 0.3% -0.16 [-0.57, 0.37] Subtatal (5% Cf) 470 472 2.42% 0.00 [-0.41, 0.45] Xiong XM 2017 3.14 0.32 38 3.2 0.2 38 4.9% -0.06 [-0.41, 0.45] Xiong XM 2015 2.15 1.3 55 2.18 0.6% 0.00 [-0.42, 0.02] 1.11.74 at months Chen CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.31, 0.51] Subtatal (5% Cf) 470 472 2.42% 0.00 [-0.41, 0.45] Subtatal (5% Cf) 571 48 0.57 32 1.2% 0.00 [-0.43, 0.45] 1.11.724 months Chen CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.55, 0.67] Test for overall effect: Z = 0.02; (P = 0.006); P = 69% Test for overall effect: Z = 0.00; Ch ² = 0.02; (P = 0.006); P = 69% Test for overall effect: Z = 0.00; Ch ² = 76.74, df = 54 (P = 0.025); P = 0% Test for overall effect: Z = 0.00; Ch ² = 76.74, df = 54 (P = 0.025); P = 0% Test for overall effect: Z = 0.00; Ch ² = 76.74, df = 54 (P = 0.025); P = 0% Te	Subtotal (95% CI)	2.00 0.00	423	413	20.3%	0.02 [-0.06, 0.09]	•
1.11.5 6 months Chen CM 2010 3.93 1.62 27 4.09 1.2 23 0.2% -0.16 [-0.94, 0.62] Shi X 2022 1.33 0.47 40 1.24 0.61 45 2.1% 0.09 [-0.14, 0.32] Tang J 2019 2.7 0.8 83 2.6 0.4 95 2.8% 0.09 [-0.38, 0.46] Xing XM 2019 1.7 0.85 38 1.65 0.79 25 0.8% 0.00 [-0.48, 0.28] Yan L 2015 2.36 0.64 36 2.051 32.36 0.06 [-0.38, 0.06] Zhang YI 2022 1.8 1.1 29 1.7 1.3 38 0.4% 0.10 [-0.48, 0.68] Zhang YI 2022 1.8 1.3 0.32 69 5.2% -0.06 [-0.17, 0.06] Subtotal (8% Cl) 4.29 4.44 16.8% -0.10 [-0.57, 0.37] Sin X 2022 0.83 5.40 0.96 0.42 2.7% -0.36 [-0.62, -0.06] Xin Zu 20.43 0.86 0.55 0.61 1.3 0.36 0.66 2.2% 0.06 [-0.18, 0.06] Xin Zu 20.5 0.55	Heterogeneity: Tau ² = 0 Test for overall effect: 2	0.00; Chi ² = 8.3 Z = 0.42 (P = 0.	0, df = 8 (P = 0.4 67)	0); ² = 4%	6		
Chen CM 2010 3.93 1.62 27 4.09 1.2 23 0.2% -0.6 [-0.94, 0.62] Shi X 2022 1.33 0.47 40 1.24 0.61 45 2.1% 0.09 [-0.14, 0.32] Tang J 2019 2.7 0.8 63 2.6 0.4 95 2.8% 0.05 [-0.36, 0.46] Xi Dg XM 2019 1.7 0.85 38 1.65 0.79 25 0.8% 0.05 [-0.36, 0.46] Yan L 2015 2.9 1.1 55 2.9 1.1 53 0.8% 0.00 [-0.41, 0.41] Zhang YI 2022 1.8 1.1 29 1.7 1.3 38 0.4% 0.00 [-0.41, 0.41] Zhang YI 2022 1.8 1.1 29 1.7 1.3 38 0.4% 0.00 [-0.41, 0.41] Zhang YI 2022 1.8 1.1 29 1.7 1.3 38 0.4% 0.00 [-0.47, 0.05] Subtotal (95% CI) 428 444 16.8% 0.03 [-0.66, 0.13] Heterogeneily: Tau ² = 0.05; (P = 0.51) 1.11.6 12 months Liu CL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.12 [0.06, 0.16] Liu CL 2018 2.6 1.1 42 2.7 1.1 43 0.6% -0.10 [-0.57, 0.37] Shi X 2022 0.83 0.5 40 0.96 0.42 45 2.7% -0.18 [-0.33, 0.07] Tan HT 2018 2.2 0.7 66 2.1 0.6 6 2.2% 0.06 [-0.13, 0.16] Liu CL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.01 [-0.03, 0.45] Xu DL 2024 0.6 0.5 62 0.9 0.8 7 4 2.3% -0.30 [-0.52, 0.06] Xu DL 2024 0.6 0.5 62 0.9 0.8 7 4 2.3% -0.30 [-0.52, 0.06] Xu DL 2024 0.6 0.5 62 0.9 0.8 7 4 2.3% -0.30 [-0.52, 0.06] Xu DL 2024 0.6 0.5 62 0.9 0.8 7 4 2.3% -0.30 [-0.52, 0.06] Xu DL 2024 0.5 0.5 2.6 0.9 0.8 7 4 2.3% -0.30 [-0.52, 0.06] Xu DL 2025 2.25 0.77 38 1.84 0.57 32 1.2% 0.41 [0.09, 0.73] Subtotal (95% CI) 470 472 2.42% 0.40 [-0.48, 0.41] Zhang L2 2015 2.42 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.18, 0.61] Tat fr 2010 2.42 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.12, 0.12] Heterogeneily: Tau ² = 0.00; Ch ³ = 76.74, df = 9 (P = 0.0006); ¹² = 69% Test for overall effect: Z = 0.50 (P = 0.52) Test for overall effect: Z = 0.50 (P = 0.52), ff = 1.64 (P = 0.28); ¹² = 0% Test for overall effect: Z = 0.50 (P = 0.51) Total (95% CI) 22559 2598 2598 100.0% 0.01 [-0.03, 0.05] Heterogeneily: Tau ² = 0.00; Ch ³ = 76.74, df = 54 (P = 0.02); ¹² = 30% Test for overall effect: Z = 0.50 (P = 0.52) Test for overall effect: Z = 0.50 (P = 0.52) Test for overall effect: Z = 0.50 (P = 0.51) Total (95% CI) 2559 2598 2598 100.0% D.01 [-0.03, 0.05] Heterogeneily: Tau ²	1.11.5 6 months	a actions.• ann					
Shi X 2022 1.33 0.47 40 124 0.61 45 2.1% 0.09 [0.14, 0.32] Tang J 2019 2.7 0.8 63 2.6 0.4 95 2.6% 0.10 [-0.06, 0.29] Xlong XM 2019 1.7 0.85 38 1.65 0.79 25 0.8% 0.05 [-0.36, 0.46] Xu DL 2024 1.5 0.5 62 1.6 0.8 74 2.9% -0.10 [-0.28, 0.08] Yan L 2015 2.8 0.4 36 2 0.51 32 1.6% 0.36 [0.09, 0.63] Zhang YI 2022 1.8 1.1 25 2.9 1.1 53 0.8% 0.00 [0.41, 0.41] Zhang YI 2022 1.8 1.1 29 1.7 1.3 38 0.4% 0.10 [-0.46, 0.68] Zhou RL 2020 1.24 0.31 69 1.3 0.32 69 5.2% -0.06 [-0.17, 0.05] Subtal (95% CI) 429 429 444 16.8% 0.31 [-0.06, 0.13] Hotorogenelly: Tau ² = 0.01; Chl ^a = 10.74, df = 8 (P = 0.22); P = 25% Test for overall effect: Z = 0.85 (P = 0.51) 1.11.6 12 months Liu UL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.12 [0.08, 0.16] Liu WX 2018 2.8 1.1 42 2.7 1.1 43 0.6% -0.10 [-0.57, 0.37] Shi X 2022 0.83 0.5 40 0.98 0.42 45 2.7% -0.13 [-0.38, 0.07] Tan HT 2018 2.2 0.7 66 2.1 0.6 66 2.2% 0.10 [-0.12, 0.32] Xlong XM 2019 1.38 0.82 38 1.32 0.75 25 0.8% 0.06 [-0.33, 0.45] Xu DL 2024 0.5 0.5 62 0.9 0.8 74 2.3% -0.30 [-0.52, -0.08] Xu DL 2024 0.5 0.5 62 0.9 0.8 74 2.3% -0.06 [-0.18, 0.06] Yan L 2015 2.5 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.48, 0.46] Yang AF 2016 2.26 0.77 36 1.84 0.57 32 1.2% 0.41 [0.09, 0.73] Subtabal (95% CI) 470 472 24.2% 0.41 [0.09, 0.73] Subtabal (95% CI) 2.25 0.77 36 1.84 0.57 32 1.2% 0.41 [0.09, 0.73] Subtabal (95% CI) 2.25 0.77 36 1.84 0.57 32 0.7% 0.00 [-0.45, 0.45] Test for overall effect: Z = 0.01; Chl ^a = 0.02; Chl ^a = 0.02; P = 0.98) 1.11.7 24 months Test for overall effect: Z = 0.00; Chl ^a = 7.74, df = 54 (P = 0.02); P = 30% Test for overall effect: Z = 0.01; Chl ^a = 7.74, df = 54 (P = 0.02); P = 30% Test for overall effect: Z = 0.01; Chl ^a = 64 (P = 0.02); P = 30% Test for overall effect: Z = 0.01; Chl ^a = 64 (P = 0.02); P = 30% Test for overall effect: Z = 0.00; Chl ^a = 7.74, df = 54 (P = 0.02); P = 30% Test for overall effect: Z = 0.01; Chl ^a = 64 (P = 0.02); P = 30% Test for overall effect: Z = 0.01; Chl ^a = 64 (P = 0.02); P = 30% Test for overall effect: Z = 0.02	Chen CM 2010	3.93 1.62	27 4.09	.2 23	0.2%	-0.16 [-0.94, 0.62]	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Shi X 2022	1.33 0.47	40 1.24 0.	61 45	2.1%	0.09 [-0.14, 0.32]	±=
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	lang J 2019 Xiong XM 2019	2.7 0.8	63 2.6 (38 1.65 0	1.4 95 79 25	2.8%	0.10 [-0.09, 0.29]	
Yan L 2015 2.8 1.1 55 2.9 1.1 53 0.8% 0.00 [0.41, 0.41] Zhang L0 2015 2.36 0.64 36 2 0.51 32 1.6% 0.36 [0.09, 0.63] Zhang YI 2022 1.8 1.1 29 1.7 1.3 38 0.4% 0.10 [-0.48, 0.68] Zhou RL 2020 1.24 0.31 59 1.3 0.32 59 5.2% -0.06 [-0.17, 0.05] Subtrail (6% Ci) 429 444 16.8% 0.03 [-0.6, 0.13] Heterogeneily: Tau ² = 0.01; Chi ² = 10.74, df = 8 (P = 0.22); P = 25% Test for overall effect Z = 0.56 (P = 0.51) 1.11.6 12 months Liu CL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.12 [0.08, 0.16] Liu WX 2018 2.6 1.1 42 2.7 1.1 43 0.6% -0.10 [-0.57, 0.37] Shi X 2022 0.83 0.5 40 0.96 0.42 45 2.7% -0.13 [-0.38, 0.07] Shi X 2022 0.83 0.5 40 0.96 0.42 45 2.7% -0.13 [-0.38, 0.07] Shi X 2022 0.83 0.5 40 0.96 0.42 45 2.7% -0.13 [-0.38, 0.47] Xiong XM 2019 1.38 0.82 38 1.32 0.75 25 0.8% 0.06 [-0.33, 0.45] Xue W 2017 3.14 0.32 38 3.26 0.1 3 53 0.6% 0.00 [-0.48, 0.46] Yan L 2015 2.6 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.48, 0.46] Yan L 2015 2.56 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.48, 0.46] Yan L 2015 2.25 0.77 38 1.84 0.57 32 1.2% 0.41 [0.09, 0.73] Subtrail (6% Ci) 470 472 24.2% Test for overall effect Z = 0.02; Chi ² = 29.42, df = 9 (P = 0.0006); P = 69% Test for overall effect Z = 0.02; Chi ² = 29.42, df = 9 (P = 0.0006); P = 69% Test for overall effect Z = 0.00; Chi ² = 0.68; P = 0.48; P = 9% Test for overall effect Z = 0.00; Chi ² = 7.4, df = 54 (P = 0.02); P = 30% Test for overall effect Z = 0.00; Chi ² = 7.4, df = 54 (P = 0.02); P = 30% Test for overall effect Z = 0.00; Chi ² = 7.4, df = 54 (P = 0.02); P = 30% Test for overall effect Z = 0.00; Chi ² = 7.4, df = 54 (P = 0.02); P = 30% Test for overall effect Z = 0.00; Chi ² = 7.4, df = 54 (P = 0.02); P = 30% Test for overall effect Z = 0.01; Chi ² = 6.98; P = 0.02; Chi ² = 30% Test for overall effect Z = 0.02; Chi ² = 6.98; P = 0.02; P = 30% Test for overall effect Z = 0.02; Chi ² = 6.98; P = 0.02; P = 30% Test for overall effect Z = 0.02; Chi ² = 6.98; P = 0.98; P = 0%	Xu DL 2024	1.5 0.5	62 1.6 0	.6 74	2.9%	-0.10 [-0.28, 0.08]	-+
Δnam yr 2020 1.8 1.1 29 1.6% 0.36 [0.09, 0.63] Zhang Yr 2021 1.8 1.1 29 1.8 0.16 [0.48, 0.68] Zhou Kl. 2020 1.24 0.31 6.9 1.3 0.32 59 5.2% -0.06 [-0.17, 0.05] Subtotal (95% Cl) 429 444 16.8% 0.03 [-0.06, 0.13] -1.16% 0.03 [-0.06, 0.16] Liu CL 2015 5.42 0.12 48 5.3 0.1 50 8.5% 0.12 [0.08, 0.16] Liu CL 2015 5.42 0.12 48 5.3 0.1 50 8.5% 0.10 [-0.57, 0.37] Shi X 2022 0.83 0.5 40 0.96 0.42 45 2.7% -0.13 [-0.33, 0.07] Yan J Z016 2.6 1.1 42 2.7 1.4 30.6% -0.06 [-0.18, 0.06] -0.30 [-0.52, -0.06] Xue W 2017 3.14 0.32 0.32 2.3% -0.30 [-0.52, -0.06] -0.30 [-0.52, 0.07] Yang AF Z016 2.56 1.3 53 0.6% 0.00 [-0.42, 0.45] -1.6 [-0.55, 0.67] -1.6 [-0.55, 0.67] -1.6	Yan L 2015	2.9 1.1	55 2.9	.1 53	0.8%	0.00 [-0.41, 0.41]	
The form the form the form the form that the form the form that the form the form that the form the fo	Zhang LG 2015 Zhang YT 2022	2.36 0.64	36 20. 29 17	51 32 3 38	1.6%	0.36 [0.09, 0.63]	
Subtotal (95% CI) 429 444 16.8% 0.03 [-0.06, 0.13] Heterogeneity: Tau ² = 0.01; Ch ² = 10.74, df = 8 (P = 0.22); ² = 25% Test for overall effect Z = 0.85 (P = 0.51) 1.11.6 12 months Liu CL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.12 [0.08, 0.16] Liu MX 2018 2.6 1.1 42 2.7 1.1 43 0.6% -0.10 [-0.57, 0.37] Tan HT 2018 2.2 0.7 66 2.1 0.6 66 2.2% 0.10 [-0.12, 0.32] Xiong XM 2019 1.38 0.82 38 1.32 0.75 25 0.8% 0.06 [-0.33, 0.45] Xu DL 2024 0.6 0.5 62 0.9 0.8 74 2.3% -0.30 [-0.52, -0.08] Xu DL 2024 0.6 0.5 62 0.9 0.8 74 2.3% -0.30 [-0.52, -0.08] Yan L 2015 2.26 1.3 52 6.6 1.3 53 0.6% 0.000 [-0.40, 0.49] Yang AF 2018 2.26 1.3 52 6.6 1.3 53 0.6% 0.000 [-0.40, 0.49] Yang AF 2018 2.26 1.6 45 2.73 1.57 48 0.3% -0.15 [-0.81, 0.61] Zhang L 2015 2.25 0.77 36 1.84 0.57 32 1.2% 0.41 [0.09, 0.73] Subtotal effect: Z = 0.02 (P ³ = 29.42, df = 9 (P = 0.0006); ³ = 69% Test for overall effect: Z = 0.02 (P = 0.99) 1.11.7 24 months Cher CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.55, 0.67] Zhang L 2015 2.1 0.9 24 2.1 0.7 26 0.7% 0.00 [-0.45, 0.45] Subtotal effect: Z = 0.01; Ch ³ = 0.02; (P ³ = 0.98); ³ = 0% Test for overall effect: Z = 0.11 (P = 0.81); ³ = 0% Test for overall effect: Z = 0.01; Ch ³ = 76.74, df = 54 (P = 0.02); ³ = 30% Test for overall effect: Z = 0.50; CP = 0.82] Test for subcroup differences: Ch ³ = 1.44, df = 6 (P = 0.96), P = 0%	Zhou RL 2020	1.24 0.31	59 1.3 0.	32 59	5.2%	-0.06 [-0.17, 0.05]	-
Heterogeneity: Tau ² = 0.01; Ch ² = 10.74, df = 8 (P = 0.22); ² = 25% Test for overall effect: Z = 0.85 (P = 0.51) 1.11.6 12 months Liu CL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.12 [0.06, 0.16] Liu MX 2018 2.6 1.1 42 2.7 1.1 43 0.6% -0.10 [-0.57, 0.37] Tan HT 2018 2.2 0.7 66 2.1 0.6 66 2.2% 0.10 [-0.12, 0.32] Xiong XM 2019 1.38 0.82 38 1.32 0.75 25 0.8% 0.06 [-0.33, 0.45] Xu DL 2024 0.6 0.5 62 0.9 0.8 74 2.3% -0.30 [-0.52, -0.08] Xu DL 2024 0.6 0.5 62 0.9 0.8 74 2.3% -0.30 [-0.52, -0.08] Xu DL 2015 2.26 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.18, 0.06] Yan L 2015 2.26 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.18, 0.06] Yang AF 2018 2.58 1.86 45 2.73 1.57 46 0.3% -0.15 [-0.81, 0.51] Zhang LG 2015 2.25 0.77 36 1.84 0.57 32 1.2% 0.41 [0.09, 0.73] Subtotal (95% Cl) 470 472 2.42.% 0.00 [-0.12, 0.12] Heterogeneily: Tau ² = 0.02; Ch ³ = 29.42, df = 9 (P = 0.0006); ³ = 69% Test for overall effect: Z = 0.01 (P = 0.99) 1.11.724 months Cher CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.55, 0.67] Zhang L 2015 2.1 0.9 24 2.1 0.7 26 0.7% 0.00 [-0.43, 0.38] Heterogeneily: Tau ² = 0.00; Ch ³ = 0.02, df = 1 (P = 0.88); ³ = 0% Test for overall effect: Z = 0.11 (P = 0.81) Test for overall effect: Z = 0.01; Ch ³ = 54 (P = 0.02); ³ = 30% Test for overall effect: Z = 0.00; Ch ³ = 76.74, df = 54 (P = 0.02); ³ = 30% Test for overall effect: Z = 0.00; Ch ³ = 76.74, df = 54 (P = 0.02); ³ = 30% Test for overall effect: Z = 0.01; Ch ³ = 64 (P = 0.02); ³ = 30% Test for overall effect: Z = 0.01; Ch ³ = 64 (P = 0.02); ³ = 30% Test for overall effect: Z = 0.02; Ch ³ = 64 (P = 0.02); ³ = 30% Test for overall effect: Z = 0.11 (P = 0.81) Test for overall effect: Z = 0.12 (Lillatoral] Test for overall effect: Z = 0.12 (Lillatoral] Test for overall effect: Z = 0.12 (Lillatoral] Test for overall effect: Z = 0.13 (Lillatoral] Test for overall effect: Z = 0.144, df = 6 (P = 0.98), P = 0%	Subtotal (95% CI)		429	444	16.8%	0.03 [-0.06, 0.13]	•
1.11.6 12 months Liu CL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.12 [0.08, 0.16] Liu KX 2018 2.6 1.1 42 2.7 1.4 43 0.6% -0.10 [-0.57, 0.37] Shi X 2022 0.83 0.5 40 0.96 0.42 45 2.7% -0.13 [-0.33, 0.07] Tan HT 2018 2.2 0.7 66 2.1 0.6 66 2.2% -0.10 [-0.13, 0.45] Xi DL 2024 0.6 0.5 62 0.9 0.8 74 2.3% -0.30 [-0.52, -0.08] Xu BV 2017 3.14 0.32 38 3.2 0.27 2.5 0.8% 0.06 [-0.48, 0.49] Yan L 2015 2.5 1.3 52 2.6 1.3 53 0.6% 0.00 [-0.48, 0.49] Yan L 2015 2.55 0.77 36 1.84 0.57 32 1.2% 0.30 [-0.55, 0.67] Zhang L 2015 2.52 0.77 36 1.84 0.57 32 0.4% 0.06 [-0.55, 0.67] Zhang L 2015 2.1	Heterogeneity: Tau ² = 0 Test for overall effect: 2	0.01; Chl² = 10. Z = 0.65 (P = 0.	74, df = 8 (P = 0 51)	.22); ² = 2	5%		
Lu CL 2015 5.42 0.12 48 5.3 0.1 50 8.6% 0.12 [0.08, 0.16] Lu MX 2018 2.6 1.1 42 2.7 1.1 43 0.8% -0.10 [-0.57, 0.37] Shi X 2022 0.83 0.5 40 0.96 0.42 5 2.7% -0.13 [-0.33, 0.07] Tan HT 2018 2.2 0.7 66 2.1 0.6 66 2.2% 0.10 [-0.12, 0.32] Xuo W 2017 3.14 0.32 38 3.2 0.2 38 4.9% -0.06 [-0.33, 0.45] Xu DL 2024 0.6 0.5 62 0.9 0.8 74 2.3% -0.30 [-0.52, -0.06] Xu W 2017 3.14 0.32 38 3.2 0.2 38 4.9% -0.06 [-0.18, 0.66] Yan L 2015 2.6 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.49, 0.49] Yan J 2015 2.6 1.3 55 2.6 1.3 53 0.6% Subtotal (95% CI) 470 472 24.2% 0.00 [-0.12, 0.12] Heterogeneily: Tau ² = 0.02; Ch ² = 29.42, df = 9 (P = 0.0006); P = 69% Test for overall effect Z = 0.01 (P = 0.98) Heterogeneily: Tau ² = 0.00; Chi ² = 0.02, df = 1 (P = 0.88); P = 0% Test for overall effect Z = 0.01 (P = 0.91) Total (95% CI) 2559 2598 100.0% 0.01 [-0.03, 0.05] Heterogeneily: Tau ² = 0.00; Chi ² = 76.74, df = 54 (P = 0.96), P = 0% Test for overall effect: Z = 0.50 (P = 0.62); P = 30% Test for overall effect: Z = 0.50 (P = 0.44, df = 6 (P = 0.96), P = 0%	1.11.6 12 months						
Lu mA 2010 2.6 1.1 42 2.7 1.1 43 0.8% -0.10 $P_{0.57}$ 0.37 Tan HT 2018 2.2 0.7 66 2.1 0.6 66 2.2% 0.10 $P_{0.52}$ 0.33 0.07 Tan HT 2018 2.2 0.7 66 2.1 0.6 66 2.2% 0.10 $P_{0.52}$ 0.33 0.07 Tan HT 2018 2.2 0.7 66 2.1 0.6 66 2.2% 0.10 $P_{0.52}$ 0.33 0.07 Tan HT 2018 2.2 0.7 66 2.1 0.6 66 2.2% 0.08 $P_{0.52}$ 0.33 0.05 Tan HT 2018 2.2 0.7 66 2.1 0.6 66 2.2% 0.08 $P_{0.52}$ 0.33 0.65 Xue W 2017 3.14 0.32 38 3.2 0.2 38 4.9% -0.06 $P_{0.52}$ 0.08 Van L 2015 2.6 1.3 55 2.6 1.3 53 0.6% 0.000 $P_{0.48}$ 0.49 Yan L 2015 2.6 1.3 55 2.6 1.3 53 0.6% 0.000 $P_{0.48}$ 0.49 Yan J 2018 2.58 1.68 45 2.73 1.57 48 0.3% -0.15 $P_{0.48}$ 0.41 $P_{0.08}$ 0.73 Subtotal (95% C1) 470 472 2.42.% 0.40 $P_{0.0006}$; $P = 69\%$ Test for overall effect: Z = 0.02 ($P = 0.99$) 1.11.7 24 months Cher CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 $P_{0.55}$ 0.67 Tah for U 210 2.22 1.31 27 2.76 0.88 23 0.4% 0.06 $P_{0.55}$ 0.67 Test for overall effect: Z = 0.11 ($P = 0.88$); $P = 0\%$ Test for overall effect: Z = 0.11 ($P = 0.99$) 1.11.7 24 months Cher CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 $P_{0.55}$ 0.67 Test for overall effect: Z = 0.00; Chi ^a = 0.02, ch ^a = 10, P = 0% Test for overall effect: Z = 0.01; Chi ^a = 0.02, ch ^a = 10, P = 0.02; $P = 30\%$ Test for overall effect: Z = 0.50; $P = 0.52$) Test for subcroup differences: Chi ^a = 1.44, df = 5 ($P = 0.98$), $P = 0\%$	Llu CL 2015	5.42 0.12	48 5.3 0	.1 50	8.6%	0.12 [0.08, 0.16]	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Liu MX 2018 Shi X 2022	2.6 1.1	42 2.7	.1 43 42 AF	0.6% 2.7%	-0.10 [-0.57, 0.37]	
Xiong XM 2019 1.38 0.82 38 1.32 0.75 25 0.8% 0.06 [-0.33, 0.45] Xu DL 2024 0.6 0.5 62 0.9 0.8 74 2.3% -0.36 [-0.52, -0.08] Yang Value W 2017 3.14 0.32 38 3.2 0.2 38 4.9% -0.06 [-0.16, 0.06] Yang Value W 2017 2.46 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.49, 0.49] Yang AF 2018 2.58 1.86 45 2.73 1.57 46 0.3% -0.15 [-0.81, 0.51] Yang AF 2018 2.58 1.86 45 2.73 1.57 46 0.3% -0.15 [-0.81, 0.51] Yang AF 2018 2.58 1.86 45 2.73 1.57 46 0.3% -0.15 [-0.81, 0.51] Heterogeneity: Tau ² = 0.02; Chl ² = 29.42, df = 9 (P = 0.0006); P = 69% Test for overall effect Z = 0.02; Chl ² = 0.99) 1.11.7 24 months Chen CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.55, 0.67] Zhang L 2015 2.1 0.9 24 2.1 0.7 26 0.7% 0.00 [-0.34, 0.38] Heterogeneity: Tau ² = 0.02; Chl ² = 0.02; df = 1 (P = 0.88); P = 0% Test for overall effect Z = 0.11 (P = 0.1) Total (95% C1) 2559 2598 100.0% 0.01 [-0.03, 0.05] Heterogeneity: Tau ² = 0.00; Chl ² = 76.74, df = 54 (P = 0.02); P = 30% Test for overall effect Z = 0.50 (P = 0.50) Test for overall effect Z = 0.50 (P = 0.82) Test for subarcoup differences: ChP = 1.44, df = 6 (P = 0.96), P = 0%	Tan HT 2018	2.2 0.7	66 2.1 0	.6 66	2.2%	0.10 [-0.12, 0.32]	+
Xu DL 2024 0.6 0.5 62 0.9 0.8 74 2.3% -0.30 [-0.52, -0.08] Xu W 2017 3.14 0.32 38 3.2 0.2 38 4.9% -0.06 [-0.16, 0.06] Yan L 2015 2.6 1.3 55 2.6 1.3 53 0.6% 0.00 [-0.49, 0.49] Yang JG 2015 2.25 0.77 36 1.84 0.57 32 1.2% 0.41 [0.09, 0.73] Subtotal (95% Ct) 470 472 24.2% 0.00 [-0.12, 0.12] Heterogeneity: Tau ² = 0.02; Chi ² = 29.42, df = 9 (P = 0.0006); I ² = 69% Test for overall effect Z = 0.02; Chi ² = 0.02, df = 1 (P = 0.88); I ² = 0% Test for overall effect Z = 0.01; Chi ² = 76.74, df = 54 (P = 0.02); I ² = 30% Test for overall effect Z = 0.50 (P = 0.52) Test for subcroup differences: Chi ² = 1.44, df = 6 (P = 0.96); I ² = 0%	Xiong XM 2019	1.38 0.82	38 1.32 0.	75 25	0.8%	0.06 [-0.33, 0.45]	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Xu DL 2024	0.6 0.5	62 0.9 0	8 74	2.3%	-0.30 [-0.52, -0.08]	
Yang AF 2018 2.58 1.86 45 2.73 1.57 46 0.3% $-0.15 [-0.81, 0.51]$ Zhang LG 2015 2.25 0.77 36 1.84 0.57 32 1.2% $0.41 [0.09, 0.73]$ Sublockal (8% CI) 470 472 24.2% $0.41 [0.09, 0.73]$ Hoterogeneity: Tau ² = 0.02; Ch ² = 28.42; df = 9 (P = 0.0006); P = 69% Test for overall effect: Z = 0.02 (P = 0.99) 1.11.7 24 months Chen CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% $0.06 [-0.55, 0.67]$ Zhang L 2015 2.1 0.9 24 2.1 0.7 26 0.7% $0.00 [-0.45, 0.45]$ Sublockal (95% CI) 51 49 1.0% $0.02 [-0.34, 0.38]$ Heterogeneity: Tau ² = 0.00; Ch ² = 0.02; df = 1 (P = 0.88); P = 0% Test for overall effect: Z = 0.11 (P = 0.91) Total (95% CI) 2559 2598 100.0% $0.01 [-0.03, 0.05]$ Heterogeneity: Tau ² = 0.50; Ch ² = 76.74, df = 54 (P = 0.92); P = 30% Test for overall effect: Z = 0.50 (P = 0.52) Test for subcroup differences: ChP = 1.44, df = 6 (P = 0.96). P = 0%	Yan L 2015	2.6 1.3	55 2.6 ⁻	.2 38	4.9%	0.00 [-0.18, 0.06]	
Zhang LG 2015 2.25 0.77 36 1.84 0.57 32 1.2% 0.41 [0.09, 0.73] Subtobal (8% Ci) 470 472 24.2% 0.00 [-0.12, 0.12] Heterogeneity: Tau ² = 0.02; Chi ² = 29.42, df = 9 (P = 0.0006); i ² = 69% Test for overall effect Z = 0.02 (P = 0.99) 1.11.7 24 months Chen CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.55, 0.67] Zhang L 2015 2.1 0.9 24 2.1 0.7% 0.00 [-0.45, 0.45] Heterogeneily: Tau ² = 0.00; Chi ² = 10.2; df = 1 (P = 0.88); i ³ = 0% 1.0% 0.00 [-0.45, 0.45] Test for overall effect Z = 0.11 (P = 0.91) 2559 2598 100.0% 0.01 [-0.03, 0.05] Test for overall effect Z = 0.00; Chi ² = 76.74, df = 54 (P = 0.02); i ³ = 30% 1.0% 0.01 [-0.03, 0.05] -1 Test for overall effect Z = 0.02; P = 0.52) Test for overall effect Z = 0.50 (P = 0.52) 1 Favours [Bilateral] Favours [Unilateral]	Yang AF 2018	2.58 1.66	45 2.73 1.	57 46	0.3%	-0.15 [-0.81, 0.51]	
1.11.7 24 months Chen CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.55, 0.67] The torogeneity: Taut = 0.02; Chi ² = 0.29; 1.11.7 24 months 0.00 [-0.34, 0.38] Chen CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.55, 0.67] Zhang L 2015 2.1 0.9 2.1 0.7 26 0.7% 0.00 [-0.34, 0.38] Heterogeneity: Tau* = 0.00; Chi ² = 0.02; df = 1 (P = 0.88); I ² = 0% 0.01 [-0.03, 0.05] 1 Test for overall effect: Z = 0.11 (P = 0.91) 2559 2598 100.0% 0.01 [-0.03, 0.05] Test for overall effect: Z = 0.50 (P = 0.62) 2598 100.0% 0.01 [-0.03, 0.05] -1 Test for overall effect: Z = 0.50 (P = 0.62) Test for subaroup differences: ChP = 1.44. df = 6 (P = 0.96); P = 0% Favours [Billateral] Favours [Unilateral]	Zhang LG 2015 Subtotal (95% CI)	2.25 0.77	36 1.84 0. 470	57 32	1.2%	0.41 [0.09, 0.73]	▲
1 rest for Overain entect: 2 = 0.02 (P = 0.99) 1.11.7 24 months Chen CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.55, 0.67] Drang L 2015 2.1 0.9 24 2.1 0.7 26 0.7% 0.00 [-0.45, 0.45] Subtotal (95% CI) 51 49 1.0% 0.02 [-0.34, 0.38] Heterogeneity: Tau ² = 0.00; Chi ² = 0.02; df = 1 (P = 0.88); l ² = 0% Total (95% CI) 2559 2559 2568 100.0% 0.01 [-0.03, 0.05] Heterogeneity: Tau ² = 0.00; Chi ² = 76.74, df = 54 (P = 0.02); l ² = 30% Test for overall effect: Z = 0.50 (P = 0.62) Test for subaroup differences: Chi ² = 1.44, df = 6 (P = 0.96). P = 0%	Heterogeneity: Tau ² = 0	0.02; Chi ² = 29.	42, df = 9 (P = 0	.0006); ² :	= 69%	2.00 [-0.16, 0.16]	Ţ
1.11.7 24 months Chen CM 2010 2.82 1.31 27 2.76 0.88 23 0.4% 0.06 [-0.55, 0.67] Zhang L 2015 2.1 0.9 24 2.1 0.7 26 0.7% 0.00 [-0.45, 0.45] Subtatal (95% CI) 51 49 1.0% 0.02 [-0.34, 0.38] Heterogeneily: Tau ² = 0.00; Chi ² = 0.02; df = 1 (P = 0.88); i ² = 0% Test for overall effect: Z = 0.11 (P = 0.91) Total (95% CI) 2559 2598 100.0% 0.01 [-0.03, 0.05] Heterogeneily: Tau ² = 0.00; Chi ² = 76.74, df = 54 (P = 0.02; i ² = 30% Test for overall effect: Z = 0.50 (P = 0.52) Test for subaroup differences: Chi ² = 1.44, df = 6 (P = 0.96). P = 0%	est for overall effect: 2	z = 0.02 (P = 0.	99)				
Chang L 2015 2.1 0.9 2.4 2.1 0.7 26 0.7% 0.00 [-0.35, 0.07] Subtotal (95% CI) 51 1.0 2.4 2.1 0.7 26 0.7% 0.00 [-0.35, 0.07] Subtotal (95% CI) 51 1.0 2.6 0.7% 0.00 [-0.34, 0.38] Heterogeneity: Tau ² = 0.00; Chi ² = 0.02; df = 1 (P = 0.88); l ² = 0% 0.02 [-0.34, 0.38] 0.02 [-0.34, 0.38] Total (95% CI) 2559 2598 100.0% 0.01 [-0.03, 0.05] 0.11 [-0.05, 0.05] Heterogeneity: Tau ² = 0.00; Chi ² = 76.74, df = 54 (P = 0.02); l ² = 30% 0.01 [-0.03, 0.05] -1 -0.5 0 5 Test for overall effect: Z = 0.50 (P = 0.52) Test for subaroup differences: ChP = 1.44, df = 6 (P = 0.96), P = 0% Favours [Bilateral] Favours [Bilateral] Favours [Unilateral]	1.11.7 24 months Chen CM 2010	282 1 21	27 276 0	RR 33	0.4%	0.061.055.067	
Subtotal (95% CI) 51 49 1.0% 0.02 [-0.34, 0.38] Heterogeneity: Tau ² = 0.00; Chi ² = 0.02, df = 1 (P = 0.88); I ² = 0% Total (95% CI) 2559 2598 100.0% 0.01 [-0.03, 0.05] Heterogeneity: Tau ² = 0.00; Chi ² = 76.74, df = 54 (P = 0.02); I ² = 30% Test for overall effect: Z = 0.50 (P = 0.52) Test for subaroup differences: Chi ² = 1.44, df = 6 (P = 0.96). P = 0%	Zhang L 2015	2.1 0.9	24 2.1 0	0.7 26	0.4%	0.00 [-0.45, 0.45]	<u> </u>
Heterogeneity: Tau ² = 0.00; Chi ² = 0.02; df = 1 (P = 0.88); I ² = 0% Total (95% Cf) 2559 2598 100.0% 0.01 [-0.03, 0.05] Heterogeneity: Tau ² = 0.00; Chi ² = 76.74, df = 54 (P = 0.02); I ² = 30% Test for overall effect: Z = 0.50 (P = 0.82) Test for subaroup differences: Chi ² = 1.44, df = 6 (P = 0.96). I ² = 0% Favours [Bilateral] Fevours [Dilateral]	Subtotal (95% CI)		51	49	1.0%	0.02 [-0.34, 0.38]	-
Total (95% Ci) 2559 2598 100.0% 0.01 [-0.03, 0.05] Heterogeneity: Tau ² = 0.00; Chi ² = 76.74, df = 54 (P = 0.02); i ² = 30% -1 -0.5 0 0.5 1 Test for overall effect: Z = 0.50 (P = 0.62) Test for subaroup differences: Chi ² = 1.44. df = 6 (P = 0.96). I ² = 0% Favours [Bilateral] Favours [Bilateral] Favours [Chilateral]	Heterogeneity: Tau ² = 0 Test for overall effect: 2	0.00; Chi ² = 0.0 Z = 0.11 (P = 0.	2, df = 1 (P = 0.8 91)	18); ² = 0%	6		
Heterogeneity: Tau ² = 0.00; Chi ² = 76.74, df = 54 (P = 0.02); I ² = 30% -1 -0.5 0.5 1 Test for overall effect: Z = 0.50 (P = 0.62) -1 -0.5 0.5 1 Test for subaroup differences: Chi ² = 1.44, df = 6 (P = 0.96). P = 0% Favours [Bilateral] Favours [Initiateral]	Total (95% CI)		2559	2598	100.0%	0.01 [-0.03, 0.05]	•
less for overall effect: L = 0.50 (P = 0.52) Test for subaroup differences: ChP = 1.44. df = 6 (P = 0.96). P = 0% Favours [Unllateral]	Heterogeneity: Tau ² = 0	0.00; Chi ² = 76.	74, df = 54 (P =	0.02); ² =	30%	_	-1 -0.5 0 0.5 1
	Test for overall effect: 2	Z = 0.50 (P = 0.	62) 44. df = 6./D -	1961 IZ-	0%		Favours [Bilateral] Favours [Unllateral]
	may not supprised of the	ienues: unr = 1	ul = 0 (P =		u 70		

Study or Subgroup	Bliateral		Unllatera	ıl		Mean Difference	Mean Difference
	Mean SD	Total M	an SD	Total	Weight	IV. Random, 95% Cl	IV. Random, 95% Cl
1.12.1 Post-operation	i i				-		
Geng ZH 2021	19.4 3.6	40 2	0.8 4.6	31	2.3%	-1.40 [-3.37, 0.57]	
Liu CL 2015	35.46 1.89	48 36	.08 2.13	50	4.6%	-0.62 [-1.42, 0.18]	
Liu MX 2018	19.8 6.4	42 1	9.7 2.6	43	2.1%	0.10 [-1.99, 2.19]	
Shi X 2022	31.66 9.23	40 3	0.8 9.49	45	0.8%	0.86 [-3.12, 4.84]	
Tang J 2019	26.5 2.9	83 2	5.8 2	95	4.7%	0.70 [-0.04, 1.44]	~
Xiong XM 2019	32.73 5.05	38 33	.74 7.05	25	1.1%	-1.01 [-4.21, 2.19]	
Xue W 2017	23 2.34	38 22	.32 2.05	38	4.1%	0.68 [-0.31, 1.67]	
Zhang L 2015	27.3 4.2	24 2	6.1 3.4	26	2.1%	1.20 [-0.93, 3.33]	+
Zhang LC 2023	37.5 4.21	36 37	.77 3.72	35	2.4%	-0.27 [-2.12, 1.58]	
Subtotal (95% CI)		389		388	24.2%	0.11 [-0.45, 0.67]	♦
Heterogeneity: Tau ² =	0.18; Chi ² = 10	.95, df = 8	(P = 0.20); ² = 27	7%		
Test for overall effect:	Z = 0.37 (P = 0	.71)	•				
		,					
1.12.2 14 days							
Chen CM 2010	19.85 6.45	33 21	.32 4.19	25	1.4%	-1.47 [-4.22, 1.28]	+
Chen CM 2014	25.51 4.53	20 28	55 4.22	19	1.4%	-3.04 [-5.790.29]	
Zhang I C 2023	28 89 2 21	36 28	69 2 78	35	37%	0 20 1-0 97 1 371	+-
Subtotal (95% CI)	10.00 1.11	89		79	6.6%	-1.13 [-3.13, 0.88]	◆
Heterogeneity: Tau ² =	1 92 [.] Chi ² = 5 [.]	13 df = 2	P = 0.08	$ ^2 = 619$	%		
Test for overall effect:	7 = 1.02, 0 = 0.000	27)	(i – 0.00),	1 - 01	/0		
Test for Overall effect.	2 - 1.10 (P - 0	.21)					
1.12.3 1 month							
	364 50	175 9	57 59	200	3 70/	0 70 [-0 49 4 99]	<u>+</u>
Viena VM 2010	00.4 0.9	20 00	20 575	200	1 40/	0.70 [-0.40, 1.00]	
	22.10 0.4/	35 23	0 1 5	20	1.4%	-0.00 [-0.00, 2.00]	
Au DL 2024	30.0 3.6	02 3	0.1 0./	/4	2.9%	-1.50 [-3.08, 0.08]	
Tang AF 2018	15.33 2.52	45 14	.08 2.47	46	4.1%	0.05 [-0.38, 1.68]	_
Znang LC 2023 Subtetal (SEV CI)	20.94 2.81	36 2	1.2 2.67	35	3.5%	-0.20 [-1.53, 1.01]	▲
Subtotal (95% CI)		330	-	300	19.9%	0.00 [-0.80, 0.80]	Y
Heterogeneity: Tau ² =	0.31; Chi ² = 6.	53, df = 4	(P = 0.16);	$l^2 = 39$	%		
Test for overall effect:	Z = 0.01 (P = 0)	.99)					
4 40 4 0							
1.12.4 3 months							
Feng YH 2023	32.14 3.28	50 32	.09 3.21	50	3.5%	0.05 [-1.22, 1.32]	
Geng ZH 2021	20.5 3.9	40 2	0.3 4.7	31	2.2%	0.20 [-1.85, 2.25]	T
Tang J 2019	24.1 2.3	83 2	3.8 1.9	95	5.0%	0.30 [-0.33, 0.93]	T
Yang AF 2018	15.87 3.52	45 14	.76 3.41	46	3.2%	1.11 [-0.31, 2.53]	T
Subtotal (95% CI)		218		222	13.8%	0.36 [-0.15, 0.86]	
Heterogeneity: Tau ² =	0.00; Chi ² = 1.	35, df = 3	(P = 0.72);	l² = 0%			
Test for overall effect:	Z = 1.38 (P = 0	.17)					
1.12.5 6 months							
Chen CM 2010	22.33 4.4	20 24	.35 4.22	19	1.5%	-2.02 [-4.73, 0.69]	
		40 7	0.8 7.52	45	1.0%	2.42 [-0.97, 5.81]	
Shi X 2022	23.22 8.31	40 2					
Shi X 2022 Tang J 2019	23.22 8.31 23.5 2.5	83 2	2.9 1.8	95	4.9%	0.60 [-0.05, 1.25]	-
Shi X 2022 Tang J 2019 Xiong XM 2019	23.22 8.31 23.5 2.5 18.84 5.05	83 2 38 18	2.9 1.8 .25 5.36	95 25	4.9% 1.5%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6	40 2 83 2 38 18 62 2	2.9 1.8 .25 5.36 8.2 3.5	95 25 74	4.9% 1.5% 4.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02	40 2 83 2 38 18 62 2 59 2	2.9 1.8 25 5.36 8.2 3.5 3.2 6.04	95 25 74 59	4.9% 1.5% 4.0% 2.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI)	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02	40 2 83 2 38 18 62 2 59 2 302	2.9 1.8 2.5 5.36 8.2 3.5 3.2 6.04	95 25 74 59 317	4.9% 1.5% 4.0% 2.0% 15.0 %	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² =	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Chi ² = 5.1	83 2 38 18 62 2 59 2 302 04, df = 5	2.9 1.8 2.25 5.36 8.2 3.5 3.2 6.04 (P = 0.41);	95 25 74 59 317 ² = 1%	4.9% 1.5% 4.0% 2.0% 15.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: :	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Chi ² = 5.1 Z = 2.04 (P = 0	40 2 83 2 38 18 62 2 59 2 302 04, df = 5 0.04)	2.9 1.8 2.25 5.36 8.2 3.5 3.2 6.04 (P = 0.41);	95 25 74 59 317 ² = 1%	4.9% 1.5% 4.0% 2.0% 15.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: :	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Chi ² = 5.1 Z = 2.04 (P = 0	40 2 83 2 38 18 62 2 59 2 302 04, df = 5 0.04)	2.9 1.8 .25 5.36 8.2 3.5 3.2 6.04 (P = 0.41);	95 25 74 59 317 ² = 1%	4.9% 1.5% 4.0% 2.0% 15.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 1.12.6 12 months	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Chi ² = 5.1 Z = 2.04 (P = 0	40 2 83 2 38 18 62 2 59 2 302 04, df = 5 0.04)	2.9 1.8 2.5 5.36 8.2 3.5 3.2 6.04 (P = 0.41);	95 25 74 59 317 I ² = 1%	4.9% 1.5% 4.0% 2.0% 15.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : 1.12.6 12 months Liu CL 2015	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Chi ² = 5.1 Z = 2.04 (P = 0 47.88 2.21	40 2 83 2 38 18 62 2 59 2 302 04, df = 5 0.04) 48 47	2.9 1.8 .25 5.36 8.2 3.5 3.2 6.04 (P = 0.41);	95 25 74 59 317 ² = 1%	4.9% 1.5% 4.0% 2.0% 15.0% 4.5%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.6 12 months Liu CL 2015 Liu XX 2018	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ² = 5. Z = 2.04 (P = 0 47.88 2.21 20.1 3.5	40 2 83 2 38 18 62 2 59 2 302 04, df = 5 0.04) 48 47 42 1	2.9 1.8 2.5 5.36 8.2 3.5 3.2 6.04 (P = 0.41); 3.54 1.97 9.9 4.4	95 25 74 59 317 ² = 1% 50 43	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ² = 5.1 Z = 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7 21	40 2 83 2 38 18 62 2 302 04, df = 5 0.04) 48 47 42 1 40 13	2.9 1.8 .25 5.36 8.2 3.5 3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47	95 25 74 59 317 ² = 1% 50 43 45	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 1.3%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5 32]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Chi ² = 5. Z = 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14	40 2 83 2 38 18 62 2 302 04, df = 5 .04) 48 47 42 1 40 13 38 14	2.9 1.8 2.5 5.36 8.2 3.5 3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36	95 25 74 59 317 ² = 1% 50 43 45 25	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 1.3% 2.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.81]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Yu DI 2024	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Chi ² = 5. Z = 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1	40 2 83 2 38 16 62 2 59 2 302 04, df = 5 04) 48 47 42 1 40 13 38 14 62 2	2.9 1.8 .25 5.36 .8.2 3.5 .3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 75 1.8	95 25 74 59 317 ² = 1% 50 43 45 25 74	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 1.3% 2.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] 2.80 [-67, -1.93]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ^{μ} = 5. Z = 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 25.8 1.66	40 2 83 2 38 16 62 2 59 2 302 04, df = 5 0.04) 48 47 42 1 40 13 38 14 62 2 45 2	2.9 1.8 .25 5.36 .8.2 3.5 3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 (7.5 1.8	95 25 74 59 317 ² = 1% 50 43 45 25 74 46	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 1.3% 2.0% 4.4%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [0.81, 0.51]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	40 2 83 2 38 16 62 2 59 2 302 04, df = 5 .04) 48 47 42 1 40 13 38 14 62 2 45 2 275	2.9 1.8 .25 5.36 .8.2 3.5 .3.2 6.04 (P = 0.41); .54 1.97 .9.9 4.4 .32 6.47 .62 4.36 .7.5 1.8 .73 1.57	95 25 74 59 317 ² = 1% 50 43 45 25 74 46 283	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 1.3% 2.0% 4.4% 4.9%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] 0.14 [-4.41, 16]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI)	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Chi ² = 5.0 Z = 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 2.58 1.66 2.04; Chi ² = 32	40 2 83 2 83 2 59 2 302 59 2 302 48 47 42 1 40 12 48 47 42 1 40 12 48 14 62 2 45 2 275	2.9 1.8 .25 5.36 .8.2 3.5 3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .62 4.36 7.5 1.8 .73 1.57	95 25 74 59 317 ² = 1% 50 43 45 25 74 283 201): ²	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 1.3% 2.0% 4.4% 4.9% 4.9% 19%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (85% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Chi ² = 5. Z = 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 2.58 1.66 2.04; Chi ² = 37 - 0.21 (P = 0	$\begin{array}{c} 43 & 2 \\ 83 & 2 \\ 38 & 16 \\ 62 & 2 \\ 59 & 2 \\ 302 \\ 04, df = 5 \\ .04) \\ 48 & 47 \\ 42 & 1 \\ 40 & 13 \\ 38 & 14 \\ 62 & 2 \\ 45 & 2 \\ 275 \\ (.23, df = 6 \\ 82) \\ (.23, df = 6 \\ 82) \end{array}$	2.9 1.8 .25 5.36 .8.2 3.5 .3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 .75 1.8 .73 1.57 ; (P < 0.00	95 25 74 59 317 ² = 1% 50 43 45 25 74 46 283 001); ²	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 1.3% 4.2% 1.3% 4.4% 4.9% 19.8% = 87%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: :	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c} 40 \\ 83 \\ 83 \\ 59 \\ 20 \\ 302 \\ 04, df = 5 \\ 0.04 \\ 0 \\ 48 \\ 47 \\ 40 \\ 13 \\ 38 \\ 14 \\ 62 \\ 2 \\ 275 \\ .23, df = 5 \\ .23, df = 5 \\ .83 \\ \end{array}$	2.9 1.8 .25 5.36 .8.2 3.5 .3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 .7.5 1.8 .73 1.57 ; (P < 0.00	95 25 74 59 317 ² = 1% 50 43 45 25 74 46 283 001); ²	4.9% 1.5% 4.0% 2.0% 15.0% 15.0% 4.5% 2.7% 1.3% 2.0% 4.4% 4.9% 19.8% = 87%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.7 24 months	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ² = 5.1 2 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 2.58 1.66 2.04; Ch ² = 37 Z = 0.21 (P = 0	40 2 83 2 38 16 62 2 59 2 302 04, df = 5 .04) 48 47 42 1 40 13 38 14 62 2 275 .23, df = 5 .83)	2.9 1.8 .25 5.36 .8.2 3.5 3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 .7.5 1.8 .73 1.57 ; (P < 0.00	95 25 74 59 317 ² = 1% 50 43 45 25 74 46 283 001); ²	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 1.3% 2.0% 4.4% 4.9% 19.8% = 87%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.39] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: <i>:</i> 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: <i>:</i> 1.12.7 24 months	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Chi ² = 5. Z = 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 2.58 1.66 2.04; Chi ² = 37 Z = 0.21 (P = 0 19.85 2.45	40 2 83 2 38 18 62 2 59 2 302 04, df = 5 04) 48 47 42 1 40 13 38 14 62 2 275 (23, df = 5 .83)	2.9 1.8 .25 5.36 .8.2 3.5 .3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 .75 1.8 .73 1.57 ; (P < 0.00	95 25 74 59 317 1 ² = 1% 50 43 45 25 74 46 283 001); 1 ²	4.9% 1.5% 4.0% 2.0% 15.0% 15.0% 4.5% 2.7% 1.3% 2.0% 4.4% 4.9% 19.8% = 87%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : 1.12.7 24 months Chen CM 2010 Chen CM 2010	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Chi ² = 5. Z = 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 2.58 1.66 2.04; Chi ² = 37 Z = 0.21 (P = 0 19.85 6.45	$\begin{array}{c} 40 \\ 83 \\ 83 \\ 83 \\ 84 \\ 83 \\ 82 \\ 59 \\ 302 \\ 04, df = 5 \\ 0.04) \\ 48 \\ 47 \\ 40 \\ 13 \\ 38 \\ 14 \\ 62 \\ 275 \\ (.23, df = 5) \\ (.83) \\ 277 \\ 21 \\ 275 \\ (.23, df = 5) \\ (.83) \\ 27 \\ 21 \\ 27 \\ 21 \\ 20 \\ 27 \\ 21 \\ 20 \\ 27 \\ 21 \\ 20 \\ 27 \\ 21 \\ 20 \\ 27 \\ 21 \\ 20 \\ 20 \\ 21 \\ 20 \\ 20$	2.9 1.8 .25 5.36 .8.2 3.5 .3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 .73 1.57 5 (P < 0.00 .32 4.19	95 25 74 59 317 ² = 1% 50 43 45 25 74 46 283 001); ²	4.9% 1.5% 4.0% 2.0% 15.0% 15.0% 4.5% 2.7% 1.3% 2.0% 4.4% 19.8% 19.8% 19.8% 19.8%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16] -1.47 [-4.45, 1.51] 2.9 [-6.45, 1.51]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.7 24 months Chen CM 2010 Chen CM 2014	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ^{μ} = 5.1 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 2.58 1.66 2.04; Ch ^{μ} = 37 Z = 0.21 (P = 0 19.85 6.45 18.43 3.75	$\begin{array}{c} 40 \\ 83 \\ 83 \\ 83 \\ 84 \\ 83 \\ 84 \\ 84 \\ 84$	2.9 1.8 .25 5.36 .8.2 3.5 .3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 (7.5 1.8 .73 1.57 5 (P < 0.00 .32 4.19 .37 4.32	95 25 74 59 317 ² = 1% 50 43 45 25 7 46 283 001); ² 23 19	4.9% 1.5% 4.0% 2.0% 15.0% 15.0% 4.5% 2.7% 4.5% 2.0% 4.4% 4.9% 19.8% = 87%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.7 24 months Chen CM 2010 Chen CM 2014 Zhang L 2015	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c} 40 \\ 83 \\ 83 \\ 38 \\ 18 \\ 62 \\ 2 \\ 302 \\ 04, df = 5 \\ .04) \\ 48 \\ 47 \\ 42 \\ 1 \\ 40 \\ 13 \\ 38 \\ 14 \\ 62 \\ 275 \\ .23, df = 5 \\ .83) \\ 27 \\ 20 \\ 22 \\ 24 \\ 1 \\ 7 \\ 1 \\ 20 \\ 27 \\ 24 \\ 1 \\ 7 \\ 7 \\ 1 \\ 20 \\ 27 \\ 24 \\ 1 \\ 7 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$	2.9 1.8 .25 5.36 .8.2 3.5 3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 (7.5 1.8 .73 1.57 5 (P < 0.00 .32 4.19 .37 4.32 8.9 2.6	95 25 74 59 317 1 ² = 1% 50 43 45 25 74 46 283 2001); 1 ² 23 19 266	4.9% 1.5% 4.0% 2.0% 15.0% 15.0% 4.5% 2.7% 1.3% 4.8% 2.0% 4.4% 4.9% 19.8% = 87%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16] -1.47 [-4.45, 1.51] -3.94 [-6.48, -1.40] 1.00 [-1.09, 3.09] 4.09 [4.64]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 1.12.7 24 months Chen CM 2010 Chen CM 2011 Zubtotal (95% CI)	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ² = 5.1 Z = 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 2.58 1.66 2.04; Ch ² = 37 Z = 0.21 (P = 0 19.85 6.45 18.43 3.75 19.9 4.6	40 2 83 2 38 18 62 2 59 2 302 04, df = 5 04) 48 47 42 1 40 13 38 14 62 2 45 2 275 (.23, df = 5 8.83) 27 21 20 22 24 1 71 71 71 71 71 71 71 71 71 7	2.9 1.8 .25 5.36 .8.2 3.5 .3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 .62 4.36 .75 1.8 .73 1.57 .62 4.30 .37 4.32 .37 4.32 .8.9 2.6	95 25 74 49 317 1 ² = 1% 50 43 45 283 0001); l ² 23 19 26 68	4.9% 1.5% 4.0% 2.0% 15.0% 15.0% 4.5% 2.7% 1.3% 4.4% 4.9% 19.8% = 87% 1.3% 1.3% 1.3% 5.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16] -1.47 [-4.45, 1.51] -3.94 [-6.48, -1.40] 1.00 [-1.09, 3.09] -1.40 [-4.44, 1.63]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: : 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: : 1.12.7 24 months Chen CM 2010 Chen CM 2014 Zhang L 2015 Subtotal (95% Cl) Heterogeneity: Tau ² =	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c} 40 \\ 83 \\ 83 \\ 83 \\ 2 \\ 59 \\ 2 \\ 302 \\ 04, df = 5 \\ 0.04) \\ 48 \\ 47 \\ 40 \\ 13 \\ 38 \\ 14 \\ 40 \\ 13 \\ 38 \\ 14 \\ 62 \\ 2 \\ 275 \\ .23, df = 5 \\ .83) \\ 27 \\ 21 \\ 20 \\ 22 \\ 24 \\ 1 \\ 71 \\ .01 \\ 61 \\ 61 \\ 2 \\ .27 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 1$	2.9 1.8 2.5 5.36 8.2 3.5 3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .52 4.36 (7.5 1.8 .73 1.57 5 (P < 0.00 .32 4.19 .37 4.32 8.9 2.6 (P = 0.01); (P = 0.01);	95 25 74 59 317 1 ² = 1% 50 43 45 25 74 46 283 0001); l ² 23 19 26 68 8 1 ² = 77 ⁶	4.9% 1.5% 4.0% 2.0% 15.0% 15.0% 4.5% 2.7% 1.3% 4.4% 4.4% 4.9% 1.3% 1.8% 2.0% 4.5%	-1.47 [-4.45, 1.51] -1.47 [-4.44, 1.63] -1.40 [-4.44, 1.63]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.7 24 months Chen CM 2010 Chen CM 2010 Chen CM 2014 Zhang L 2015 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ² = 5.1 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 2.58 1.66 2.04; Ch ² = 37 Z = 0.21 (P = 0 19.85 6.45 18.43 3.75 19.9 4.6 5.52; Ch ² = 8. Z = 0.91 (P = 0	$\begin{array}{c} 40 \\ 40 \\ 83 \\ 38 \\ 83 \\ 38 \\ 16 \\ 62 \\ 2 \\ 302 \\ 04, df = 5 \\ .04) \\ 48 \\ 47 \\ 42 \\ 14 \\ 62 \\ 275 \\ .23, df = 5 \\ .23, df = 5 \\ .83) \\ 27 \\ 21 \\ 275 \\ .23, df = 5 \\ .83) \\ 27 \\ 24 \\ 171 \\ 71, df = 2 \\ .37) \end{array}$	2.9 1.8 2.5 5.36 8.2 5.36 8.2 3.5 3.2 6.04 (P = 0.41); 5.54 1.97 9.9 4.4 3.2 6.47 6.2 4.36 (7.5 1.8 1.57 1.57 5.(P < 0.00) 3.32 4.19 3.37 4.32 8.9 2.6 (P = 0.01);	95 25 74 59 317 2 = 1% 50 43 45 25 74 46 283 001); l ² 23 19 268 88 283 19226 283 192268 283 192268 283 283 295 25 74 46 9 25 74 74 9 25 74 74 9 25 74 74 9 25 74 74 74 75 74 74 74 75 74 74 74 74 74 75 74 74 75 74 74 74 74 75 74 74 74 74 74 74 74 74 74 74 74 74 74	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 4.5% 2.7% 4.4% 4.9% 19.8% = 87% 1.3% 1.6% 2.1% 5.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16] -1.47 [-4.45, 1.51] -3.94 [-6.48, -1.40] 1.00 [-1.09, 3.09] -1.40 [-4.44, 1.63]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : 1.12.7 24 months Chen CM 2010 Chen CM 2010 Chen CM 2014 Zhang L 2015 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: :	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ² = 5.1 2 = 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 2.58 1.66 2.04; Ch ² = 37 Z = 0.21 (P = 0 19.85 6.45 18.43 3.75 19.9 4.6 5.52; Ch ² = 8. Z = 0.91 (P = 0	$\begin{array}{c} 40 \\ 40 \\ 83 \\ 83 \\ 2 \\ 38 \\ 85 \\ 82 \\ 302 \\ 204, df = 5 \\ .04) \\ 48 \\ 47 \\ 42 \\ 1 \\ 40 \\ 13 \\ 81 \\ 42 \\ 1 \\ 40 \\ 13 \\ 81 \\ 42 \\ 1 \\ 45 \\ 275 \\ .23, f = 5 \\ .83) \\ 27 \\ 24 \\ 1 \\ 71 \\ 71 \\ df = 2 \\ .37) \\ .37) \\ \end{array}$	2.9 1.8 .25 5.36 .8.2 3.5 3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 62 4.36 62 4.36 (P < 0.00) .32 4.19 .37 4.32 8.9 2.6 (P = 0.01);	95 25 74 59 317 25 70 43 45 25 74 46 283 001); l ² 23 19 26 68 8 8 28 27 74	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 1.3% 4.5% 2.0% 4.4% 4.9% 19.8% = 87% 1.3% 1.6% 2.1% 5.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.22] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16] -1.47 [-4.45, 1.51] -3.94 [-6.48, -1.40] 1.00 [-1.09, 3.09] -1.40 [-4.44, 1.63]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 Total (95% CI)	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ² = 5.1 2 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 2.47 3.1 2.58 1.66 2.04; Ch ² = 37 Z = 0.21 (P = 0 19.85 6.45 18.43 3.75 19.9 4.6 5.52; Ch ² = 8. Z = 0.91 (P = 0	40 2 83 2 38 18 62 2 59 2 302 04, df = 5 04) 48 47 42 1 40 13 38 14 62 2 45 2 275 (.23, df = 5 83) 27 21 20 22 24 1 71 71 2 27 3 (.37) 1700	2.9 1.8 .25 5.36 8.2 3.5 3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 (7.5 1.8 .73 1.57 5 (P < 0.00 .32 4.19 .37 4.32 8.9 2.6 (P = 0.01); 	95 25 74 59 317 1 ² = 1% 50 43 45 25 74 46 283 001); l ² 23 19 26 68 8 1 ² = 77 ⁴	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 13.0% 2.7% 13.8% 4.4% 4.9% 19.8% = 87% 1.3% 1.6% 2.1% 5.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16] -1.47 [-4.45, 1.51] -3.94 [-6.48, -1.40] 1.00 [-1.09, 3.09] -1.40 [-4.44, 1.63]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : 1.12.7 24 months Chen CM 2010 Chen CM 2010 Chen CM 2014 Zhang L 2015 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: : Total (95% CI) Heterogeneity: Tau ² =	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ² = 5.1 2 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 2.58 1.66 2.04; Chi ² = 37 Z = 0.21 (P = 0 19.85 6.45 18.43 3.75 19.9 4.6 5.52; Chi ² = 8. Z = 0.91 (P = 0 0.66; Chi ² = 90	40 2 83 2 38 18 62 2 59 2 302 04, df = 5 04) 48 47 42 1 40 13 38 14 62 2 275 (.23, df = 5 .83) 27 21 20 22 24 1 71 71, df = 2 .37) 1700 .88, df = 3	2.9 1.8 2.5 1.8 2.5 3.6 8.2 3.5 3.2 6.04 (P = 0.41); 5.54 1.97 9.9 4.4 3.2 6.47 6.2 4.36 (7.5 1.8 1.73 1.57 5.(P < 0.00) 3.2 4.19 3.7 4.32 8.9 2.6 (P = 0.01); 5.5 (P < 0.0	95 25 74 59 317 1 ² = 1% 50 43 45 25 74 45 283 3001); l ² 23 19 26 68 8 8 19 = 775 1745 20001); l	4.9% 1.5% 4.0% 2.0% 15.0% 15.0% 4.5% 2.7% 4.5% 2.7% 1.3% 4.4% 4.9% 1.3% 1.8% 2.0% 4.4% 4.9% 5.0% %	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16] -1.47 [-4.45, 1.51] -3.94 [-6.48, -1.40] 1.00 [-1.09, 3.09] -1.40 [-4.44, 1.63] -0.06 [-0.44, 0.32]	
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.7 24 months Chen CM 2010 Chen CM 2014 Zhang L 2015 Subtotal (95% CI) Heterogeneity: Tau ² = Total (95% CI) Heterogeneity: Tau ² = Total (95% CI) Heterogeneity: Tau ² = Total (95% CI)	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ^{μ} = 5.] Z = 2.04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 2.58 1.66 2.04; Ch ^{μ} = 37 Z = 0.21 (P = 0 19.85 6.45 18.43 3.75 19.9 4.6 5.52; Ch ^{μ} = 8. Z = 0.91 (P = 0 0.66; Ch ^{μ} = 90 Z = 0.29 (P = 0	40 2 83 2 38 18 62 2 302 04, df = 5 04, df = 5 04) 48 47 42 1 40 13 38 14 62 2 275 .23, df = 5 .83) 27 21 20 22 24 1 71 71, df = 2 .37) 1700 .88, df = 5 .77)	2.9 1.8 2.5 5.36 8.2 3.5 3.2 6.04 (P = 0.41); 5.54 1.97 9.9 4.4 3.2 6.4 (P = 0.41); 3.2 6.4 3.2 6.4 (P = 0.41); 3.2 6.2 (P = 0.00) 3.2 6.2 (P = 0.00); 5 (P < 0.00) 5 (P < 0.00)	95 25 55 317 2 = 1% 50 43 35 50 43 45 25 74 46 88 283 3001); 2 23 19 26 68 88 2 = 77 50 1745 50 0001); 1	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 1.3% 1.3% 1.8% 2.1% 5.0% 4.4% 4.9% 1.3% 1.6% 2.1% 5.0% 4.5% 2.1% 5.0% 4.5% 2.1% 5.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.5% 2.0% 4.4% 4.5% 2.0% 4.4% 4.5% 2.0% 4.4% 4.6% 2.0% 4.4% 4.6% 2.0% 4.4% 4.6% 2.0% 4.4% 4.6% 2.0% 4.4% 4.6% 2.0% 4.4% 4.6% 2.0% 4.6% 2.0% 4.4% 4.6% 2.0% 4.6% 2.0% 4.4% 4.6% 2.0% 4.6%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.05] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.83] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16] -1.47 [-4.45, 1.51] -3.94 [-6.48, -1.40] 1.00 [-1.09, 3.09] -1.40 [-4.44, 1.63] -0.06 [-0.44, 0.32]	-10 -5 0 5 10 Favours [Bilateral]
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J 1.12.7 24 months Chen CM 2010 Chen CM 2010 Chen CM 2014 Zhang L 2015 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: J Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: J Total (95% CI)	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ² = 5.1 2 .04 (P = 0 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 24.7 3.1 2.58 1.66 2.04; Ch ² = 37 Z = 0.21 (P = 0 19.85 6.45 18.43 3.75 19.9 4.6 5.52; Ch ² = 8. Z = 0.91 (P = 0 0.66; Ch ² = 90 Z = 0.29 (P = 0 rences: Ch ² = 90	$\begin{array}{c} 40 \\ 40 \\ 83 \\ 2 \\ 38 \\ 83 \\ 2 \\ 38 \\ 82 \\ 38 \\ 82 \\ 302 \\ 302 \\ 302 \\ 302 \\ 302 \\ 302 \\ 302 \\ 302 \\ 40 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10$	2.9 1.8 2.5 5.36 8.2 3.5 3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 7.5 1.8 .73 1.57 5 (P < 0.00 .32 4.19 .37 4.32 8.9 2.6 (P = 0.01); 5 (P < 0.0 6 (P = 0.5	95 25 74 59 317 1 ² = 1% 50 43 45 25 74 46 62 283 0001); 1 ² 23 19 26 68 1 ⁹ = 779 1745 50001); 1 ¹	4.9% 1.5% 4.0% 2.0% 15.0% 4.5% 2.7% 1.3% 2.0% 4.4% 4.9% 19.8% = 87% 1.3% 1.6% 2.1% 5.0% % 100.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.32] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16] -1.47 [-4.45, 1.51] -3.94 [-6.48, -1.40] 1.00 [-1.09, 3.09] -1.40 [-4.44, 1.63] -0.06 [-0.44, 0.32]	-10 -5 0 5 10 Favours [Bilateral]
Shi X 2022 Tang J 2019 Xiong XM 2019 Xu DL 2024 Zhou RL 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: : 1.12.6 12 months Liu CL 2015 Liu MX 2018 Shi X 2022 Xiong XM 2019 Xu DL 2024 Yang AF 2018 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: : 1.12.7 24 months Chen CM 2010 Chen CM 2014 Zhang L 2015 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: : Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: : Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: : Test for subarous diffe	23.22 8.31 23.5 2.5 18.84 5.05 28.9 2.6 23.14 6.02 0.01; Ch ² = 5.1 2 2.04 (P = 0) 47.88 2.21 20.1 3.5 15.71 7.21 15.34 4.14 2.47 3.1 2.58 1.66 2.04; Ch ² = 37 Z = 0.21 (P = 0) 19.85 6.45 19.9 4.6 5.52; Ch ² = 8. Z = 0.91 (P = 0) 0.66; Ch ² = 90 0.66; Ch ²	40 2 83 2 38 18 62 2 59 2 302 04, df = 5 04) 48 47 42 1 40 13 38 14 62 2 45 2 275 (.23, df = 5 .83) 27 21 20 22 24 1 71 71 2 27 2 24 1 71 71 2 27 21 20 22 24 1 71 71 2 23, df = 5 .83) 27 21 20 22 24 4 71 71 71 2 24 4 71 71 71 5.24, df = 3 .77)	2.9 1.8 .25 5.36 8.2 3.5 3.2 6.04 (P = 0.41); .54 1.97 9.9 4.4 .32 6.47 .62 4.36 (7.5 1.8 .73 1.57 5 (P < 0.00 .32 4.19 .37 4.32 8.9 2.6 (P = 0.01); 5 (P < 0.0 6 (P = 0.5	95 25 57 74 59 317 50 4 4 4 6 283 2001); l ² 23 19 92 68 8 l ² = 77 ⁴ 1745 0001); l ³ = (4.9% 1.5% 2.0% 15.0% 4.5% 2.7% 4.5% 2.7% 1.3% 2.0% 4.4% 1.3% 1.8% 2.0% 1.3% 1.6% 2.1% 5.0% 4.5% 1.3% 2.0% 1.3% 1.3% 2.0% 1.3% 2.0% 1.5% 2.0% 1.5% 2.0% 1.5% 2.0% 1.5% 2.0% 1.5% 2.0% 1.5% 2.0% 1.5% 2.0% 1.5% 2.0% 1.5% 2.0% 1.5% 2.0% 1.5% 2.0% 1.5% 2.0% 1.5% 2.0% 1.5% 2.0% 1.3% 2.0% 2.0% 1.3% 2.0%	0.60 [-0.05, 1.25] 0.59 [-2.05, 3.23] 0.70 [-0.33, 1.73] -0.06 [-2.24, 2.12] 0.53 [0.02, 1.05] 0.34 [-0.49, 1.17] 0.20 [-1.49, 1.89] 2.39 [-0.54, 5.22] 0.72 [-1.44, 2.88] -2.80 [-3.67, -1.93] -0.15 [-0.81, 0.51] -0.14 [-1.44, 1.16] -1.47 [-4.45, 1.51] -3.94 [-6.48, -1.40] 1.00 [-1.09, 3.09] -1.40 [-4.44, 1.63] -0.06 [-0.44, 0.32]	-10 -5 0 5 10 Favours [Bilateral]

	Bilate	ral	Unilate	ral		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fixed, 95% Cl
Chen CM 2014	9	20	15	19	4.3%	0.22 [0.05, 0.90]		
Chen L 2011	2	24	4	25	1.8%	0.48 [0.08, 2.89]		
Cheng YH 2019	9	26	6	22	2.1%	1.41 [0.41, 4.87]		
Feng YH 2023	0	50	4	50	2.2%	0.10 [0.01, 1.95]	•	
Geng ZH 2021	4	40	6	31	3.1%	0.46 [0.12, 1.81]		
luang SC 2021	4	46	5	46	2.3%	0.78 [0.20, 3.11]		
.iL 2014	5	38	7	37	3.1%	0.65 [0.19, 2.27]		
iu CL 2015	15	48	9	50	3.1%	2.07 [0.80, 5.33]		
iu MX 2018	3	42	10	43	4.6%	0.25 [0.06, 1.00]		
.u JH 2022	1	37	3	42	1.4%	0.36 [0.04, 3.63]		· · · ·
u ZH 2022	15	175	19	208	8.0%	0.93 [0.46, 1.89]		
/lu ZZ 2022	7	80	11	73	5.3%	0.54 [0.20, 1.48]		
Rebollede BJ 2013	2	23	7	21	3.4%	0.19 [0.03, 1.05]		
Shi X 2022	9	40	12	45	4.4%	0.80 [0.30, 2.16]		
an HT 2018	5	66	10	66	4.7%	0.46 [0.15, 1.43]		
(u DL 2024	6	62	13	74	5.4%	0.50 [0.18, 1.41]		
′an L 2014	12	158	22	151	10.5%	0.48 [0.23, 1.01]		
'an L 2015	4	54	10	54	4.7%	0.35 [0.10, 1.20]		
/in F 2016	3	11	2	11	0.7%	1.69 [0.22, 12.81]		
/uQ 2020	3	16	4	16	1.6%	0.69 [0.13, 3.75]		
hang L 2015	5	24	9	26	3.4%	0.50 [0.14, 1.78]		
hang LG 2015	19	36	9	32	2.3%	2.86 [1.04, 7.85]		
hang YH 2020	13	59	12	53	5.0%	0.97 [0.40, 2.35]		
hou MW 2013	1	30	1	37	0.4%	1.24 [0.07, 20.71]		
hou RL 2020	3	59	11	59	5.3%	0.23 [0.06, 0.89]		
nou X 2019	6	66	15	64	7.0%	0.33 [0.12, 0.91]		
'otal (95% Cl)		1330		1355	100.0%	0.64 [0.51, 0.80]		◆
otal events	165		236					
leterogeneity: Chi ² =	33.28, df =	25 (P	= 0.12); P	² = 25%	b			
est for overall effect:	Z = 3.98 (P < 0.0	001)				0.01	U.1 1 10 10 Eavours [Rilatoral] Eavours [Unilatoral]
								ravouis [oliateral] ravouis [oliilateral]
KE 9								

The outcome quality level for postoperative pain rate, as assessed by GRADE, was "moderate."

Publication bias

A funnel plot was employed to evaluate publication bias. In the studies that reported operation time and overall complication rate, the funnel plot displayed asymmetry (Figures 11, 12, respectively), indicating a possible occurrence of publication bias. Furthermore, we detected publication bias in bone cement dose, radiation dose, bone cement leakage rate, and refracture rate (see Supplementary File 2, Figures S9–S13), which indicated a possible occurrence of publication bias.

Discussion

The aging global population has led to a rising incidence of OVCFs, particularly in regions with advanced demographic aging such as North America, Europe, and East Asia (49). Individuals aged 65 and older are disproportionately affected, with peak prevalence observed in those over 80 years (50). This age-related

susceptibility is driven by progressive bone density loss, which is further exacerbated in postmenopausal women due to estrogen deficiency (51, 52). While men exhibit lower overall incidence, aging males, particularly those undergoing androgen deprivation therapy for prostate cancer, face increasing OVCF risks (53). Dual-energy x-ray absorptiometry-measured bone mineral density remains the gold standard for diagnosing osteoporosis [WHO/ International Society for Clinical Densitometry (ISCD) criteria: T-score ≤ -2.5 at lumbar spine or femur] and stratifying OVCF risks (54). Although preoperative BMD assessment is not universally mandated, its integration could refine patient selection for PKP, especially in borderline cases or younger populations with secondary osteoporosis (55). In accordance with the DGOU (German Society for Orthopaedics and Trauma) classification system, the inclusion criteria prioritized patients with Type 4-5 OVCFs-characterized by persistent pain (>3 weeks) unresponsive to conservative therapy, vertebral height loss >30%, and/or dynamic instability on imaging (56). These criteria align with recommendations for PKP-a minimally invasive procedure involving vertebral stabilization via polymethylmethacrylate cement injection, aiming to stabilize fractures and restore vertebral height (57). However, controversy persists regarding unilateral vs. bilateral approaches; while unilateral PKP may

	Bilater	al	Unilate	rai		Odds Katio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% Cl
Chen CM 2014	9	20	15	19	3.2%	0.22 [0.05, 0.90]	
Chen L 2011	2	24	4	25	1.4%	0.48 [0.08, 2.89]	
Cheng YH 2019	9	26	6	22	1.6%	1.41 [0.41, 4.87]	
Feng YH 2023	2	50	9	50	3.3%	0.19 [0.04, 0.93]	
Geng ZH 2021	4	40	6	31	2.3%	0.46 [0.12, 1.81]	
luang SC 2021	4	46	5	46	1.7%	0.78 [0.20, 3.11]	
_i L 2014	8	38	12	37	3.6%	0.56 [0.20, 1.57]	
iu CL 2015	26	48	15	50	2.5%	2.76 [1.20, 6.32]	
iu MX 2018	8	42	15	43	4.5%	0.44 [0.16, 1.19]	
_u JH 2022	1	37	5	52	1.5%	0.26 [0.03, 2.33]	
_u ZH 2022	31	175	32	208	9.1%	1.18 [0.69, 2.03]	
Mu ZZ 2022	19	80	24	73	7.2%	0.64 [0.31, 1.29]	
Rebollede BJ 2013	2	23	7	21	2.5%	0.19 [0.03, 1.05]	
Shi X 2022	9	40	12	45	3.3%	0.80 [0.30, 2.16]	
Fan HT 2018	5	66	10	66	3.5%	0.46 [0.15, 1.43]	
Fang J 2019	5	83	7	95	2.3%	0.81 [0.25, 2.64]	
Ku DL 2024	6	62	25	74	7.8%	0.21 [0.08, 0.55]	
Yan L 2014	27	158	37	151	11.8%	0.64 [0.36, 1.11]	
Yan L 2015	4	54	10	54	3.5%	0.35 [0.10, 1.20]	
Yang AF 2018	3	45	2	46	0.7%	1.57 [0.25, 9.88]	
rin F 2016	3	11	2	11	0.5%	1.69 [0.22, 12.81]	
ru Q 2020	3	16	4	16	1.2%	0.69 [0.13, 3.75]	
Zhang L 2015	5	24	9	26	2.6%	0.50 [0.14, 1.78]	
Zhang LG 2015	19	36	9	32	1.7%	2.86 [1.04, 7.85]	
Zhang YH 2020	13	59	12	63	3.4%	1.20 [0.50, 2.90]	
Zhou MW 2013	2	30	1	37	0.3%	2.57 [0.22, 29.82]	
Zhou RL 2020	3	59	11	59	3.9%	0.23 [0.06, 0.89]	
Zhou X 2019	11	66	28	64	8.9%	0.26 [0.11, 0.58]	
Fotal (95% CI)		1458		1516	100.0%	0.67 [0.56, 0.81]	•
Fotal events	243		334				
leterogeneity: Chi ² = 5	3.25, df =	27 (P	= 0.002);	² = 49	%		
Test for overall effect: 2	z = 4.09 (F	° < 0.0	001)				Favours [Bilateral] Favours [Unilateral]

reduce surgical trauma and complication risks (58), bilateral PKP is advocated for superior fracture stability and pain relief (59). This study systematically compares both techniques to establish evidence-based selection criteria tailored to patient-specific factors.

Our meta-analysis pooled data from 35 RCTs involving 3,362 participants. Unilateral and bilateral PKP demonstrated comparable effectiveness in pain relief, functional improvement, and quality of life enhancement during long-term follow-up. Short-term outcomes at 6 months favored bilateral PKP, with significant differences in ODI scores (P = 0.04) and Cobb angle correction (P < 0.00001), potentially attributable to its more symmetrical cement distribution pattern (43). However, long-term follow-up results indicate that the differences in pain relief and functional improvement between the two methods are not statistically significant. Moreover, we also found that there was no significant difference between unilateral PKP and bilateral PKP in the Cobb angle and vertebral height, suggesting that unilateral PKP is equivalent to bilateral PKP in terms of long-term efficacy. While Chen et al. (60) reported superior final pain relief with unilateral PKP in their 17-RCT analysis (P = 0.006), our larger sample (35 RCTs) and GRADE-evaluated evidence found equivalent long-term efficacy between the approaches. This discrepancy may reflect our inclusion of trials with standardized outcome measurement protocols and extended follow-up durations.

While unilateral and bilateral PKP demonstrated equivalent long-term outcomes for pain (VAS), function (ODI), and vertebral alignment (Cobb angle), unilateral PKP exhibited superior perioperative performance. This meta-analysis found that unilateral PKP had a shorter operation time compared to bilateral PKP (P < 0.00001). The surgical duration for unilateral PKP is typically shorter as it requires a procedure on only one side of the vertebra. In contrast, bilateral PKP requires procedures on both sides of the vertebra, thereby increasing the number of punctures and consequently the surgical duration and the degree of surgical trauma (61). Chen et al. (62) conducted a meta-analysis of seven studies (six were level-II evidence and one was level-III evidence), demonstrating that unilateral PKP was associated with significantly shorter operative time compared to bilateral PKP surgery. This is consistent with our findings. A meta-analysis revealed that the unilateral approach was associated with a higher mean x-ray exposure frequency than the bilateral approach (P < 0.05) (63). Conversely, Yin et al. (64) analyzed 10 studies and found that unilateral PKP patients received lower mean radiation doses than bilateral PKP patients





—a conclusion concordant with our results. A pooled analysis suggests both unilateral and bilateral PKP represent viable options for patients with OVCF, with comparable long-term follow-up imaging outcomes and quality of life measures (65). The unilateral approach requires unilateral vertebral bone cement injection. This technique confines cement distribution to one side of the vertebral body, potentially resulting in non-uniform cement dispersion (66). In contrast, the bilateral approach employs cement injection through both pedicles. This dualpathway administration enables more symmetrical cement distribution within the vertebral body due to bilateral reinforcement and support (67).

Unilateral PKP not only has advantages in terms of surgical duration and radiation dosage but also demonstrates a slight edge in terms of safety, with a lower incidence of complications. Furthermore, the rate of bone cement leakage in unilateral PKP is notably lower, likely due to the reduced number of punctures and the shortened operating time in the unilateral approach, thereby diminishing the risk associated with the procedure (61, 66). The primary complications encompass adjacent nerve damage, vertebral fractures, and instances of bone cement leakage. Previous studies have indicated that there is no significant difference in the risk of cement leakage (P > 0.05, RR = 0.86: 0.36-2.06) and postoperative adjacent-level fractures (P > 0.05, RR = 0.91: 0.25-3.26) between unilateral PKP and bilateral PKP (66). In addition, another research study has demonstrated that there are no differences in cement leakage and adjacent vertebral fractures (P = 0.06 and P = 0.97, respectively) (68). Despite the concurrence of our findings with prior research regarding the incidence of adjacent vertebral fractures, our study reveals a divergence in the occurrence of bone cement leakage. Analyzing the previous study revealed that fewer than 15 studies were included, and only English-language studies were considered, introducing a language bias that could have inflated the effect sizes. Conversely, our study incorporates 35 RCTs, significantly augmenting the sample size, and includes a diverse array of linguistic sources, thereby mitigating such bias. Consequently, this enhances the generalizability of the research outcomes, rendering them more credible. Furthermore, our study demonstrated that unilateral PKP involves a significantly smaller volume of bone cement compared to bilateral PKP, as the bilateral approach requires simultaneous cement injection through bilateral pedicles into the vertebral body, thereby increasing cement volume and ensuring more homogeneous distribution within the vertebral structure. The biomechanical properties of PMMA cement distribution may play a pivotal role in pain alleviation as appropriate interdigitation with the trabecular bone reduces micromotion at fracture sites, thereby diminishing adverse stimuli (69). Research indicates a positive correlation between cement injection volume and analgesic efficacy in patients undergoing PKP, with increased cement volume enhancing fracture vertebral stability and consequently reducing pain (70). However, while this achieves superior stabilization of fractured segments, the approach elevates the risk of cement leakage and may induce excessive vertebral stiffness due to oversized cement volumes, potentially leading to asymmetric stress distribution and an

increased risk of adjacent vertebral fractures (63). Future investigations should focus on quantitative analysis of cement dispersion patterns (e.g., computed tomography-based threedimensional reconstruction) to optimize injection protocols, enabling more uniform cement distribution, effective restoration of vertebral height and structural integrity, and demonstration of superior long-term therapeutic outcomes.

However, the significant heterogeneity observed in operative time $(I^2 = 97\%)$, cement volume $(I^2 = 97\%)$, and radiation dose $(I^2 = 94\%)$ likely stems from multiple interacting factors. Differences in surgical protocols across institutions (unilateral PKP via extrapedicular vs. transpedicular approaches) and operator experience levels may substantially influence time metrics. Unreported variations in vertebral collapse severity (DGOU classification subtypes) and bone quality (T-score stratification beyond the -2.5 threshold) could modulate cement volume requirements. Disparate definitions of "operative time" (skin incision-to-closure vs. fluoroscopy time inclusion) and cement quantification methods (volumetric CT vs. intraoperative syringe measurement) were identified as potential contributors. While sensitivity analyses failed to isolate dominant sources, this likely reflects the cumulative effect of minor variations across studies rather than a single explanatory factor. Future meta analyses for PKP surgery should stratify studies by surgical technique standardization to mitigate such heterogeneity.

Regarding balanced decision-making between unilateral and bilateral PKP, clinicians should prefer unilateral PKP for elderly patients (≥80 years) with cardiopulmonary comorbidities, or those requiring urgent mobilization (e.g., dementia risk mitigation), as the shorter operative time and lower cement volume align with frailty-safety paradigms. Furthermore, bilateral PKP should be considered for younger patients (<65 years) with severe vertebral collapse (>40% height loss) or dynamic instability, where cement symmetry may delay adjacent fractures. Unilateral PKP's radiation dose advantage makes it preferable in low-resource settings with limited fluoroscopy shielding. Conversely, acute pain control of bilateral PKP may be utilized to reduce postoperative opioid dependence. Finally, developing risk calculators that integrate evidence-based pathways such as fracture morphology (DGOU classification), bone quality (T-score trajectory), and cement viscosity thresholds (highviscosity PMMA reduces leakage) will empower surgeons to tailor approaches without compromising safety-efficacy balance.

Current limitation

This study is not without its limitations. To begin with, despite the inclusion of 35 RCTs, the statistical power of several studies might be compromised due to their relatively small sample sizes (fewer than 50 participants). Second, the heterogeneity across these studies is notably high, with disparities in surgical techniques, types of bone cement, and baseline patient characteristics, all of which could potentially influence the consistency and comparability of the results. Third, the limited duration of follow-up in some studies underscores the need for more extensive long-term efficacy data. Finally, while the focus of this research has been principally on primary outcome measures, secondary outcomes such as patient satisfaction and improvements in quality of life may not have been adequately assessed. In addition, there remains a need to explore the distribution of bone cement and biomechanical aspects in unilateral vs. bilateral PKP procedures to better inform clinical practice.

Conclusion

In conclusion, this meta-analysis provides valuable insights into the comparative effectiveness of unilateral vs. bilateral PKP for the treatment of OVCFs. While bilateral PKP generally offers superior outcomes, the increased risk of complications necessitates careful consideration. Future research should aim to address the identified limitations, particularly in terms of inclusivity and long-term follow-up, to provide a more comprehensive understanding of these treatment options.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author contributions

LX: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. WL: Conceptualization, Data curation, Investigation, Methodology, Software, Supervision, Writing – original draft, Writing – review & editing. JY: Conceptualization, Data curation, Investigation, Methodology, Software, Supervision, Writing – original draft, Writing – review & editing. LL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. TL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2025. 1591686/full#supplementary-material

SUPPLEMENTARY FILE 1 Literature retrieval strategy.

SUPPLEMENTARY FILE 2 Secondary meta-analysis results.

References

1. Wani IM, Arora S. Computer-aided diagnosis systems for osteoporosis detection: a comprehensive survey. *Med Biol Eng Comput.* (2020) 58(9):1873–917. doi: 10.1007/s11517-020-02171-3

2. Capdevila-Reniu A, Navarro-López M, López-Soto A. Osteoporotic vertebral fractures: a diagnostic challenge in the 21(st) century. *Rev Clin Esp (Barc).* (2021) 221(2):118–24. doi: 10.1016/j.rce.2019.09.006

3. Adejuyigbe B, Kallini J, Chiou D, Kallini JR. Osteoporosis: molecular pathology, diagnostics, and therapeutics. *Int J Mol Sci.* (2023) 24(19):14583. doi: 10.3390/ ijms241914583

4. Patel D, Liu J, Ebraheim NA. Managements of osteoporotic vertebral compression fractures: a narrative review. *World J Orthop.* (2022) 13(6):564–73. doi: 10.5312/wjo. v13.i6.564

5. Keshavarzi F, Arazpour M. Effect of spinal orthoses on osteoporotic elderly patients kyphosis, back muscles strength, balance and osteoporotic vertebral fractures: (A systematic review and meta-analysis). *J Rehabil Assist Technol Eng.* (2024) 11:20556683241268605. doi: 10.1177/20556683241268605

6. Prost S, Pesenti S, Fuentes S, Tropiano P, Blondel B. Treatment of osteoporotic vertebral fractures. *Orthop Traumatol Surg Res.* (2021) 107(1s):102779. doi: 10.1016/ j.otsr.2020.102779

7. Lu Q, Liu C, Wang D, Liu H, Yang H, Yang L. Biomechanical evaluation of calcium phosphate-based nanocomposite versus polymethylmethacrylate cement for percutaneous kyphoplasty. *Spine J.* (2019) 19(11):1871–84. doi: 10.1016/j. spinee.2019.06.007

8. Zhu J, Zhang K, Luo K, Qiu Z, Yang S, Cui F, et al. Mineralized collagen modified polymethyl methacrylate bone cement for osteoporotic compression vertebral fracture at 1-year follow-up. *Spine (Phila Pa 1976)*. (2019) 44(12):827–38. doi: 10.1097/BRS. 00000000002971

9. Zhu D, Hu JN, Wang L, Cui W, Zhu JC, Ma S, et al. A modified unilateral extrapedicular approach applied to percutaneous kyphoplasty to treat lumbar osteoporotic vertebral compression fracture: a retrospective analysis. *Pain Physician.* (2023) 26(3):E191–201. doi: 10.36076/ppj.2023.26.E191

10. Sun Y, Li X, Ma S, Chong H, Cai TC, Li KM, et al. Comparison of the efficacy and safety of unilateral and bilateral approach kyphoplasty in the treatment of osteoporotic vertebral compression fractures: a meta-analysis. *Jt Dis Relat Surg.* (2024) 35(3):491–503. doi: 10.52312/jdrs.2024.1701

11. Cao DH, Gu WB, Zhao HY, Hu JL, Yuan HF. Advantages of unilateral percutaneous kyphoplasty for osteoporotic vertebral compression fractures-a systematic review and meta-analysis. *Arch Osteoporos.* (2024) 19(1):38. doi: 10.1007/s11657-024-01400-8

12. Li T, Yan J, Liu X, Hu J, Wang F. Efficacy and safety of conservative treatment compared with surgical treatment for thoracolumbar fracture with score 4 thoracolumbar injury classification and severity (TLICS): a systematic review and meta-analysis. *Clin Spine Surg.* (2023) 37(5):230–41. doi: 10.1097/BSD. 000000000001503

13. Li T, Yan J, Hu J, Liu X, Wang F. Efficacy and safety of electroacupuncture for carpal tunnel syndrome (CTS): a systematic review and meta-analysis of randomized controlled trials. *Front Surg.* (2022) 9:952361. doi: 10.3389/fsurg.2022.952361

14. Ceng Y, Xu J. Staged injection of bone cement in percutaneous vertebroplasty. Chin J Tissue Eng Res. (2013) 17(12):2116–22. doi: 10.3969/j.issn.2095-4344.2013.12. 004

15. Chen C, Bian J, Zhang W, Zhang W, Zhao C, Wei H. Unilateral versus bilateral vertebroplasty for severe osteoporotic vertebral compression fractures. *J Spinal Disord Tech.* (2014) 27(8):E301-4. doi: 10.1097/BSD.00000000000118

16. Chen C, Chen L, Gu Y, Xu Y, Liu Y, Bai X, et al. Kyphoplasty for chronic painful osteoporotic vertebral compression fractures via unipedicular versus bipedicular approachment: a comparative study in early stage. *Injury.* (2010) 41(4):356–9. doi: 10.1016/j.injury.2009.09.021

17. Chen L, Yang H, Tang T. Unilateral versus bilateral balloon kyphoplasty for multilevel osteoporotic vertebral compression fractures: a prospective study. *Spine*. (2011) 36(7):534–40. doi: 10.1097/BRS.0b013e3181f99d70

18. Cheng Y, Liu Y. Percutaneous curved vertebroplasty in the treatment of thoracolumbar osteoporotic vertebral compression fractures. J Int Med Res. (2019) 47(6):2424–33. doi: 10.1177/0300060519836917

19. Feng Y, Li F, Qin F, Chen W, Zhang S, Xie C, et al. Efficacy and safety of percutaneous vertebroplasty via unilateral pedicle approach for osteoporotic vertebral burst fracture. *Hainan Med J.* (2023) 34(20):2941–5. doi: 10.3969/j.issn. 1003-6350.2023.20.012

20. Geng Z, Zhou Q, Shang G, Ji Y, Kou H, Liu H. Short-term efficacy of the percutaneous vertebroplasty using a curved versus straight vertebroplasty needle in osteoporotic vertebral compression fractures. *Orthopedics.* (2021) 44(1):e131–8. doi: 10.3928/01477447-20201012-03

21. Huang S, Ni F, Pan B. Comparison of the short-term efficacy of PKP through unilateral or bilateral approaches in the treatment of thoracolumbar vertebral compression fractures. *Anhui Med Pharmaceutical J.* (2021) 25(9):1732–5. doi: 10. 3969/j.issn.1009-6469.2021.09.008

22. Li L, Wang M, Ma H, Zhou X, Zhou J, Chen Y, et al. Comparison of unilateral and bilateral penetrating kyphoplasty for osteoporotic centrum compression fractures. *Orthop J China*. (2014) 22(8):678–82. doi: 10.3977/j.issn.1005-8478.2014.08.02

23. Li Q, Lu M, Zheng C. Unilateral versus bilateral percutaneous kyphoplasty for the treatment of osteoportic compression fractures: a prospective case control study. *Med J Wuhan Univ.* (2012) 33(4):567–70. doi: 10.14188/j.1671-8852.2012.04.024

24. Liu C, Hu Y, Wang G, Tang Y, Wang X, Hou H. Curative effects of unipedicular and bipedicular vertebroplasty in treating osteoporotic vertebral compression fractures in the elderly population. *J. Xi'an Jiaotong Univ (Medical Science).* (2015) 36(6):857–61. doi: 10.7652/jdyxb201506029

25. Liu MX, Xia L, Zhong J, Dou NN, Li B. Is it necessary to approach the compressed vertebra bilaterally during the process of PKP? *J Spinal Cord Med.* (2020) 43(2):201–5. doi: 10.1080/10790268.2018.1451238

26. Lu J, Huang L, Chen W, Luo Z, Yang H, Liu T. Bilateral percutaneous kyphoplasty achieves more satisfactory outcomes compared to unilateral percutaneous kyphoplasty in osteoporotic vertebral compression fractures: a comprehensive comparative study. *J Back Musculoskelet Rehabil.* (2023) 36(1):97–105. doi: 10.3233/BMR-210225

27. Lu Z, Sun T, Zhang J, Zhang W, Yang M, Li Z. Kyphoplasty via different approaches for osteoporotic vertebral compression fractures. *Chin J Tissue Eng Res.* (2023) 27(36):5834–9. doi: 10.12307/2023.792

28. Mu Z, Shao H. Influence of surgical approach on postoperative complications of osteoporotic thoracolumbar fracture and analysis of risk factors for postoperative refracture. *Shanxi Medical Journal.* (2022) 51(7):848–55. doi: 10.3969/j.issn.1000-7377.2022.07.019

29. Rebolledo BJ, Gladnick BP, Unnanuntana A, Nguyen JT, Kepler CK, Lane JM. Comparison of unipedicular and bipedicular balloon kyphoplasty for the treatment of osteoporotic vertebral compression fractures: a prospective randomised study. *Bone Joint J.* (2013) 95-b(3):401-6. doi: 10.1302/0301-620X.95B3.29819

30. Shi X, Li P, Li J, Bao C, Xiang J, Lu Y. Comparative evaluation of an innovative deflectable percutaneous kyphoplasty versus conventional bilateral percutaneous kyphoplasty for osteoporotic vertebral compression fractures: a prospective, randomized and controlled trial. *Spine J.* (2023) 23(4):585–98. doi: 10.1016/j.spinee. 2022.12.012

31. Tan H, Meng Z, Huang T, Li J, Wang T, Fu G. Comparison of clinical efficacy of unilateral and bilateral PKP in the treatment of osteoporotic vertebral compression fractures. *Orthop J China*. (2017) 25(16):1511–4. doi: 10.3977/j.issn.1005-8478.2017. 16.15

32. Tang J, Guo WC, Hu JF, Yu L. Unilateral and bilateral percutaneous kyphoplasty for thoracolumbar osteoporotic compression fractures. *J Coll Phys Surg Pakistan*. (2019) 29(10):946–50. doi: 10.29271/jcpsp.2019.10.946

33. Xiong XM, Sun YL, Song SM, Yang MY, Zhou J, Wan D, et al. Efficacy of unilateral transverse process-pedicle and bilateral puncture techniques in percutaneous kyphoplasty for Kummell disease. *Exp Ther Med.* (2019) 18(5):3615–21. doi: 10.3892/etm.2019.7980

34. Xu D, Ruan C, Wang Y, Hu X, Ma W. Comparison of the clinical effect of unilateral transverse process extrapedicular and bilateral transpedicular percutaneous kyphoplasty for thoracolumbar osteoporotic vertebral compression fracture. *Front Surg.* (2024) 11:1395289. doi: 10.3389/fsurg.2024.1395289

35. Xue W. Comparison of the effect of unilateral and bilateral percutaneous puncture vertebroplasty on osteoporotic thoracolumbar vertebral compression fractures. *J Xinxiang Med Univ.* (2017) 34(1):69–71. doi: 10.7683/xxyxyxb.2017.01.020

36. Yan L, He B, Guo H, Liu T, Hao D. The prospective self-controlled study of unilateral transverse process-pedicle and bilateral puncture techniques in percutaneous kyphoplasty. *Osteoporos Int.* (2016) 27(5):1849–55. doi: 10.1007/s00198-015-3430-5

37. Yan L, Jiang R, He B, Liu T, Hao D. A comparison between unilateral transverse process-pedicle and bilateral puncture techniques in percutaneous kyphoplasty. *Spine.* (2014) 39(26 Spec No.):B19–26. doi: 10.1097/BRS.00000000000493

38. Yang A, Zou J, Lu Q, He C. Comparison of high viscosity cement PVP for treatment of osteoporotic vertebral compression fractures by unilateral and bilateral approach. *J Pract Med.* (2018) 34(14):2377–80. doi: 10.3969/j.issn.1006-5725.2018. 14.024

39. Yin F, Sun Z, Song S, Wei X, Liu X, Yin Q, et al. A comparative study on treatment of mid-thoracic osteoporotic vertebral compression fracture using percutaneous kyphoplasty with unilateral and bilateral approaches. *Chin J Reparative Reconstr Surg.* (2016) 30(1):77–81. doi: 10.7507/1002-1892.20160016

40. Yu Q, Long J, Kang X. Effect analysis of unilateral and bilateral percutaneous vertebroplasty for Kummell's disease. *Guizhou Med J.* (2020) 44(4):574–6. doi: 10. 3969/j.issn.1000-744X.2020.04.023

41. Zhang L, Liu Z, Wang J, Feng X, Yang J, Tao Y, et al. Unipedicular versus bipedicular percutaneous vertebroplasty for osteoporotic vertebral compression fractures: a prospective randomized study. *BMC Musculoskelet Disord.* (2015) 16:145. doi: 10.1186/s12891-015-0590-6

42. Zhang L, Yang W, Ding G, Li P, Xiao Z, Chen Y, et al. Dispersion effect of bone cement after vertebroplasty using individualized unilateral external pedicle approach and bilateral pedicle approach. *Chin J Tissue Eng Res.* (2024) 29(4):800–8. doi: 10. 12307/2025.253

43. Zhang L-G, Gu X, Zhang H-L, Zhang Q-G, Cai X-B, Tao K. Unilateral or bilateral percutaneous vertebroplasty for acute osteoporotic vertebral fracture: a prospective study. *J Spinal Disord Tech.* (2015) 28(2):E85–8. doi: 10.1097/BSD. 00000000000147

44. Zhang Y, Chen X, Ji J, Xu Z, Sun H, Dong L, et al. Comparison of unilateral and bilateral percutaneous kyphoplasty for bone cement distribution and clinical efficacy: an analysis using three-dimensional computed tomography images. *Pain Physician.* (2022) 25(6):E805–13.

45. Zhang Y, Zhu G, Li S, Lin Y, Zeng L, Zhong H, et al. Comparison of efficacy of two methods in treatment of osteoporotic vertebral compression fracture in the elderly patients. *J Clin Orthop.* (2020) 23(3):336–40. doi: 10.3969/j.issn.1008-0287.2020.03. 012

46. Zhou M, Li S, Liu H, Wang C, Liang Y, Sun F, et al. Effect analysis of unilateral and bilateral percutaneous balloon kyphoplasty for aged patients with thoracolumbar vertebral compression fractures. *Chin J Osteoporos*. (2013) 19(5):488–90. doi: 10.3969/ jissn.1006-7108.2013.05.015

47. Zhou R, Li G, Liang W, Feng J. Clinical analysis of percutaneous vertebroplasty with unilateral and bilateral hydraulic delivery of high viscosity bone cement in the treatment of osteoporotic vertebral compression fractures. *J Trauma Surg.* (2020) 22(5):345–9. doi: 10.3969/j.issn.1009-4237.2020.05.006

48. Zhou X, Dong G, Han J, Yan J. Effect of different cement injection and repair methods on percutaneous kyphoplasty for elderly patients with osteoporotic thoracolumbar vertebral compression. *J Trauma Surg.* (2019) 21(11):863–8. doi: 10. 3969/j.issn.1009-4237.2019.11.16

49. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. *Jama*. (2009) 301(5):513–21. doi: 10.1001/jama.2009.50

50. Jordan KM, Cooper C. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol. (2002) 16(5):795-806. doi: 10.1053/berh.2002.0264

51. Jackson RD, Mysiw WJ. Insights into the epidemiology of postmenopausal osteoporosis: the Women's Health Initiative. *Semin Reprod Med.* (2014) 32(6):454–62. doi: 10.1055/s-0034-1384629

52. Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD. Low bone mineral density and fracture burden in postmenopausal women. *Can Med Assoc J.* (2007) 177(6):575–80. doi: 10.1503/cmaj.070234

53. Vilaca T, Eastell R, Schini M. Osteoporosis in men. *Lancet Diabetes Endocrinol.* (2022) 10(4):273–83. doi: 10.1016/S2213-8587(22)00012-2

54. El Maghraoui A, Roux C. DXA Scanning in clinical practice. Qjm. (2008) 101(8):605–17. doi: 10.1093/qjmed/hcn022

55. Wang J, Xie X, Gou Y, Wu Y, Pu H, Chen Q, et al. Forearm bone mineral density as a predictor of adjacent vertebral refracture after percutaneous kyphoplasty in patients with osteoporotic vertebral compression fracture: a retrospective analysis. *J Orthop Surg Res.* (2024) 19(1):788. doi: 10.1186/s13018-024-05258-x

56. Schnake KJ, Blattert TR, Hahn P, Franck A, Hartmann F, Ullrich B, et al. Classification of osteoporotic thoracolumbar spine fractures: recommendations of the spine section of the German Society for Orthopaedics and Trauma (DGOU). *Global Spine J.* (2018) 8(2 Suppl):46s–9. doi: 10.1177/2192568217717972

57. Aparisi F. Vertebroplasty and kyphoplasty in vertebral osteoporotic fractures. Semin Musculoskelet Radiol. (2016) 20(4):382–91. doi: 10.1055/s-0036-1592431

58. Phillips FM. Minimally invasive treatments of osteoporotic vertebral compression fractures. *Spine (Phila Pa 1976)*. (2003) 28(15 Suppl):S45-53. doi: 10. 1097/01.BRS.0000076898.37566.32

59. Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. *N Engl J Med.* (2009) 361(6):557–68. doi: 10.1056/NEJMoa0900429

60. Chen Y, Zhang H, Chen H, Ou Z, Fu Y, Zhang J. Comparison of the effectiveness and safety of unilateral and bilateral percutaneous vertebroplasty for osteoporotic vertebral compression fractures: a protocol for systematic review and

meta-analysis. Medicine (Baltimore). (2021) 100(51):e28453. doi: 10.1097/MD. 00000000028453

61. Gangi A, Guth S, Imbert JP, Marin H, Dietemann JL. Percutaneous vertebroplasty: indications, technique, and results. *Radiographics*. (2003) 23(2):e10. doi: 10.1148/rg.e10

62. Chen X, Guo W, Li Q, Ou Z, Lao Z, Liu Y, et al. Is unilateral percutaneous kyphoplasty superior to bilateral percutaneous kyphoplasty for osteoporotic vertebral compression fractures? Evidence from a systematic review of discordant meta-analyses. *Pain Physician*. (2018) 21(4):327–36.

63. Cheng X, Long HQ, Xu JH, Huang YL, Li FB. Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analysis. *Eur Spine J.* (2016) 25(11):3439–49. doi: 10.1007/s00586-016-4395-6

64. Yin P, Ji Q, Wang Y, Liu Y, Wu Y, Yu Y, et al. Percutaneous kyphoplasty for osteoporotic vertebral compression fractures via unilateral versus bilateral approach: a meta-analysis. *J Clin Neurosci.* (2019) 59:146–54. doi: 10.1016/j.jocn.2018.10.112

65. Tan G, Li F, Zhou D, Cai X, Huang Y, Liu F. Unilateral versus bilateral percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures: a systematic review of overlapping meta-analyses. *Medicine (Baltimore)*. (2018) 97(33):e11968. doi: 10.1097/MD.000000000011968

66. Chen H, Tang P, Zhao Y, Gao Y, Wang Y. Unilateral versus bilateral balloon kyphoplasty in the treatment of osteoporotic vertebral compression fractures. *Orthopedics.* (2014) 37(9):e828–35. doi: 10.3928/01477447-20140825-61

67. Wang S, Xu H, Ni W, Huang Q, Wang X. Unilateral versus bilateral balloon kyphoplasty in treatment of osteoporotic vertebral compression fractures: a randomized controlled trial protocol. *Medicine (Baltimore)*. (2020) 99(25):e20524. doi: 10.1097/MD.00000000020524

68. Feng H, Huang P, Zhang X, Zheng G, Wang Y. Unilateral versus bilateral percutaneous kyphoplasty for osteoporotic vertebral compression fractures: a systematic review and meta-analysis of RCTs. *J Orthop Res.* (2015) 33(11):1713–23. doi: 10.1002/jor.22957

69. Morimoto T, Toda Y, Hakozaki M, Paholpak P, Watanabe K, Kato K, et al. A new era in the management of spinal metastasis. *Front Oncol.* (2024) 14:1374915. doi: 10.3389/fonc.2024.1374915

70. Wang M, Zhang L, Fu Z, Wang H, Wu Y. Selections of bone cement viscosity and volume in percutaneous vertebroplasty: a retrospective cohort study. *World Neurosurg.* (2021) 150:e218–27. doi: 10.1016/j.wneu.2021.02.133